[COMPANY_001] Research and Development
ICL670, deferasirox 
Protocol CICL670F2202 / [STUDY_ID_REMOVED]
A randomized, open -label, multicenter, tw o arm, phase II 
study to ev aluate treatment compliance, efficacy
 and safety 
of an improv ed deferasirox formulation (granules) in 
pediatric patients w ith iron overload
Document type: Amended Protocol Version
EUDRACT number: 2013 -004739 -55
Version number: 06 (Clean ) 
Development 
phase:II
Document status: Final
Release date: 24-Jun-2021
Property of [COMPANY_001]
Confidential
May not be used, divulged, published, or otherwise disclosed
without the consent of [COMPANY_001]

[COMPANY_001] Confidential Page 2
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
Table of contents
Table of contents ................................................................................................................. [ADDRESS_419973] of abbreviations ............................................................................................................ 7
Glossary  of terms ................................................................................................................. 9
Protocol summary :
............................................................................................................. 10
Amendment 6 (24-Jun-2021) ............................................................................................ 17
Amendment 5 (06 -Dec-2017) ............................................................................................ 20
Amendment 4 (15 -Jun-
2017) ............................................................................................ 23
Amendment 3 (24 -Aug-2016) ........................................................................................... 26
Amendment 2 ( 15-Jun- 2016 ) ................................ ................................ ............................ 29
Amendment 1 (01 -Dec-2015) ............................................................................................ 30
1Background ................................ ................................ ................................ ........................ 37
1.1 Overview of disease pathogenesis, epi[INVESTIGATOR_013] .............. 37
1.1.1 Overview of beta -thalassemia ............................................................... 37
1.1.2 Overview of sickle cell disease ............................................................. 38
1.2
Introduction to investigational treatment(s) and other study  treatment(s) ............. 38
1.2.1 Overview of deferasirox dispersible tablet ........................................... 38
1.2.2 Overview of deferasirox granules ......................................................... 39
2Rationale ................................ ................................ ................................ ............................ 39
2.1 Study  rationale and purpose ................................................................................... 39
2.2 Rationale for the stud y design ............................................................................... 41
2.3 Rationale for dose and regimen selection .............................................................. 43
3Objectives and endpoints ................................ ................................ ................................ ...43
4Study  design ...................................................................................................................... 46
4.1 Description of stud y design ................................................................................... 46
4.2 Timing of interim anal yses and design adaptations ............................................... 48
4.3 Definition of end of the study ................................................................................ 48
4.4 Early study termination .......................................................................................... 48
4.5 Rationale for Public Health Emergency  mitiga tion procedures ............................ 48
5Population .......................................................................................................................... 48
5.1 Patient population .................................................................................................. 48
5.2 Inclusion criteria .................................................................................................... 49
5.3 Exclusion criteria ................................................................................................... 49
6Treatment ................................ ................................ ................................ ........................... 50

[COMPANY_001] Confidential Page 3
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
6.1 Study  treatment ................................ ................................ ................................ ......50
6.1.1 Dosing regimen ..................................................................................... 50
6.1.2 Treatment duration ................................................................................ 53
6.2 Dose modifications ................................................................................................ 53
6.2.1 Permitted study  drug adjustments ......................................................... 53
6.2.2 Treatment interruption and treatment discontinuation .......................... 61
6.2.3 Follow -up for toxicities ......................................................................... 61
6.2.4 Follow up on potential drug -induced liver 
injury  (DILI) cases ............ 61
6.2.5 Anticipated risks and safety  concerns of the study drug ....................... 62
6.3 Prior and Concomitant medications ....................................................................... 63
6.3.1 Permitted concomitant therap y requiring caution and/or action ........... 63
6.3.2 Prohibited concomitant therap y
............................................................ 64
6.4 Patient numbering, treatment assignment or randomization ................................. 64
6.4.1
Patient numbering ................................................................................. 64
6.4.2
Treatment assignment or randomization............................................... 64
6.4.3 Treatment blinding ................................................................................ 65
6.5 Study  drug preparation and dispensation ............................................................... 65
6.5.1 Study  drug packaging and labeling ....................................................... 65
6.5.2 Drug supply  and storage ........................................................................ 66
6.5.3 Study  drug compliance and accountabilit y
........................................... 66
6.5.4 Disposal and destruction ....................................................................... 66
7
Visit schedule and assessments ......................................................................................... 66
7.1 Study  flow and visit schedule ................................................................................ 66
7.1.1 Screening ............................................................................................... 78
7.1.2 Treatment period ................................................................................... 79
7.1.3 Discontinuation of study treatment ....................................................... 80
7.1.4 Withdrawal of consent .......................................................................... 81
7.1.5 Follow up period ................................................................................... 81
7.2 Assessment ty pes................................................................................................... 81
7.2.1 Compliance with prescribed treatment .................................................. 81
7.2.2
Serum Ferritin ....................................................................................... 81
7.2.3 Patient / Observer Reported Outcomes ................................................. 82
7.2.4 Safety  and tolerability  assessments ....................................................... 83
7.2.5 Pharmacokinetics .................................................................................. 89
7.2.6 Resource utilization ............................................................................... 91
8Safety  monitoring and reporting ................................ ................................ ........................ 91

[COMPANY_001] Confidential Page 4
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
8.[ADDRESS_419974] abnormalities ................................................................ 93
8.2 Serious adverse events ........................................................................................... 93
8.2.1
Definitions............................................................................................. 93
8.2.2
Reporting............................................................................................... 94
8.3 Emergency  unblinding of treatment assignment ................................................... 94
8.4 Pregnancies ............................................................................................................ 95
8.5 Warnings and precautions ...................................................................................... 95
8.6 Data Monitoring Committee .................................................................................. 95
8.7 Steering Committee ............................................................................................... 95
9Data collection and management ................................ ................................ ....................... 96
9.1 Data confidentiality ............................................................................................... 96
9.2 Site monitoring ...................................................................................................... 96
9.3
Data collection....................................................................................................... 97
9.4 Database management and quality  control ............................................................ 97
10Statistical methods and data anal ysis................................................................................ 98
10.1 Analy sis sets .......................................................................................................... 98
10.1.1 Full Anal ysis Set ................................................................................... 98
10.1.2 Safety  Set
.............................................................................................. 98
10.1.3 Per protocol Set ..................................................................................... 99
10.1.4 Pharmacokinetic Analy sis Set ............................................................... 99
10.2 Patient demographics/other baseline characteristics ............................................. 99
10.3 Treatments (duration of exposure, concomitant therapi[INVESTIGATOR_014], percentage of 
planned dose taken) ............................................................................................. 100
10.4 Primary  objective ................................................................................................. 100
10.4.1 Variables and anal ysis set ................................................................... 100
10.4.2
Statistical method of analysis .............................................................. 101
10.4.3 Handling of missing values/discontinuations
...................................... 102
10.4.4 Supportive analy ses............................................................................. 102
10.5 Secondary  objectives ........................................................................................... 102
10.5.1
To evaluate both formulations on change in serum ferritin and 
compliance measured b y stick pack /tablet count after [ADDRESS_419975] 
naïve and pre -treated patients .............................................................. 102

[COMPANY_001] Confidential Page 5
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
10.5.3 To evaluate both formulations on patient satisfaction and 
palatability  using PRO/ObsRO questionnaires ................................... 103
10.5.4
To evaluate both formulations on overal l safet y, measured b y 
frequency  and severit y of adverse events and changes in laboratory 
values ................................................................................................... 103
10.5.5 To evaluate compliance using a daily  PRO/ObsRO questionna ire.....105
10.5.6 Pharmacokinetics ................................................................................ 105
10.6 Other anal yses...................................................................................................... 106
10.6.1 Other safety  data ................................................................................. 106
10.7 Interim anal ysis.................................................................................................... 108
10.8
Sample size calculation........................................................................................ 108
11Ethical considerations and administrative procedure s
.................................................... 110
11.1 Regulatory
 and ethical compliance ...................................................................... 110
11.2 Responsibilities of the investigator and IRB/ IEC/REB ....................................... [ADDRESS_419976] keepi[INVESTIGATOR_14906] ..................... 111
11.7 Confidentiality  of study  documents and patient records ..................................... 112
11.8
Audits and inspections......................................................................................... 112
11.9 Financial disclosures ............................................................................................ 112
12Protocol adherence .......................................................................................................... 112
12.1 Amendments to the protocol ................................................................................ 112
13References (available upon request) ................................................................................ 113
14Appendices ...................................................................................................................... 115
14.1
Equivalent dose guidance .................................................................................... 115
14.2 Dosing tables (Deferasirox DT, Deferasirox granules) ....................................... [ADDRESS_419977] of tables
Table 3-1 Objectives and related endpoints ................................ .......................... 44
Table 6-1 Dose and treatment schedule................................ ................................ .52
Table 6-2 Criteria for interruption and re- initiation of Deferasirox treatment ......54
Table 7-1 Visit evaluation schedule ................................ ................................ ......68

[COMPANY_001] Confidential Page 6
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
Table 7-2 Visit evaluation schedule (for the optional extension phase) ................ 74
Table 7-3 Central Imaging Assessments Collection Plan ..................................... 85
Table 7
-4 Central Clinical laboratory parameters collection plan, [Egy pt: 
Local Laboratory ].................................................................................. 86
Table 7
-5 PK blood collection log (all patients).................................................... 90
Table 7
-6 PK sample labels ................................................................................... 91
Table 10
-1 Definition of notab le/extended ranges for laboratory  tests ................. 105
Table 10-2 Definition of notable ranges for pulse rate and weight ....................... 107
Table 10-3 Precision in the estimate of the serum ferritin change ........................ 109
Table 14-1 Patients pre- treate d with deferasirox ................................................... 115
Table 14
-2 Patients pre- treated with deferoxamine ............................................... 115
Table 14
-3 Examples of light meal ........................................................................ 116
Table 14
-4 Dosing table for deferasirox DT ......................................................... 119
Table 14-5 Dosing table for deferasirox granules ................................................. 121

[COMPANY_001] Confidential Page 7
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
List of abbreviations
AE Adverse Event
AESI Adverse Events of Special Interest
ALP Alkaline Phosphatase
ALT Alanine aminotransferase/glutamic pyruvic transaminase/GPT
AST Aspartate aminotransferase/glutamic oxaloacetic transaminase/GOT
AUC Area Under Curve
AV Atrioventricular 
CMV Cytomegalovirus
CRF Case Report/Record Form; the term CRF can be applied to either EDC or Paper
CRO Contract Research Organization
COVID -[ADDRESS_419978]
DFO Deferoxamine
DS&E Drug Safety and Epi[INVESTIGATOR_339529] -Barr Virus
ECG Electrocardiogram
eCRS Electronic Case Retrieval Strategy
ELISA Enzyme -Linked Immunosorbent Assay
EOT End Of Treatment
FAS Full Analysis Set
FCT Film-coated tablet
GCP Good Clinical Practice
GGT Gamma -glutamyl transferase
GI Gastrointestinal
HCV Hepatitis C Virus
HDL High Density Lipoprotein
HIV Human Immunodeficiency Virus
HSV Herpes Simplex Virus
IA Interim Analysis
IB Investigator’s Brochure
ICF Informed Consent Form
ICH International Council for Harmonization
ICT Iron chelation therapy
IEC Independent Ethics Committee
IMP Investigational Medicinal Product
INR International Normalized Ratio
IRB Institutional Review Board
IRT Interactive Response Technology that includes Interactive Voice Response System (IVRS) and 
Interactive W eb Response System (IW RS)
LDH Lactate Dehydrogenase
LDL Low Density Lipoprotein
LFTs Liver Function Tests
MCH Mean cell Hemoglobin

[COMPANY_001] Confidential Page 8
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
MCHC Mean cell Hemoglobin Concentration
MCV Mean cell Volume
NSAIDs Nonsteroidal Anti -Inflammatory Drugs
ObsRO Observer Reported Outcomes
p.o. per os/by [CONTACT_1966]/orally
PAS Pharmacokinetics Analysis Set
PD Pharmacodynamic
PHI Protected Health Information
PK Pharmacokinetics
PPS Per Protocol Set
PRBC Pack Red Blood Cells
PRO Patient Reported Outcome
RBC Red Blood Cell
REB Research Ethics Board
SAE Serious Adverse Event
SAP Statistical Analysis Plan
SCD Sickle Cell Disease
SD Standard Deviation
SICT Satisfaction Iron Chelation Therapy
SJS Stevens -Johnson syndrome
SOC System Organ Class
TBIL Total Bilirubin
ULN Upper Limit of Normal range
UPCR Urine Protein Creatinine Ratio
WBC White Blood Cells
WHO ATC Anatomical Therapeutic Chemical classification system

[COMPANY_001] Confidential Page 9
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
Glossary  of terms
Assessment A procedure used to generate data required by [CONTACT_339548] (total daily or weekly etc.) 
Enrollment Point/time of patient entry into the study; the point at which informed consent must 
be obtained (i.e. prior to starting any of the procedures described in the protocol)
Inves tigational drug The study treatment whose properties are being tested in the study; this definition is 
consistent with US CFR 21 Section 312.3 and is synonymous with “investigational 
new drug.”
Investigational treatment Drug whose properties are being tes ted in the study as well as their associated 
placebo and active treatment controls (when applicable). This also includes 
approved drugs used outside of their indication/approved dosage, or that are tested 
in a fixed combination. Investigational treatment g enerally does not include other 
study treatments administered as concomitant background therapy required or 
allowed by [CONTACT_230753]/dosage
Medication number A unique identifier on the label of each study treatment package which is linked to 
one of the treatment groups of a study
New formulation Granules or film -coated tablets (FCT) –both are of the same qualitative and 
quantitative composition, using the same active ingredients at the same doses, and 
the same exc ipi[INVESTIGATOR_840] (with exception of the film -coating ingredients only used in the 
FCT). In the context of this study, the new formulation is provided by [CONTACT_339549].
Patient Number A unique identifying number assigned to each patient who enrolls in the study
Period A subdivision of the study timeline; divides stages into smaller functional segments 
such as screening, baseline, titration, washout, etc.
Premature patient 
withdrawalPoint/time when the patient exits from the study prior to the planned complet ion of 
all study treatment administration and/or assessments; at this time all study 
treatment administration is discontinued and no further assessments are planned.
Randomization number A unique treatment identification code assigned to each randomized p atient, 
corresponding to a specific treatment arm assignment
Stage related to study 
timelineA major subdivision of the study timeline; begins and ends with major study 
milestones such as enrollment, randomization, completion of treatment, etc.
Stick pa ck Aluminum foil pouches, or sachets used to package the deferasirox granules.
Stop study participation Point/time at which the patient came in for a final evaluation visit or when study 
treatment was discontinued whichever is later
Study treatment Includes any drug or combination of drugs in any study arm administered to the 
patient as part of the required study procedures, including placebo and active drug 
run-ins.
Study treatment 
discontinuationPoint/time when patient permanently stops taking study treatment for any reason; 
may or may not also be the point/time of premature patient withdrawal
Treatment group A treatment group defines the dose and regimen or the combination, and may 
consist of 1 or more cohorts. Cohorts are not expanded, new coho rts are enrolled.
Variable Identifier used in the data analysis; derived directly or indirectly from data collected 
using specified assessments at specified time points

[COMPANY_001] Confidential Page 10
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
Protocol summary :
Protocol number CICL670F2202
Title A randomized, open -label, multicenter, two arm, phase II study to evaluate 
treatment compliance, efficacy and safety of an improved deferasirox formulation 
(granules) in pediatric patients with iron overload
Brief title Study to evaluate treatment compliance, efficacy and safety o f an improved 
deferasirox formulation (granules) in pediatric patients (2 -<18 years old) with iron 
overload
Sponsor and
Clinical Phase[COMPANY_001]
Phase II
Investigation ty pe Drug
Study  type Interventional
Purpose and rationale The purpose of the present study is to:
assess the compliance of the granule and the dispersible tablet (DT) 
formulations in pediatric patients with iron overload over 24 weeks and 48 
weeks of treatment, using stick pack/tablet count and pre -dose 
pharmacokinetic (PK) concentrations and a PRO questionnaire.
assess the clinical benefit due to improved compliance of the new formulation 
by [CONTACT_339550], after 24 and 
48 weeks of treatment.
assess Patient / Observer Reported Outcomes (PRO/ObsRO) on palatability 
and treatment satisfaction
assess the safety of both formulations
examine the pre -and post -dose concentrations of both formulations using 
sparse PK sampling
explore exposure -response (PK/PD) relationships for measures of safety and 
effectiveness
assess long term safety of granules formulation via an optional extension 
phase consisting of up to 5 years for those who complete 48 weeks of core 
treatment phase and choose to continue in the extension phase
Primary  Objective(s) To evaluate patient compliance (using stick pack or tablet counts) and change in 
serum ferritin over time for both formulations of deferasirox, i.e., granules and 
dispersible tablet (DT) in iron chelation therapy (ICT) naïve patients in the first 24 
weeks of treatment during the core phase.
Secondary  Objectives To evaluate both formulations on patient compliance (using stick pack or 
tablet counts) and change in serum ferritin in ICT naïve patients, after 48 
weeks of treatment
To evaluate both formulations on change in serum ferritin in ICT naïve and 
pretreated patients, after 24 weeks and 48 weeks of treatment
To evaluate both formulations on patient satisfaction and palatability using 
PRO/ObsRO questionnaires
To evaluate both formulations on overall safety
Toevaluate compliance using a daily PRO/ObsRO questionnaire
To evaluate pre -dose PK data to support the assessment of compliance
To obtain pre -and post -dose concentrations to explore exposure -response 
relationships
To assess long -term safety of the granule s formulation during the optional 
extension phase for patients who choose to continue

[COMPANY_001] Confidential Page 11
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
Study  design This is a randomized, open -label, multicenter, two arm, phase II study to 
evaluate treatment compliance and change in serum ferritin of a deferasirox 
granul e formulation and a deferasirox DT formulation in children and adolescents 
aged ≥ 2 and < [ADDRESS_419979] of 
improved compliance on iro n burden. Randomization will be stratified by [CONTACT_339551] (2 to <10 years, 10 to <18 years) and prior iron chelation therapy (Yes/ 
No). There will be two study phases which include a 1 year core phase where 
patients will be randomized to a 48 week treatment period to either Deferasirox 
DT or granules, and an optional extension phase where all patients will receive 
the granules up to 5 years from entering extension phase . Patients who 
demonstrated benefit to granules or DT in the core phase, and/or express th e 
wish to continue in the optional extension phase on granules, will be offered this 
possibility until there is local access to the new formulation (granules or FCT) or 
up to [ADDRESS_419980] completed a minimum of 12 weeks of treatment exposure or 
discontinued from treatment core phase a t the time of the cutoff date will be 
included in the interim analysis.
Population Up to 216 naïve and pre -treated ([ADDRESS_419981] naïve and up to 120 pre -treated ) male 
and female children and adolescents aged ≥ 2 and < [ADDRESS_419982] 96 (48 per treatment arm) patients should be iron chelation naïve.
The optional extension phase will g ive the patients who have participated and 
completed the 48 weeks core treatment phase as per protocol, the possibility to 
extend treatment with granules for a maximum of 5 years after completing the 
core treatment phase or until there is local access to n ew formulation (granules 
or FCT), whichever occurs first. All patients who choose to continue in the 
extension phase will receive granules during the optional extension phase.
There will be two study phases which include a 1 year core phase where 
patients will be randomized to a 48 week treatment period to either Deferasirox 
DT or granules, and an optional extension phase where all patients will receive 
the granules up to 5 years from entering extension phase . Patients who 
demonstrated benefit to granules or DT in the core phase, and/or express the 
wish to continue in the optional extension phase on granules, will be offered this 
possibility until there is local access to the new formulation (granules or FCT) or 
up to [ADDRESS_419983].
Inclusion criteria Written informed consent/assent before any study -specific procedures. 
Consent will be obtained from patients, parent(s) or legal guardians. 
Investigators will also obtain consent/assent of patients according to local 
guidelines.
Male and female children and adolescents aged ≥ 2 and < 18 years.* 
[[LOCATION_009]: Male and female children and adolescents aged ≥ 2 and < 18 
years, however children aged ≥ 2 and ≤ 6 years can be enrolled only when 
deferoxamine treatment is cont raindicated or inadequate in these patients 
as per investigator decision] *Applicable to core phase only. Once in the 
core phase patients can turn 18 years and still be considered eligible, also 
for participation in the optional extension phase.
Any transf usion -dependent anemia associated with iron overload requiring 
iron chelation therapy and with a history of transfusion of approximately 20 
PRBC units, and a treatment goal of reduction, not maintenance of iron 
burden as measured by [CONTACT_292009].
Serum ferritin > 1000 ng/mL, measured at screening Visit 1 and screening 
Visit 2 (the mean value will be used for eligibility criteria).

[COMPANY_001] Confidential Page 12
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
Completion of core phase per protocol (For the optional extension phase 
criteria only).
Exclusion criteria Creatinine clearance below the contraindication limit in the locally approved 
prescribing information.  Creatinine clearance will be estimated from serum 
creatinine (using the Schwartz formula) at screening Visit 1 or screening 
Visit 2.
Serum creatinine > 1.[ADDRESS_419984] at screening Visit 1 or screening Visit 2. 
ALT or AST >3.[ADDRESS_419985] at screening visit 1 or screening visit 2.
Direct (conjugated) bilirubin >[ADDRESS_419986] at screening visit 1 or screening visit 2.
(Criterion no longer applicable, removed as part of Amendment 1): Prior iron 
chelation therapy
Liver disease with severity of Child -Pugh class B or C.
Significant proteinuria as indicated by a urinary protein/creatinine ratio >0.5 
mg/mg in a second morning urine sample at screening Visit 1 or screening 
Visit 2.
Patients w ith significant impaired gastrointestinal (GI) function or GI disease 
that may significantly alter the absorption of oral deferasirox (e.g. ulcerative 
diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, 
or small bowel resection).
Clinical or laboratory evidence of active Hepatitis B or Hepatitis C (HBsAg in 
the absence of HBsAb OR HCV Ab positive with HCV RNA positive).
Patients with psychiatric or addictive disorders which prevent them from 
giving their informed consent/assent or und ergoing any of the treatment 
options or patients unwilling or unable to comply with the protocol (including 
use of electronic devices for ePRO).
Local access to new formulation (granules or FCT) is available for the patient 
(For the optional extension phase criteria only).
Investigational and 
reference therapyPatients will be randomized to either Deferasirox granules or Deferasirox DT 
(Exjade) in the core phase.
All patients who choose to continue in the extension phase will receive 
deferasirox granules i n the extension phase.
Efficacy  assessments The co -primary efficacy endpoints assessed during the core phase will be:
Compliance measured by [CONTACT_339552]/tablet count over 24 weeks of treatment 
(i.e. assessed at week 25 visit).
Change from baseline in serum ferritin after 24 weeks of treatment (i.e. 
Serum Ferritin at week 25 visit).
Primary  endpoint 
assessmentsCompliance will be measured by [CONTACT_339552]/tablet count over 24 weeks of 
treatment (i.e. assessed at week 25 visit): it will be performed by [CONTACT_339553] 4 weeks (weeks 5, 9, 13, 17, 21, 25 and End of Treatment 
(EOT ) (core)/777 visits) during the core phase based on the amount of 
medication dispensed, returned and reported as lost/wasted by [CONTACT_102] / 
caregiver
Serum ferritin test will be p erformed at Screening Visits 1 and 2 and every 4 
weeks from week 5 till after 24 weeks of treatment (i.e. assessed at week 25 
visit)..
Secondary  endpoint 
assessmentsCore phase:
Compliance will be measured by [CONTACT_339552]/tablet count over 48 weeks of 
treatment: it will be performed by [CONTACT_339554] 4 weeks (weeks 5, 
9, 13, 17, 21, 25 29, 33, 37, 41, 45, and EOT(core)/777 visits) during the 
core phase based on the amount of medication dispensed, returned and 
reported as lost/wasted by [CONTACT_102] / caregiver
Serum ferritin test will be performed at Screening Visits 1 and 2 and every 4 
weeks from week 5 till end of treatment visit.

[COMPANY_001] Confidential Page 13
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
The study will include the use of a Satisfaction with Iron Chelation Therapy 
questionnaire, a Palatability questionnaire a nd a compliance diary to 
evaluate both formulations on these patient / observer reported outcomes.
Safety will be monitored by [CONTACT_339555]:
Hematology, chemistry (including renal and hepatic parameters), urinalysis
Adverse events; including renal toxicity (including renal failure), hepatic 
toxicity (including hepatic failure) and gastrointestinal hemorrhage, which 
will be actively monitored until symptom resolution or until the condition 
stabilizes
Vital signs
Physical examinations
Ocular examinations
Auditory examinations
Cardiac examinations (ECG and echocardiogram)
Growth parameters and development parameters
Deferasirox concentrations will be measured in plasma at predefined time 
points on all patients. [Egypt: PK samples will no t be collected due to 
restriction on sample exportation]
Pharmacokinetic samples collected by [CONTACT_339556] 
[Egypt: PK samples will not be collected] will be analyzed using modeling 
approaches to explore PK/PD (safety and efficacy) rel ationships.
Optional Extension phase:
Long term safety of granules in the optional extension phase:
Overall safety, as measured by [CONTACT_339557]
(including active monitoring for renal toxicit y;including renal failure, hepatic 
toxicity; including hepatic failur e,and gastrointestinal hemorrhag e),and 
changes in laboratory values from baseline (s erum creatinine, creatinine 
clearance, ALT, AST, RBC and W BC). In addition, vital signs, physical,
ophthalmological, audiometric, and growth and development evaluations will 
be assessed.
Other assessments Daily questionnaire on study treatment compliance completed through core 
phase only.
Data analy sis Anal ysis sets:
The Full Analysis Set 1 (FAS -1) comprises all ICT naïve patients to whom study 
treatment has been assigned by [CONTACT_17628]. The Full Analysis Set 2 (FAS -2) 
comprises all ICT pre -treated patients to whom study treatment has been 
assigned by [CONTACT_17628]. The Full Analysis Set 3 (FAS -3) comprises all ICT 
pre-treated and naïve patients to whom study treatment has been assigned by 
[CONTACT_17628]. According to the intent to treat principle, patients will be analyzed 
according to the treatment and stratification factors they have been assigned to 
during the randomization procedu re.
The Safety Set [ADDRESS_419987] naïve patients from the FAS -1 without 
any major protocol deviation.
The major protocol deviations that will lead to exclusion of patients from the PPS 
will be detailed in the Statistical Analysis Plan ( SAP).
The Pharmacokinetic Analysis Set (PAS) consists of all patients who have at 

[COMPANY_001] Confidential Page 14
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
least one evaluable pre or post-dose PK concentration (deferasirox). More 
details are provided in Section 10.1.4 .
Statistical Analy ses:
Primary  efficac y endpoints: All analyses for the primary objective will be 
performed based on core period and on the FAS -1 and presented by [CONTACT_6490]: deferasirox DT and deferasirox granule formulation. The co -primary 
efficacy variables are:
Compliance measured by [CONTACT_339552] /tablet count based on amount of 
medication dispensed, returned and reported as lost/wasted by [CONTACT_339558] 24 weeks of treatment (i.e. assessed at week 25 visit). 
Complian ce will be calculated as the ratio of total count consumed to total 
count prescribed, where
total count consumed is derived from cumulative dispensed, returned and 
lost/wasted counts over 24 weeks of treatment (i.e. assessed at week 25 
visit);
total count prescribed is cumulative prescribed count over 24 weeks of 
treatment (i.e. assessed at week 25 visit).
Change from baseline in serum ferritin after 24 weeks of treatment (i.e. 
serum ferritin assessment at week 25 visit).
The primary efficacy analysis will be the comparison of means between the two 
treatment arms of change from baseline after 24 weeks of treatment in SF and 
mean relative consumed stick pack /tablet count over 24 weeks of treatment.
Analysis of covariance (ANCOVA) will be performed for compar ison between 
treatment groups at a one -sided 5% level of significance. The ANCOVA model 
for compliance endpoint will include treatment group and age group (2 to<10 
years, 10 to <18 years), as factors. The model for serum ferritin endpoint will 
also include the serum ferritin value at baseline as covariate.
The trial will be claimed successful if the superiority of granule formulation 
relative to DT formulation could be demonstrated with regard to both endpoints. 
Therefore, no adjustment of the type I error (alpha) is required.
Sample size calculation: The primary objective is to evaluate patient 
compliance (using stick packs or tablets counts) and change in serum ferritin 
(SF) over time for both formulations of deferasirox in pediatric ICT naïve patients 
with iron overload after [ADDRESS_419988] to both co -primary endpoints.
The assumptions made for this study were as follows:
For serum ferritin:
An expected improvement between both formulations in SF change from 
baseline after 24 weeks of treatment of −450 ng/mL with a standard deviation 
(SD) of 900 ng/mL based on results from study CICL670A0107 in pediatric 
patients treated with Exjade on ≥25 mg/kg/day after 24 weeks of treatment.
For compliance over 24 weeks of treatment using stick packs or tablets 
counts:
An expected improvement between both formulations in mean relative 
consumed tablet count of 10% with a SD equal to 17.625% based on the pooled 
analysis on pediatric patients (77) from Exjade studies [ICL670A2206] (39), 
[ICL670A2204] (24) and [ICL670A2214] (14).
The sample size driven by [CONTACT_339559], has been determined 
to obtain 76% power at one -sided 5% level o f significance for showing 
superiority of granule formulation over DT formulation with respect to change 
from baseline after 24 weeks of treatment in serum ferritin, assuming a dropout 
rate of 5%.
A sample size of [ADDRESS_419989] 76% power to de tect a difference in 
means of 400.0 ng/mL assuming that the common SD is 800.0 ng/mL using a 

[COMPANY_001] Confidential Page 15
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
two group t -test with a 0.[ADDRESS_419990] a 10% difference in mean compliance is about 84%.
In add ition, the clinical trial will enroll patients previously treated with iron 
chelation. Considering that a direct comparison of granule and DT formulations 
in terms of efficacy is not foreseen in previously chelated patients, the required 
sample size is not based on power calculations as usual. The selection of 
number of patients is based on the precision in the estimate of SF change at 48 
weeks of treatment and on practical considerations.
A maximum of 120 patients (60 patients will be in each formulation g roup) 
previously chelated patients will be enrolled. Sixty patients will provide an 
estimate of SF change with precision (half -width of 95% confidence interval) 
equal to 303.6.
The table below lists the precisions in the estimates of SF change for differen t 
numbers of patients using the estimated SD obtained from the CICL670A0107 
study results in pediatric patients treated with Exjade on ≥25 mg/kg/day at week 
48 of treatment .
Precision in the estimate of the serum ferritin change
Number of 
patientsHalf-width of 95%  confidence interval in the estimate 
of the SF change
40 371.8
45 350.6
50 332.6
55 317.1
60 303.6
The total required sample size for this clinical trial is up to 108 patients for each 
treatment group (up to 216 patients in total), including 48 iron chelation naive 
patients per group (96 patients in total).
Safety :The assessment of safety will be based mainly on the frequency and 
severity of AEs and changes in laboratory values. Other safety data (e.g., ECGs, 
vital signs, echocardiogram, ocular, auditory examinations) will also be 
summarized. For all safety analyse s, the safety set will be used.
Pharmacokinetics:
Pre- and post -dose concentrations will be summarized descriptively and 
graphically presented.
The analyses will be based on the PAS.
To explore PKPD relationship:
Serum ferritin change from baseline will be fitted by a linear mixed effect model 
with log - transformed matching pre-dose concentrations as covariates and 
subject as random effect.
Serum creatinine change from baseline, serum creatinine clearance change from 
baseline and urine protein creatinine ratio change from baseline will be fitted by 
a linear mixed effect model with log -transformed matching pre-dose 
concentrations and post -dose concentrations respectively as covariates and 
subject as random effect.  Incidence of notable serum creatinine eve nts will be 
analyzed by a logistic regression fitted by [CONTACT_339560] -transformed pre -dose concentrations and post -dose concentrations 
respectively.
Incidence of notable serum creatinine clearance events will be analyzed by a 
logistic regression fitted by [CONTACT_339561] -
transformed pre -dose concentrations post -dose concentrations respectively.
For all statistical models other covariates such as demographic characteristics 
may be included if appropriate.
All analyses will be based on the Safety Set or FAS of the core phase. 

[COMPANY_001] Confidential Page 16
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
Interim analy sis:
All the analyses included in the interim analysis will be descriptive. Testing of 
hypotheses will not be performed and no decisions regarding the fu ture course 
of the trial is anticipated at the time of the IA and the trial will continue. Therefore 
adjustment for multiplicity is not performed. Descriptive statistics will be provided 
by [CONTACT_339562] (i.e. change from baseline in serum 
ferritin and compliance measured by [CONTACT_339552] /tablet count) and key safety 
data.
Key words New formulation, deferasirox, chelation, iron overload, compliance, satisfaction, 
palatability, PRO, PK, safety, PK/PD

[COMPANY_001] Confidential Page 17
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
Amendment 6 (24-Jun -2021) 
Amendment rationale 
As of 24-Jun-2021, 67 patients are ongoing in the extension phase of the study . All patients had
completed the Core phase of the study  by 18-Dec- 2018. The primary  analysis for this study  was 
completed on 07 -Dec-2018 (data cut -off date 31-May-2018). 
The main purpose of this amendment is to introduce the requirement for central collection and 
assessment of photographs from ocular examinations (lens photographs and wide angle fundus 
photographs) collected during the study  by a [COMPANY_001] designated imagin g Contract Research 
Organization (CRO). This change is in response to a Health Authority request to submit 
CAL YPSO ophthalmic data (for up to 2 years of follow up) to support the ocular safet y 
evaluation of deferasirox. 
Clarification was also added to state that for patients who need correction, the best corrected 
visual acuit y should be tested when performing the distance visual acuity  test and that the 
corrected visual acuity  should be documented in the source records.
In addition, mitigation procedures have 
been implemented throughout the protocol to ensure 
participant safety  and trial integrit y during a Public Health emergency, as declared b y Local or 
Regional authorities i.e. pandemic, epi[INVESTIGATOR_6519]. 
Finally , assessment of the study  Risk/Benefit in light of the ongoing coronavirus disease 2019 
(COVID -19) pandemic at the time of this protocol amendment concluded that there are no 
additional risks related to COVI D-[ADDRESS_419991] been 
postmarketing reports of cytopenias in patients treated with deferasirox and patients with 
cytopenias may be at higher risk of COVID -19 with a poorer prognosis. The periodic 
monitoring of blood counts and interruption of study  treatment in patients who develop 
unexplained cy topenia, as defined in the protocol, are expected to mitigate this risk.
Changes to the protocol
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underline for insertions.
List of Abbreviations (LOA) and Protocol summary  (data analy sis): Aligned with 
updates in the protocol.
Section 4.5: New section added, describing the rationale for public health emergency 
mitigation procedures.
Section 6.5: Included public health emergency  mitigation guidelines, regarding the 
delivery  of IMP directly  to the participant’s home at the discretion of the Investigator.
Section 7.1: Updated to add a ±
30-day window for yearl y assessments ,i.e. audiometry ,
ocular , and growth and development examinations, in the extension phase, to allow 
more flexibility  for the sites. 

[COMPANY_001] Confidential Page 18
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
Section 7.1: Included public health emergency  mitigation guidelines, regarding 
alternative methods of providing continued care, such as phone calls and virtual contacts, 
to replace on -site study  visits for the duration of the disruption.
Table 7-1 and Table 7-2: Separated Audiometry  and Ocula r sections and updated 
protocol section numbers.
Section 7.2.4: Included public health emergency mitigation guidelines, regarding the 
inclusion of phone or virtual calls for safet y monitoring and discussion of the 
participant’s health status for the durati on of the disruption . 
Section [IP_ADDRESS]: Removed the reference to ocular examinations from this section as a 
new section (
[IP_ADDRESS]) was added to clarify  more detail about central imaging assessments.
Section 
[IP_ADDRESS], Table 7-3: New section and table added fo r ocular examinations and 
central imaging assessments. This section was included to introduce the requirement for 
central collection and assessment by  [CONTACT_339563].
Section [IP_ADDRESS]:  I ncluded public health emergency  mitigation guidelines, regarding the 
use of a local laboratory  if the subject is unable to conduct safet y laboratory  assessments 
at the site. 
Section 8.4: Updated the duration for pregnancy  reporting 
after the estimated date of 
delivery .
Section 9.3: Included ocular examination photographs asan additional component of 
data collection.
Section 9.4: Included ocular examination photographs as an additional component of 
data being collected and processed centrally .
Section 10: Added public health emergency  mitigation guidelines regarding statistical 
methods and data analy sis.
Section 10, S ection 10.1.2, Section 10.1.3, Section 10.4.4, Section 10.5.3, Section 
[IP_ADDRESS], Section 10.5.5: Changed RAP to SAP
Section 10.2: Removed Safet y Set 4 demographic and other background data summary, 
as these are alread y presented in FAS -3 summary .  
Section 10.3: Corrected the definition of average daily  dose calculation and updated the 
concomitant medication definition to align text with the SAP. 
Section 10.4.4, Section 10.5.1: Changed the term ‘sensitiv ity analysis’ to 
‘supplementary  anal ysis’.
Section [IP_ADDRESS]: Updated AESI  maintenance and retrieval to align with the current 
[COMPANY_001] internal process.
Section [IP_ADDRESS], Table 10-2: The normal ranges for pulse rate and weight were updated 
for pediatric patients. Notable ranges for systolic and diastolic blood pressure were 
removed.

[COMPANY_001] Confidential Page 19
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
Section 11.3: Included public health emergency  mitigation guidelines, regarding the 
inclusion of remote informed consent discussion due to limits that prevent an on-site 
visit.
Section 13: Added a new reference.
IRBs/IECs
A copy of this amended protocol will be sent to the Institutional Review 
Board 
(IRBs)/Independent Ethics Committee (I ECs) and Health Authorities.
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation. 
The changes herein affect the Informed Consent. Sites are required to update and submit for 
approval a revised Informed Consent that takes into account the changes described in this 
protocol amendment.

[COMPANY_001] Confidential Page 20
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
Amendment 5 (06 -Dec -2017)
Amendment rationale 
As of 06-Dec- 2017, [ADDRESS_419992] been randomized (94 chelation naïve and 116 pre-treated 
patients).  The pre- treatment arm is fully  accrued.
The purpose of this amendment is to modify  the assessment timepoint for the primary  analysis 
(currently  change from baseline for serum ferritin and compliance after 48 weeks of treatment), 
and to reduce the sample size for the chelation naive patients , following recent interaction with 
Health Authorities. The eligibility  criteria for the extension phase have been modified.
Amendment rationales are as follows:
1.The assessment timepoint for the primary  anal ysis will be modified for serum ferritin and 
compliance to 24 weeks of treatment (as assessed at week 25 visit), in lieu of 48 weeks. A 
linear relationship between changes from baseline at 24 and 48 weeks of treatment has 
been established based on a pool of representative randomized studies (CICL 670A0105, 
CICL 670A0107, CICL670A0109 and CI CL670A2206) with serum ferritin available at [ADDRESS_419993] at 12 months. This finding supports the use of the 6 
months time -point as reliable surrogate for the 12 months time -point ([COMPANY_001] data on 
file).  Primary  endpoints based on changes from baseline after 24 weeks of treatment will 
allow an earlier disclosure of primary  anal ysis. The compliance (using drug c ount) has 
been evaluated in pediatric patients over [ADDRESS_419994] a self -reported adherence to deferasirox DT of 97% after one y ear. Therefore it 
can be assumed that the 6 month reported adherence will be very  similar and can serve as 
a surrogate (Trachtenberg  2011)The rationale is also based on the demonstrated 
relationship of efficacy  as assessed by  [CONTACT_339564], iron burden 
and continuous iron intake (Cappellini et al 2006).
2.The recruitm ent of chelation of naïve patients has been much slower than anticipated due 
to the global availability  of chelation therapi[INVESTIGATOR_339530]. Through recent 
interactions with Health Authorities, it has been discussed and agreed that the sample size 
for chelation naïve patients has been reduced to reflect the modification of primary  
endpoints. At least of 96 chelation naive patients are planned to be enrolled instead of 120 
patients. This lower sample size will allow to obtain 76% power at a one -sided 5% level of 
significance for showing superiority  of granule formulation over DT formulation with 
respect to change from baseline after 24 weeks of treatment in serum ferritin, assuming a 
dropout rate of 5%. This power is considered adequate to demonstrate targeted treatment 
effect, and will allow an earlier full recruitment of chelation naïve patients in the study , 
and therefore an earlier disclosure of primary  analy sis. 
3.Eligibility  criteria for the extension phase are being updated in order to allow pati ents who 
have participated and completed 48 weeks of treatment in the core phase and for whom 

[COMPANY_001] Confidential Page 21
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
new formulation is not yet available, to continue in the extension phase if they  derive 
clinical benefit from the study  drug, as confirmed by  [CONTACT_10670].  The c urrent criteria are 
too stringent and would unnecessarily  exclude patients who are benefiting from the study  
drug. During the extension phase patients will continue to follow the protocol including 
any dose modification guidelines and early  withdrawal/disc ontinuation guidelines as they  
did in the core phase of the study .  
Changes to the protocol
Protocol Summary  section - Purpose and rationale has been updated to assess compliance 
at 24 weeks and 48 weeks of treatment.  Population requirements reduced from 240 to 216 
naive and pre -treated patients, and 120 naive patients has been reduced to 96.  Number of 
patients per treatment arm has been reduced from 60 to 48 patients.  I nclusion/exclusion 
criteria have been updated for the extension phase.  Primary  endp oint assessments have 
been modified from [ADDRESS_419995] new primary endpoints and 
sample size.  
Duration of extension phase has been clarified throughout protocol.  
EOT/777 refer to the end of treatment core visit.  This has been updated to reference the 
EOT core visit throughout protocol.
For clarification an y reference to Week 25 is designated as ‘Week 25 visit’ and an y 
reference to 24 weeks of treatment is designated as ‘24 weeks of treatment’ thro ughout 
protocol. 
Rationale for modify ing primary  endpoints to 24 weeks of treatment has been added to 
Sections 2.1. 
Primary  endpoints have been updated throughout protocol (Sections 2.1, 2.2, Table 3 -1, 
Sections 4.2, 10.4.1, 10.4.2, 10.4.4 and 10.8)
Definition of end of study  has been updated to indicate when primary  and final anal yses 
will occur (Section 4.3).
Section “Handling of missing values/discontinuations” for the primary  endpoint has been 
added (Section 10.4.3)
Sample size has been updated throug hout protocol (Sections 2.2, 5.1 and 10.8)
Secondary  objectives/endpoints have been updated throughout protocol (Table 3 -1, 
Sections 10.5, 10.5.1 and 10.5.2) 
Re-aligned the criteria for re -starting dose after omission due to increase in direct 
(conjugated) bilirubin.  Currentl y re-starting criteria (1.5 x UL N) are not aligned with dose 
modification criteria (2.[ADDRESS_419996]).  
Eligibility  criteria for extension phas e has been updated throughout protocol (Sections 5.2, 
5.3, Table 7- 2, Sections 7.1.1, 7.2.2 and [IP_ADDRESS]) 
Section [IP_ADDRESS]:  Updated PK analytical method and provider to allow for a new PK lab to 
be used, as . is no longer the onl y lab participating in PK 
analysis for the study .
Sections 10.2 and [IP_ADDRESS]:  Changed FAS -4 to Safety  Set as FAS-4 has been removed.

[COMPANY_001] Confidential Page 22
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
Sections 10.4.[ADDRESS_419997] of protocol.
Section 13:  Addition of references to support change in primary  endpoints.  
Minor editorial changes have been made throughout protocol.
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red u nderline for insertions.
IRBs/IECs
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (I ECs) and Health Authorities.
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation. 
The changes herein affect the Informed Consent. Sites are required to update and submit for 
approval a revised Informed Consent that takes into account the changes described in this 
protocol amendment.

[COMPANY_001] Confidential Page 23
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
Amendment 4 (15 -Jun -2017)
Amendment rationale 
As of [ADDRESS_419998] been randomized (60 chelation naïve and 118 pre -treated 
patients).  The pre- treatment arm is fully  accrued.
The purpose of this amendment is to include an interim analy sis, allow for paper PRO 
complet ion, and clarify various points to improve site understanding and consistency  in 
implementation of the protocol.
Amendment rationales are as follows:
1.With this amendment, one interim anal ysis has been added to allow for early  analy sis of 
the data if requested by [CONTACT_339565] y.
2.To allow for paper PRO questionnaires use in case of technical issue or malfunctioning of 
the electronic device .
3.To clarify  the completion of the ObsPRO questionnaires for patients who turn 10 y ears 
will continue to be completed b y the caregiver.
4.To clarify  the inclusion/exclusion criteria for the optional extension phase.
5.To clarify  that when either TBIL or direct bilirubin are increased and > [ADDRESS_419999] s 
needs to be checked whether there is also an increase of A LT/AST that meets the 
definition of DILI. 
6.To modify  the dose modification and exclusion criteria for direct bilirubin to enhance 
enrolment and reduce the amount of study  drug interruptions without compromising 
safet y. Man y transfusion -dependent anemia patients have higher baseline level of direct 
bilirubin due to hemoly sis.  Implementation of these less strict exclusion and dose 
modification criteria will not have an y impact on capturing patients with Drug induced 
liver injury  as this only  occurs in case of increase of direct bilirubin > 2x ULN. 
7.To include dose modifications in case of Toxic epi[INVESTIGATOR_59373] (TEN) on Table [ADDRESS_420000] and urine 
protein/creatinine ratio have been re -defined to align with the protocol exclusion and dose 
modification criteria.
11.To clarify the endpoint fo r PK/PD analy ses: notable serum creatinine/creatinine clearance 
‘values’ replaced with ‘events’ as two consecutives lab values need to be above/below the 
range to be considered as notable. 
12.To clarify  the level of blinding of Sponsor and the procedure to m inimize the potential 
impact of treatment knowledge.

[COMPANY_001] Confidential Page 24
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
13.Clarified and corrected VES for optional extension phase (Table 7 -2).
14.For the ObsRo/PRO data anal yses, the term “Baseline” has been removed as the first 
assessment done at Week [ADDRESS_420001] been clarified to be aligned and consistent with the study  objectives
Changes to the protocol
Cover page:  Author update from  to  and from  to  
due to change in Study  Lead and Medical Lead, respectively .
List of Abbreviations –Added abbreviations used in protocol but previously  not included 
in list. 
Added details of interim anal ysis to Protocol Summary  section and Sections 4.1, 4.2 and 
10.7. 
Added consent of patients throughout protocol as patients may  be expected to become age 
of consent during course of study .
Added clarification of the inclusion/exclusion criteria for the optional extension phase 
throughout protocol.
Modified the dose modification and exc lusion criteria for direct bilirubin in Protocol 
Summary  section, Section 5.3 and Table 6-2.
Clarified that when either TBIL or direct bilirubin are increased and > [ADDRESS_420002] s 
needs to be checked whether there is also an increase of ALT/AST that me ets the 
definition of DILI (Table 6- 2). 
Included dose modifications in case of Toxic epi[INVESTIGATOR_59373] (TEN). (Table 6- 2). 
Added procedure to minimize the potential impact of treatment knowledge (Section 6.4.3).
Updated Visit Evaluation Schedule for Ext ension phase to include monthly height and 
weight (Table 7 -2 and Section [IP_ADDRESS]).
Removed Full Anal ysis Set 4 (FAS -4) from Protocol Summary  section and Section 10.1.1. 
Redefined Safety  Set 4 in Protocol Summary  section and Section 10.1.2. 
Added urine pr otein creatinine ratio change from baseline 
to explore exposure -response 
relationships in Protocol Summary  section, Table 3 -1 and Section [IP_ADDRESS].
Notable serum creatinine ‘values’ has been replaced with ‘events’ in Protocol Summary  
section, Table 3 -1 and Section [IP_ADDRESS].
Clarified starting dose as compared to pre- washout dose (Sections 2.3, 4.1 and 6.1.1).
Section 6.1.1:  Clarified need to return empty stick packs and bottles.
Section 6.4.3:  Updated language for treatment blinding.  
Table 7-2:  Clarified VES for ECG and echocardiogram assessments.  Added Urine 
pregnancy  test at EOT visit. 
Section 7.2.2:  Clarified timing of serum ferritin testing for optional extension phase 
eligibility .  

[COMPANY_001] Confidential Page 25
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
Section 7.2.3:  Updated section to allow for paper ObsRO/PRO qu estionnaires use.  
Clarified the completion of the ObsPRO questionnaires for patient after turn 10.  Clarified 
compliance diary  will no longer be collected during the optional extension phase. 
Section [IP_ADDRESS]:  Updated height and weight to align with Exjade prescribing information.
Section [IP_ADDRESS].2:  Clarified schedule for echocardiogram assessments.
Section 8.2.2:  Updated SAE reporting contact [CONTACT_8972].  
Section 8.4:  Updated pregnancy  reporting contact [CONTACT_8972].
Section 9.4:  Updated section to allow for paper PRO questionnaires use.  
Section 10.2: Redefined baseline categories for serum creatinine, creatinine clearance, 
ALT, AST and urine protein/creatinine ratio
Sections 10.5.2: Removal of the term “Baseline for ObsRO/PRO data anal yses. 
Sections 10.5.5, [IP_ADDRESS] and [IP_ADDRESS] and Protocol Summary  section: Clarified PK/PD 
and PK parameters analyses.
Section 14.3:  Clarified dosing based on patient’s body  weight. 
In addition, clarifications were added to correct typographical errors and inconsistenc ies in 
different sections throughout protocol.
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underline for insertions.
IRBs/IECs
A copy of this amende d protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (I ECs) and Health Authorities.
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation. 
The changes herein affect the Informed Consent.  Sites are required to update and submit for 
approval a revised Informed Consent that takes into account the changes described in this 
protocol amendment.

[COMPANY_001] Confidential Page 26
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
Amendment 3 (24 -Aug-2016)
Amendment rationale
At the time of this amendment thirty  nine patients have been randomized.
The purpose of this amendment is as follows:
1.To add an optional extension phase to the existing study . This optional extension phase 
will give the patients who have participated and completed the [ADDRESS_420003] access to the new formulation (granules or FCT) the 
possibility  to extend treatment with deferasirox granules for a maximum of 5 y ears after 
completing the core treatment phase or until there is local access to new formul ation 
(granules or FCT) whichever occurs first. Patients must have demonstrated benefit to 
granules or DT in the core phase, and/or express the wish to continue in the optional 
extension phase on granules in order to start the optional extension phase.
2.To sharpen the clarification of the eligibility criteria related to renal criteria in order to 
promote better Investigator understanding, leading to better adherence and improved renal 
safet y.
3.To provide the investigators with further clarified dose modificat ion guidance for renal 
monitoring with regards to creatinine clearance, increased serum creatinine and 
proteinuria. Clear guidance on how to reinitiate treatment after required dose interruption 
has also been included in order to improve patient safet y.
Inaddition, clarifications were added to correct typographical errors and inconsistencies in 
different sections.
Changes to the protocol
List of Abbreviations: Added FCT (Film-coated tablet)
Glossary  of Terms: Defined new formulation and stickpack.
Protocol Summary : Made distinctions between core phase and the optional extension 
phases in Primary  Objectives, Study  design, Inclusion criteria, Efficacy  assessments, 
Primary  endpoint assessments, Secondary  endpoint assessments, and Other assessments 
Sections.
Protocol Summary : Added details of the optional extension phase to Purpose and 
rationale, Secondary  Objectives, Population, I nclusion criteria, Exclusion criteria, 
Investigational and reference therapy, and Secondary endpoint assessments Sections.
Protocol S ummary : Further clarified laboratory  exclusion criteria
Protocol Summary : Clarified extended FAS, made distinction between core phase and the 
optional extension phase, and added extension phase details in Data anal ysis Section.
Section 1.2.2: Added descrip tion of stick pack and film -coated tablets. Added warm 
porridge as a vehicle for granule administration.
Section 2.1: Provided rationale for giving all patients granule formulation in the optional 
extension phase. Added extension phase purpose.

[COMPANY_001] Confidential Page 27
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
Section 2.2 : Distinguished between the two phases of study  treatment (core and optional 
extension). Provided rationale for including the optional extension phase.
Section 2.3: Distinguished between core and optional extension phases.
Table 3- 1: Added Objective of the optional extension phase.
Section 4.1: Added the optional extension phase design. Updated end of treatment visit 
timelines.
Figure 4 -1: Updated Study  schema.
Section 4.3: Updated definition of end of study .
Section 5.2: Updated inclusion criteria for the optional extension phase.
Section 5.3: Further clarified laboratory  exclusion criteria. Added the optional extension 
phase exclusion criteria.
Section 6.1: Distinguished study  treatment between core and the optional extension 
phases.
Section 6.1.1: Further clarified dosing regimen based on lab values and prior dosing in 
core phase. Added dose adjustment guidelines for optional extension phase. Added warm 
porridge as vehicle for granule administration.
Table 6- 1: Further clarified starting dose.
Section 6.1.2: Updated treatment duration to include the optional extension phase.
Section 6.2.1: Dose adjustment outside or protocol sections now require a written request 
from Investigator.
Table 6
-2: Further clarified dose modifications based on changes in body  weight, serum 
creatinine and/or creatinine clearance, isolated direct (conjugated) bilirubin elevation, 
serum ferritin, urine protein/creatinine ratio, as well as auditory  and ocular disturbances, 
and hy persensitivity  reactions.
Section 6.2.2: Added end of tr eatment guidance for the optional extension phase. Added 
SEC eCRF completion requirement.
Section 6.2.3: Updated follow -up for patients permanently  discontinuing due to adverse 
event or abnormal laboratory  value.
Section 6.3: Updated conmed reporting b y patient.
Section 6.3.1: Clarified timing of PK vs transfusions.
Section 6.3.2: Clarified language for use of other iron chelators.
Section 6.4.2: Made distinction between core and optional extension phases. Added the 
optional extension phase details.
Section 7.1: Made distinction between core and optional extension phases. Added the 
optional extension phase details and updates to assessments during the optional extension 
phase throughout Section 7.1.
Table 7-1: Renamed Visits 777 and 778 and specified table f or core phase of study .
Table 7- 2: Created Table 7 -2 to include the optional extension phase visits and 
assessments. Tables 7- 3 through 7 -5 numbering updated.
Section 7.1.5: Added collection of death details during follow- up period.

[COMPANY_001] Confidential Page 28
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
Section 7.2: Assessment updates for the optional extension phase have been added, 
including removal of stick pack count, removal of ePRO assessments and updated 
schedules for the assessments per Table 7 -2. Patients transitioning from being on DT in 
the core will require additional renal safety  labs per Section [IP_ADDRESS].2.
Section [IP_ADDRESS]: Clarified pregnancy  testing schedule
Table 7-4: PK collections no longer required were removed for clarit y.
Table 7- 5: Added ‘taken pre -dose’ and ‘taken post -dose’ for clarit y.
Section 8: Added c ollection of death details during follow -up period.
Section 8.4: Updated pregnancy  section for the optional extension phase.
Section 10: Clarified study  purpose. Clarified extended FAS and added FAS -4 for the 
optional extension phase throughout section. Cl arified extended Safet y Set and added 
Safety  Set-4 for the optional extension phase throughout section.
Section 10.3: Added duration of exposure in weeks for core phase. The optional extension 
phase will be in months. Clarified prior and concomitant meds.
Section 10.4: Clarified primary objective for core phase.
Section 10.5: Added the optional extension Visit 17. Made distinction between core and 
optional extension phases where needed. Added ‘Summary  tables for AEs will be repeated 
for the optional extensi on phase on the Safety  Set 4. L ab abnormalities will be described 
for the optional extension phase on the Safety  Set 4. Added ‘matching’ to log -transformed 
pre-and post -dose concentrations in Section [IP_ADDRESS].
Table 10- 2: Updated definition of notable wei ght ranges.
Section 10.6: Updated ‘Other safet y data’ section. Distinguished between assessments for 
core and optional extension phases.
Section [IP_ADDRESS]: Serum ferritin during the optional extension phase added.
Table 14- 3: Corrected body  weight ranges.
Table 14- 4: Corrected body  weight ranges.
In addition, clarifications were added to correct t ypographical errors and inconsistencies in 
different sections.
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underline for insertions.
IRBs/IECs
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (I ECs) and Health Authorities.
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation.
The changes herein affect the Informed Consent. Sites are required to update and submit for 
approval a revised Informed Consent that takes into account the changes described in this 
protocol amendment.

[COMPANY_001] Confidential Page 29
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
Amendment 2 (15-Jun -2016 )
Amendment rationale
At the time of this amendment [ADDRESS_420004] been randomized.
The purpose of this amendment is:
1. To allow the sites in Egypt to use a local laboratory  instead of central laboratory  for the 
analysis of safety  required in this trial and to exempt patients’ enrolled in Egy pt from the 
collection of PK samples. This exemption is granted to Egy pt due to national restriction on 
export of any  biological samples out of Egy pt.
2.To clarify  the inclusion criteria #[ADDRESS_420005] typographical errors and inconsistencies in 
different sections.
Changes to the protocol
Protocol Summary : inclusion criteria and secondary  endpoint assessments.
Section 2.2: added exemption to collect PK samples in Egy pt.
Section 5.2: Clarify  inclusion criteria # 2 for [LOCATION_009].
Table 6- 2: Added laboratory  testing will be done in a local laboratory  forEgypt.
Section [IP_ADDRESS]: Added laboratory  testing will be done in a local laboratory  for Egy pt.
Section 7.2.2: Added laboratory  testing will be done in a local laboratory  for Egy pt.
Section [IP_ADDRESS]: Added local laboratory  will be used in Egy pt for hematolo gy, clinical 
chemistry  and urinal ysis.
Section [IP_ADDRESS]: added exemption to collect PK samples in Egy pt.
Section 9.3: added only  safet y samples will be collected in Egypt.
Section 9.4: added data for laboratories sampling will be processed locally sites in Egypt.
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underlined for insertions.
IRBs/IECs
A copy of this amended protocol will be sent to the Institut ional Review Board 
(IRBs)/Independent Ethics Committee (I ECs) and Health Authorities.
The changes described in this amended protocol are non-substantial and do not require IRB/IEC 
approval prior to implementation.

[COMPANY_001] Confidential Page 30
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
Amendment 1 (01-Dec -2015)
Amendment ration ale
At the time of this amendment one patient has been randomized.
The purpose of this amendment is as follows:
1.Expand the study  population by  [CONTACT_339566] [ADDRESS_420006] prior history  of iron chelation treatment in addition to the 
120 chelation naïve patients originally planned, which would allow the continuation of the 
study  if the recruitment of chelation naïve patients becomes challenging to complete in a 
reasonable timeframe.
2.Modify  the sec ondary  objectives:
a.Revised sparse PK sampling schedule to reduce required blood draws and 
extensive/overnight hospi[INVESTIGATOR_4408] s in this pediatric population to improve feasibility  of 
study .
b. Addition of new objective to evaluate the change in serum ferritin in both populations 
(chelation naïve and pre- treated chelation patients)
3.In order to optimize the patient safety and the toxicity monitoring, eligibility criteria and 
the management guidelines for cardiac and hepatic toxicity  have been revised. I n addition 
pregnant and nursing (lactating) women have been included as exclusion criteria in 
alignment with the prescribing Exjade information.
4.The amendment also provides the investigators with modified dose modification rules for 
hepatic toxicity  management guideli nes. Specific work
-up guidelines for potential Drug 
Induced Liver Injury  (DILI) cases has been added to the protocol, the dose modification 
rules as well as the follow -up evaluations for hepatic toxicities have also been updated 
accordingl y.
5.ePRO assessment schedule has been updated.
6. Clarification to the concomitant medications and contraception as detailed below:
a.Guidance was updated on the use of contraception, the sentence included in the 
exclusion criteria section regarding the definition of “not of chi ld-bearing potential” 
has been removed as it was not appropriate to pediatric population but to menopause 
or post -sterilization women.
b.Guidance was updated regarding the concomitant administration of deferasirox with 
CYP3A4, CYP1A2 and CYP1A2 substrates that have a narrow therapeutic index in 
alignment with the prescribing Exjade information
7.Statistical methods and data anal ysis section has been updated in alignment with the 
updated PK sampling and the inclusion of I CT pre -treated patients.
8.Additional guida nce for iron chelation pre -treated patients starting dose has been added as 
Appendix 14.1.
9. Definition of a light meal added as Appendix 14.2.
In addition, clarifications were added to correct typographical errors and inconsistencies in 
different sections.

[COMPANY_001] Confidential Page 31
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
Changes to the protocol
Changes to List of Tables
Renumbered Table [ADDRESS_420007] of Abbreviations
Updated to follow abbreviations used in protocol
Changes to Protocol summary
Purpose and rationale, p rimary  and secondary  objectives, study  design, population, 
inclusion and exclusion criteria, secondary  endpoint assessments, other assessments and 
data anal ysis updated
Changes to Section 1.2.2 Overview of deferasirox granules
Reference to Appendix 14.2 ad ded
Changes to Section 2.1 Study  rational and purpose
Purpose of the study  updated
Changes to Section 2.2 Rationale for the stud y design
Iron chelation pre -treated patient population included
Stratification updated
Changes to Section 2.3 Rationale for dose and regime selection
Guidance for the stud y starting dose for the different population (naïve versus iron 
chelation pre -treated patients) included and allowed dose adjustments included
Changes to Section 3 Objectives and Endpoint
Primary  and Secondary  objectives and endpoints updated
Changes to Section 4 Study  Design.1 Description of study  design
Inclusion of a washout period during screening period for those iron chelation pre -treated 
patients.
Stratification updated
Guidance for the stud y starting dose f or the different population (naïve versus iron 
chelation pre -treated patient) included
Changes to Section 5.1 Patient population
Removing the sentence: Patient must be iron -chelation naïve.
Iron chelation pre -treated patient population included
Changes to Section 5.2 Inclusion criteria
Criterion #2 has been updated to include Iron chelation pre- treated patient population
Criterion #3 has been updated to include PRBC clarification for pediatric population
Changes to Section 5.3 Exclusion criteria
Criterion # 3 has been updated to exclude a lanine/aspartate transaminase (ALT/AST) > 
3.[ADDRESS_420008],
Criterion #4 is no longer applicable to be aligned with the updated patient population

[COMPANY_001] Confidential Page 32
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
Criterion #15 has been updated to clarify  the definition of females of child bearing , and 
effective contraception language has been moved to Section [IP_ADDRESS].4.
Added criterion #17 to exclude pregnant and nursing (lactating) women.
Added criterion #[ADDRESS_420009] (conjugated) bilirubin >1.5 x UL N
Added criterion #19 to exclude any  patient with history  or current diagnosis of cardiac 
disease
Changes to Section 6.1 Dosing regimen
Inclusion of a washout period during screening period for those iron chelation pre -treated 
patients.
Guidance for the stud y starting dose for the different population (naïve versus iron 
chelation pre -treated patient) and dose adjustment allowances added
Changes to Section 6.2 Dose modifications
Inclusion of a dose adjustment guideline Table 6 -2 instead of text. I n addition, inclusion of 
hepatic dose modification wording in the table.
Added new Section 6.2.4 Follow up on potential drug -induced liver injury  (DILI) cases
Added new Section 6.2.5 Anticipate risk and safety concerns of the stud y drug
Changes to Section 6.3 Prior and Concomitant medications
Removed guidance to report blood transfusions on concomitant medication CRF (separate 
blood transfusion CRF page available).
Changes to Section 6.3.1 Permitted concomitant therap y requiring caution and/or action
Guidance added related to the use of concomitant administration of deferasirox with 
CYP3A4, CYP1A2 and CYP1A2.
Changes to Section 6.3.2 Prohibited concomitant therap y
Updated as per Exjade prescribing info.
Changes to Section 6.4.2 Treatment assignment or randomization
Stratification upd ated
Changes to Section 6.4.3 Treatment blinding
Removed blinding details
Changes to Table 7 -
1
Include prior chelation assessment
Assessment schedule updated for the SICT and palatability  questionnaires.
Assessment schedule updated for the PK post -sampling . Changes to Section 7.1.1 Screening
Ocular and Audiometry  assessments guidance updated.
Changes to Section 7.1.2 Treatment period
Guidance for the stud y starting dose for the different population (naïve versus iron 
chelation pre -treated patient) included.

[COMPANY_001] Confidential Page 33
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
Changes to Section 7.1.3 End of treatment visit including study  completion and premature 
withdrawal
Section removed and new Section 7.1.4 Withdrawal of consent added to provide 
additional guidance to patients withdrawal
Changes to Section [IP_ADDRESS] Criteria of premature patient withdrawal
Section removed and new Section 7.1.3 Discontinuation of study  treatment added to 
provide additional guidance to patients who discontinued study  treatment
Section [IP_ADDRESS] PK Replacement Policy
Section removed
Changes to Sec tion 7.2.3 Patient/Observer Reported Outcomes
Visits schedule updated for the SI CT and palatability  questionnaires.
Changes to Section [IP_ADDRESS] auditory  and ocular examination
Ocular and Audiometry  assessments guidance updated.
Changes to Section [IP_ADDRESS].2 Clinical chemistry
Creatinine clearance calculation clarified for patients who turn 18 y ears old during the 
study .
Changes to Section [IP_ADDRESS].4 Pregnancy  and assessments of fertility
Guidelines for pregnancy prevention updated
Breastfeeding included as cri teria for exclusion.
Changes to Section [IP_ADDRESS].1 Electrocardiogram (ECG)
Documentation, labeling and storage of ECGs during the study  have been updated.
Changes to Section [IP_ADDRESS].2 Echocardiograph y
Documentation, labeling and storage of echocardiograph y during the study have been 
updated.
Changes to Section [IP_ADDRESS] PK blood sample collection and handling
PK sampling time points updated
Remove of Section [IP_ADDRESS] PK parameters in alignment to the updated PK objective
Changes to Section 7.2.7 Resource utiliz ation
Sentence removed in alignment with the new PK sampling.
Added Not Applicable to this section.
Changes to Section 8.1.1 Definitions and reporting
Severity  of adverse events used in this trial has been clarified.
Changes to Section [IP_ADDRESS] Definitions and reporting
Clarification of severe event.
Changes to Section 8.4 Pregnancies
Pregnancy  reporting and management updated

[COMPANY_001] Confidential Page 34
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
Changes to Section 10.1.1 Full Anal ysis set
Full Anal ysis set updated to include only  ICT naïve patient
Extended Full Analy sis set added to include ICT pre -treated and naïve patients
Updated stratification
Changes to Section 10.1.2 Safety  set
Safety  set updated to include only  ICT naïve patient
Extended Safety  set added to include I CT pre -treated and naïve patients
Changes to Section 10.1.3 Per Protocol set
Per protocol set updated to include only  ICT naïve patient
Changes to Section 10.1.4 Pharmacokinetics Analysis set
Pharmacokinetics Analy sis set updated in alignment with the updated PK sampling
Changes to Section 10.2 Patient demog raphics/other baseline characteristics
Other background data updated to include prior chelation therap y and prior deferasirox 
chelation therap y
Changes to Section 10.3 Treatment (duration of exposure, concomitant therapi[INVESTIGATOR_014], percentage of 
planned dose taken )
Section updated to include extended Safet y set
Changes to Section 10.4 Primary  objective
Primary  objective modified to include only  ICT naïve patient
Changes to Section 10.4.1 Variables and anal ysis set
Updated FAS to FAS -1
Changes to Section 10.4.2 Stat istical methods of analy sis
Updated FAS to FAS -1
Stratification factor updated
Changes to Section 10.4.3 Supportive analy sis
Primary  anal ysis updated to include extended full anal ysis set
Changes to Section 10.5.1 To evaluate both formulations on patients’ satisfaction and 
palatability  using PRO/ObsPRO questionnaires
Extended Full Analy sis set included
Scheduled of assessment for the SI CT and Palatability  questionnaires updated
Changes to Section 10.5.2 To evaluate both formulations on overall safet y, measured by 
[CONTACT_339567] y of adverse events and changes in laboratory values
Extended Safety  set included
Clarified scoring of palatability  questionnaire
Changes to Section 10.5.3 To evaluate compliance using a daily  PRO/ObsPRO questionnaire
Exten ded Full Analysis set included

[COMPANY_001] Confidential Page 35
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
Removed handling of on -treatment AE section
Updated standard descriptive anal ysis section
Changes to Section [IP_ADDRESS] Adverse Events (AEs)
Added summary  of type of AEs to be presented
Added how incidence of AESI  will be summa rized
Changes to Section 10.5.4 Pharmacokinetics
Section updated to include description of and compliance assessment Cmin and Cmax
Changes to Section [IP_ADDRESS] To evaluate pre-dose PK data to support the assessment of 
compliance
Section updated
Remove of Section [IP_ADDRESS] Derivation PK parameters in alignment to the updated PK objective.
Changes to Section [IP_ADDRESS] Description of individual PK concentrations and parameters
Section updated
Changes to Section [IP_ADDRESS] to explore PK/PD relationship
Section updat ed
Remove of Section [IP_ADDRESS] Derivation of optimal PK sampling and trial simulation in 
alignment to the updated PK objective.
Changes to Section 10.6.1 Other safety  data
Extended Safety  set included
Changes to Section [IP_ADDRESS] Vital signs and bod y weight
Added vital signs and weight
Renumbered Table 10 -4 to Table 10- 2 to align with protocol updates
Changes to Section [IP_ADDRESS] Auditory and Ocular assessment evaluations
Added ‘Week’.
Changes to Section 10.7 sample size calculation
Section updated to include the ICT pre -treated patients
Renumbered Table 10 -2 to Table 10-3 to be aligned with protocol updates.
Changes to Section 13 References (Available upon request)
Updated references to align with protocol updates
Changes to Section 14.1 equivalent dose guidan ce
Guidance added for starting dose for iron pre- treated patient
Examples of light meal added
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underlined for insertions.

[COMPANY_001] Confidential Page 36
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
IRB/IEC/REB A pproval
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (I ECs) and Health Authorities.
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation.
The changes herein affect the Informed Consent. Sites are required to update and submit for 
approval a revised Informed Consent that takes into account the changes described in this 
protocol amendment.

[COMPANY_001] Confidential Page 37
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
1 Background
1.1 Overview of diseas e pathogenesis, epi[INVESTIGATOR_339531]- dependent hemoglobinopathies, such as thalassemia and sickle cell disease (SCD) 
represent a major global health burden, with > 300000 infants born with SCD or thalassemia 
annually  and iron overload is an inevitable clinical consequence for patients with transfusion-
dependent anemias. Iron chelation therap y (ICT) is, therefore, an important and integral part of 
their supportive care.
Deferoxamine (DFO) was the only iron chelator available in the [LOCATION_002] between 1962 
and 2005. DFO is used as a subcutaneous infusion over 8 to 10 hours, 5 to 7 days a week, 
usually  overnight. Many  patients find DFO inconvenient and therefore adherence to this 
treatment is suboptimal. Deferasirox (Exjade®) becam e commerciall y available in the US in 
November 2005. As the first oral iron chelator, Exjade represented a substantial advancement 
in chelation treatment with many  benefits over parenteral therapy , especiall y for pediatric 
patients and their families. Adhe rence to prescribed iron chelation is crucial to reduce or prevent 
iron overload and has been correlated with improved patient survival (Kushner et al 2001 ; 
Borgna -Pi[INVESTIGATOR_339532] 2004, Gabutti and Pi[INVESTIGATOR_99331] 1996). The goal of chelation is to maintain a serum 
ferritin of less than 1000 ng/ml, however most patients live with significantly  higher serum 
fer
ritins due to compliance issues with their chelation therapy ( Standard of Care Guidelines for 
Thalassemia 2012 ). Pediatric patients who are not adequately  chelated risk delay ed sexual 
maturation, retard ed growth, progressive liver and heart disease, and a reduced l
ife expectancy 
(Vichinsky  2008 ).
1.1.[ADDRESS_420010] been described: thalassemia major, thalassemia intermedia 
and thalassemia minor with β
-thalassemia major being the most severe form of the disease. 
Individuals with β-thalassemia major usually  present within the first two years of life with 
severe anemia requiring regular red blood cell (RBC) transfusions. Findings in untreated or 
poorly  transfused patients with thalassemia major are growth retardatio n, pallor, jaundice, poor 
musculature, hepatosplenomegaly , development of masses from extramedullary  hematopoiesis, 
and skeletal changes that result from expansion of the bone marrow. If left untreated, 80% of 
β-thalassemia major patients die within the first 5 years of life due to anemia -related conditions. 
As such, transfusion therapy  remains the mainstay of treatment in β-thalassemia major patients.

[COMPANY_001] Confidential Page 38
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
Transfusions and oral iron chelation therapy  have dramaticall y improved the quality  of life for 
patients w ith severe anemias. Previously  a rapi[INVESTIGATOR_339533], β-
thalassemia is now a chronic disease compatible with a prolonged life expectancy . Today , life 
expectancy  varies between 25 and 55 years, depending on patient compliance with medic al 
treatment, particularl y iron chelation ( Cappellini 2008a ).
1.1.[ADDRESS_420011] common severe monogenic disorders 
worldwide (Weatherall 2010 ). It is caused by [CONTACT_339568] β -globin chain 
of hemoglobin. Erythrocy tes containing hemoglobin S have irregular morphology  and under 
low oxy gen conditions, hemoglobin S poly merizes leading to ‘sickled’ cells. The pathogenesis 
of SCD relates to the shortened lifespan of the sickled er ythrocy tes ([ADDRESS_420012] to 
a lifespan of 120 days for normal ery throcy tes) and adhesion of the sickled ery throcy tes to the 
microvascular endothelium.
Transfusion of red blood cells on a chronic or intermittent basis is therefore important in the 
management of SCD. There is increasing evidence of thevalue of transfusions particularl y in 
reducing the risk of stroke, vaso -occlusive events, acute chest s yndrome, and growth failure in 
pediatric patients with SCD.
However, progressive iron loading and tissue injury  is an inevitable result of frequent blood 
transfusions, although the pattern of hemosiderosis seems different to that described in 
thalassemia. In particular, most iron loading occurs in the liver, with little cardiac iron 
deposition.
Assessment of SCD -specific populations has demonstrated that elevated iron levels are 
associated with an increased frequency  of acute events, hospi[INVESTIGATOR_602], and death (Inati et al 
2011).
1.2 Introduction to investigational treatment(s) and other study  
treatment(s)
1.2.1 Overview  of deferasirox dispersible tablet
The orally  available tridentate iron chelator deferasirox (company  research code ICL670) was 
first approved for the treatment of chronic iron overload due to blood transfusions in adults and 
pediatric patients aged 2 years and older 
in the [LOCATION_002] in November 2005 and is currentl y 
approved for this indication in more than 100 countries. Deferasirox has also been approved in 
more than 60 countries for the treatment of chronic iron overload in patients with non-
transfusion dependent thalassemia aged 10 years and older.
Deferasirox dispersible tablet (DT) is currently  marketed as Exjade®in three dosing strengths 
(125, 250, and 500 mg) and is dosed based on body  weight, and then rounded up or down to the 
nearest whole tablet according to the available strengths. The currently  approved dose range is 
up to 40 mg/kg/day ; the approved starting dose in US is 20 mg/kg/day . Outside the US initial 
daily  doses of 10 or 30 mg/kg may be considered depending on treatment aim and transfusion 
intensity . Deferasirox DT is to be taken once daily  on an empty  stomach, at least 30 minutes 

[COMPANY_001] Confidential Page 39
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
before the next meal. Administration requires dispersion of the tablets in an appropriate amount 
of water, orange juice or apple juice, which take s approximately  3 minutes.
Detailed information on preclinical and clinical evaluation of deferasirox DT is provided in the 
current [Investigators’ Brochure].
1.2.[ADDRESS_420013] been modified. The granule formulation is packaged in aluminum foil 
pouches (alternativel y referred to as stick packs or sachets). The stick packs will be available 
in three dosin g strengths (90, 180 and 360 mg) and is dosed based on body  weight, and then 
rounded up or down to the nearest whole stick pack according to the available strengths.
The granules are of the qualitative and quantitative composition as the film-coated tablet s (FCT) 
that are currently being registered worldwide; both granules and FCT are using the same active 
ingredients at the same doses, and the same excipi[INVESTIGATOR_840] (with exception of the film-coating 
ingredients only  used in the FCT).
The granules should be admi nistered by [CONTACT_339569] a soft food (e.g., yogurt, 
applesauce or warm porridge). The dose should be immediately and completely consumed, and 
not stored for future use. The granules should be taken once a day , preferably  at the same time 
each day, and may be taken on an empty  stomach or with a light meal, (please refer to Appendix 
14.2).
2 Rationale
2.1 Stud y rationale and purpose
The availability  of deferasirox DT 
as a once -daily  oral chelation treatment provided patients 
with a treatment that was a significant improvement over parenteral deferoxamine therap y. This 
was confirmed in studies that measured satisfaction and quality  of life of oral vs. parenteral 
chelation ( Cappellini et al 2006 ; Osborne et al 2007).
Since its approval, oral chelation with deferasirox DT has become well established, with many 
children never experiencing parentera l therap y. However prescribers, patients and their care-
givers report limitations related to the convenience, palatability  and GI tolerability  of the current 
DT formulation, all factors that can play a significant role in the appropriate administration and
compliance with chelation treatment, especiall y in children. (Haghpanah et al 2014) reported 
that 30% of adult patients treated with deferasirox DT complain
 about its undesirable taste. In 
the pediatri c population, undesirable taste is expected to have even more impact on compliance 
then in the adult population. In a survey  of more than [ADDRESS_420014] frequent 
issues were 1. Frequency  of dosing (91%), 2. Side effects of medication (88%) and 3. 
Unpleasant taste (84%) (Tuleu C 2011). Depending on the degree of palatability , compliance 
rates in the pediatric population can range from 11% to 93% ( Tuleu C 2011 ).

[COMPANY_001] Confidential Page 40
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
As it is well established that long -term compliance to chelation therapy  impacts outcome in 
thalassemia and other congenital anemias (Mednick et al 2010 ); improvements in 
convenience, palatabilit y and tolerability of the formulation can bring substantial therapeutic 
benefit to patients.
[COMPANY_001] has developed a new deferasirox formu lation of granules and FCT with the same active 
substance as the deferasirox DT but with modified excipi[INVESTIGATOR_840].
After strength -adjustment, the granule formulation was shown to achieve the same overall 
exposure (AUClast and AUCinf) as the currently  approved DT formulation in single -dose 
healthy  volunteer studies; the peak serum concentrations (Cmax) were approximately  18% 
higher ([CICL670F2104] ). In addition, a food effect study  ([CICL670F2106] ) indicated that the 
granule formulation can be taken either with o
r without a light meal.
The granule formulation of deferasirox, with its improved pharmaceutical properties and 
changes in composition, offers an opportunit y to provide pediatric patients significant 
improvements such as:
the freedom to take deferasirox wi th food (due to the absence of a substantial food effect as 
shown in ([CICL670F2106] ) which obviates the requirement to take the drug on an empt y 
stomach at least 30 minutes before food and therefore allows patients more convenience 
and flexibility  in the scheduling and administration of their dail y dose;
a better tolerability  profile as the exclusion of lactose and sodium laury l sulfate in the new 
formulations alleviates concerns with use in patients with rare hereditary  problems of 
galactose intolerance, the Lapp lactase deficiency , glucose -galactose malabsorption or 
severe lactase deficiency  and may  improve the gastrointestinal tolerability  of deferasirox;
and overall, better convenience/palatabilit y as a granule formulation.
It is for these reasons that [COMPANY_001] will be providing all patients in the optional extension phase 
of the study  with the granule formulation of deferasirox. Those on DT formulation in the core 
phase will switch to the granules in the optional extension phase. The purpose of the study is 
to:
assess the compliance of the granule and the DT formulations in pediatric patients with iron 
overload treated over 24 and 48 weeks using stick 
pack/tablet count, pre-dose 
pharmacokinetic (PK) concentrations and a PRO/ObsRO questionnaire
assess theclinical benefit due to improved compliance of the new formulation by 
[CONTACT_339570] 24 and 48 weeks of 
treatment.
assess Patient / Observer Reported Outcomes (PRO/ObsRO) on palatability  and treatment 
satisfaction, both factors influencing patient compliance and adherence.
assess the safety  of both formulations; renal toxicity  (including renal failure), hepatic 
toxicity  (including hepatic failure) and gastrointestinal hemorrhage will be actively 
monitor ed
examine the pre-and post-dose concentrations of both formulations using sparse PK 
sampling.
explore exposure -response (PK/PD) relationships for measures of safet y and effectiveness

[COMPANY_001] Confidential Page 41
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
assess long term safet y of granules formulation during the optional extension phase 
consisting of up to 5 years for those who complete 48 weeks of core treatment phase
2.2 Rationale for the study  design
This is an open -label, randomized, multicenter, two arm, phase II study . Female and male 
children and adolescents aged ≥ 2 and < 18 years at enrollment with any  transfusion-dependent 
anemia requiring chelation therap y due to iron overload, and a treatment goal to reduce iron 
burden will be enrolled in this study .
Children and adolescents who are chelation naïve ( sample size of at l east96 patients) and those 
previously  treated with iron chelators (maximum sample size of 120 patients) can participate in 
this study . The addition of the previously  chelated patients will allow for an assessment of safet y 
and efficacy  between the two populations.
A washout period of [ADDRESS_420015] to ensure a balanced 
distribution of patients to the two treatment arms on stratify ing factors: age groups (2 to <10 
years (using ObsRO questionnaires) and 10 to <18 y ears (using PRO questionnaires) and prior 
ICT (Yes/No), as described in Section 4.1.
The core treatment duration of 48 weeks is considered sufficient to assess the compliance, 
serum ferritin, safety  and patient / observer reported outcome (PRO/ObsRO) profiles of the two 
formulations.
The primary  objective is to evaluate the impact in ICT naïve patients of these new 
pharmac eutical properties and changes in composition of the granule formulation on patient 
compliance and change in serum ferritin with study  treatment during the core phase, after 24 
weeks of treatment. It is well documented that compliance to chelation therap y is associated 
with clinical outcome (Standards of Care Guidelines for Thalassemia 2012 ). There are both 
direct and indirect methods to assess patient compliance, each method has advantages and 
disadvant ages. Directl y observed therapy , measurement of concentrations of drug or its 
metabolites in blood or urine, and detection or measurement in blood of a biologic marker are 
examples of direct methods of measures. Indirect methods include asking the patients about 
how eas y it is for them to take prescribed medication, performing pi[INVESTIGATOR_10685], collecting patient 
questionnaires, and assessing children’s adherence by [CONTACT_339571] a caregiver 
(Osterberg and 
Blaschke 2005 ). In the absence of a preferred standard of measurement, multiple measures are 
often used to best assess this behavior ( Partridge et al 2002
).
In the core phase, treatment compliance of a pediatric population will be assessed using both 
direct and indirect methods:
Adherence to the quantity  of prescribed medication will be estimated via stick 
pack/tablet 
counts (known more generall y throughout literature as “pi[INVESTIGATOR_10685]”) in the core phase. Pi[INVESTIGATOR_339534] -term variability  in behavior 
within and between subjects, even in a population selected for high levels of compliance. 
The Hawthorne Effect has been observed in studies where patients are aw are that a specific 
behavior is being monitored ( Partridge, et al 2002 ). This phenomenon, in which subjects 
alter a behavior because they are aware that they are under obs
ervation, may be heightened 

[COMPANY_001] Confidential Page 42
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
during pi[INVESTIGATOR_339535]. Such an effect may lead to pi[INVESTIGATOR_339536] b y subjects 
to obscure lapses in their medication adherence ( Rudd, et al 
1989).
Pre-dose PK levels will be measured in all patients at start of treatment and at regular 
intervals during the stud y period in the core phase to support the assessment of compliance. 
[Egy pt: no PK samples will be collected due to restriction on export of samples]
Adher ence with medication regimen instructions will also be recorded via a patient daily  
questionnaire in the core phase. Requiring dail y entries documenting medication behavior 
decreases recall bias from less frequent recording, but may  also overestimate adher ence 
behavior as patients tend to answer in a way  they  judge to be desirable to clinic staff. 
Asking medication consumption questions in a way  that normalizes non -
adherence can 
help mitigate some of this bias ( Osterberg and Blaschke 2005 ). This method may  also be 
subject to less of a Hawthorne Effect, particularly as patients become normalized to 
completing dail y diar y entries, which include questions about medication consumption.
The clinical benefit related to improved compliance will be assessed by [CONTACT_339572]. The starting dose and the dose adjustment considerations in this study  will 
take into account that the therapeutic goal is reduction of iron burden (as opposed to 
mainten ance of iron burden). In clinical practice it is recommended to dose adjust for efficac y 
after 3 months of treatment based on trends in serum ferritin. A treatment duration of 48 weeks; 
with dose regimens aimed to reduce iron burden provides sufficient time to determine if 
improved compliance to treatment is leading to greater reduction in serum ferritin from baseline. 
A linear relationship between changes from baseline at 24 and 48 weeks of treatment has been 
established based on a pool of representative randomized studies (CICL670A0105, 
CICL 670A0107, CICL 670A0109 and CICL 670A2206) with Serum ferritin available at [ADDRESS_420016] a 
self-reported adherence to deferasirox DT of 97% after one year. Therefore it can be assumed 
that the 6 month reported adherence will be very similar and can serve as a surrogate 
(Trachtenberg 2011).  The rationale is also based on the demonstrated relationship of efficacy 
as assessed by [CONTACT_339564], iron burden and continuous iron intake 
(Cappellini et al 2006 ).
In addition treatment satisfaction and palatability  will be measured via age adapted validated 
questionnaires in the core phase.
Overall safet y will be addressed by [CONTACT_339573], 
including renal toxicity , hepatic toxicity , and gastrointestinal hemorrhage; which will be 
activel y monitored and changes in laboratory  values. Additional safet y assessments 
will include 
vital signs, physical exam, ophthalmological, audiometric, cardiac, and growth and 
development evaluations. Time points for assessing laboratory  values have been chosen based 
on the current labeling information of deferasirox DT (Exjade®) in order to be as close as 
possible to the daily  practice in administering the study  treat ment. The rationale to include the 
optional extension phase is to collect additional safet y data about the new formulation and to 
provide access to the new deferasirox formulation (granules) to patients for continuity  of 
treatment. This optional extension phase will give the patients who have participated and 
completed the [ADDRESS_420017] access to the new 

[COMPANY_001] Confidential Page 43
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
formulation (granules or FCT) the possibility  to extend treatment with deferasirox granules until 
there is local access to the new formulation (granules or FCT) or up to [ADDRESS_420018] demonstrated benefit to granules or 
DT in the core phase, and/or express the wish to continue in the optional extension phase on 
granules in order to start the optional extension phase.
2.3 Rationale for dose and regimen selection
Deferasirox is available in three dosing strengths (125, 250 and 500 mg for DT and 90, 180 and 
360 mg for the granule formulation). For each patient the dose is calculated by [CONTACT_339574]’s weight, and then rounded up or down to the nearest tablet/stick pack 
configuration. This dosing paradigm is consistent with how deferasirox DT (Exjade®) has been 
developed with regard to safet y and efficacy.
Children and adolescents aged ≥ 2 and < 18 years at enrollment in the core phase with any 
transfusion-dependent anemia requiring chelation therap y due to iron overload will be 
randomized to either the DT or the granules treatment arm in a 1:[ADDRESS_420019] naïve patients randomized to the study  will use either the DT starting dose of20 
mg/kg/day ; which is the only approved starting dose in the US, and the commonly  
recommended starting dose in other countries, or the equivalent strength-adjusted granules 
starting dose of 14 mg/kg/day .
The deferasirox granules dose is strength -adjusted due to a higher bioavailability  of this 
formulation compared to the dispersible tablets.
All ICT pre-treated patients will use a deferasirox DT or an equivalent strength -adjusted 
granules starting dose corresponding to their closest pre-washout dose, please refer to Appendix 
14.1. Further dose adjustment, based on serum ferritin levels, safety  paramete rs and 
investigator’s judgment, will be allowed. For I CT naïve patients at study  entry the dose can be 
adjusted after [ADDRESS_420020] pre-
treated patients, the dose should be 
adjusted if necessary  every  3 months.
In the optional extension phase, all patients will be provided the deferasirox formulation 
(granules). Patients on DT formulation during the core phase will receive the equivalent 
strength -adjusted granules dose corresponding to the last DT dose in the core phase taking dose 
adjustment guidelines into account (please refer to Table 6-2and Appendix 14.1). Patients in 
granules during the core phase will continue on the same dose as was given at the end of the 
core phase taking dose adjustment guidelines into account. Please refer to Table 6-2as 
applicable.
3 Objectives and endpoints
Objectives and related endpoints are described in Table 3
-1below.

[COMPANY_001] Confidential Page 44
Amended Pr otocol Version 06 (Clean) Protocol No. CICL670F2202
Table 3-1 O bjectives and related endpoints
Objective Endpoint Anal ysis
Primary
●To evaluate both formulations on patient 
compliance, using stick pack/tablet count over [ADDRESS_420021] naïve patients during core 
phase
●To evaluate the change from baseline in serum 
ferritin  after [ADDRESS_420022] naïve patients during the core 
phase●Compliance measured by [CONTACT_339552]/tablet count  
over 24 weeks of treatment (i.e. assessed at week 25 
visit)
●Change from baseline in serum ferritin after 24 
weeks of treatment (i.e. serum ferritin at week 25 
visit)Refer to Section 10.4
Refer to Section 10.4
Secondary  (Core phase )
To evaluate both formulations on change in serum 
ferritin and compliance in ICT naive patients, after 48 
weeks of treatment●Compliance measured by [CONTACT_339552]/tablet count 
after 48 weeks of treatment
●Change from baseline in serum ferritin  after [ADDRESS_420023] n aïve and pre -treated patientsChange from baseline in serum ferritin after 24 weeks 
(i.e. assessed at week 25 visit) and 48 weeks of 
treatmentRefer to Section 10.5.2
To evaluate both formulations on p atient satisfaction 
and palatability using Patient / Observer Reported 
Outcomes (PRO/ObsRO) questionnairesDomain scores of treatment satisfaction and 
palatability over timeRefer to Section 10.5.3
To evaluate both formulations on overall safety Overall safety, as measured by [CONTACT_339575] (including active 
monitoring for renal toxicity; including renal failure, 
hepatic toxicity; including hepatic failure, and 
gastrointestinal hemorrhage), and changes in 
laboratory values from baseline (serum creatinine, 
creatinine clearance, ALT, AST, RBC and W BC). In 
addition, vital signs, physical, ophthalmological, 
audiometric, cardiac, and growth and development 
evaluations will be assesse d.Refer to Section 10.5.4
To evaluate compliance using a daily PRO/ObsRO 
questionnaireRate of dosing instructions deviations (doses missed / 
not taken at the same time every day)Refer to Section 10.5.5

[COMPANY_001] Confidential Page 45
Amended Pr otocol Version 06 (Clean) Protocol No. CICL670F2202
Objective Endpoint Anal ysis
To evaluate pre -dose PK data to support the 
assessment of compliancePre-dose deferasirox concentrations in all patients 
[except Egypt ]at Weeks 1, 3, 5, 9, 13, 17, 21, 25, 29, 
33, 37, 41 and 45 visits(13 samples) Refer to Section [IP_ADDRESS]
Post-dose data to be analyzed along with pre-dose 
PK dataPost-dose deferasirox concentrations between [ADDRESS_420024] -dose at Weeks 5 and 9 (2 s amples)Refer to Section [IP_ADDRESS]
To explore exposure -response relationships for 
measures of safety and effectiveness Serum creatinine change from baseline, notable 
serum creatinine event, serum creat inine clearance 
change from baseline and notable serum creatinine 
clearance events, urine protein creatinine ratio 
change from baseline and serum ferritin change from 
baseline, in relationship to pre -and post- dose 
deferasirox concentrations.Refer to Section [IP_ADDRESS]
Secondary  (Optional Extension phase)
To assess additional safety data about new 
formulation (granules) in pediatric populationOverall safety, as measured by [CONTACT_339576] a dverse events (including active 
monitoring for renal toxicity; including renal failure, 
hepatic toxicity; including hepatic failure, and 
gastrointestinal hemorrhage), and changes in 
laboratory values from baseline (serum creatinine, 
creatinine clearance, ALT, AST, RBC and W BC). In 
addition, vital signs, physical, ophthalmological, 
audiometric, and growth and development 
evaluations will be assessed.Refer to Section 10.5.4 and Section 10.6.1

[COMPANY_001] Confidential Page 46
Amended Protocol Version 06 (Cl ean) Protocol No. CICL670F2202
4 Study  design
4.1 Description of study  design
This is a randomized, open -label, multicenter, two arm, phase II study  to evaluate treatment 
compliance and change in serum ferritin over time of a deferasirox granule formulation and a 
deferasirox DT formulation in children and adolescents aged ≥ 2 and < 18 years at enrollment
with any transfusion -dependent anemia requiring chelation therap y due to iron overload, and 
having a treatment goal to reduce iron burden as measured b y serum ferritin.
It is a pre -requisite for the patient to provide written consent/assent to participate in this study . 
Consent will be obtained from patients, parent(s) or legal guardians. Investigators will also 
obtain patient’s consent/assent according to local guidelines. This must be in place prior to 
performing any study -related procedures or assessments, including those described at the 
screening visits ( Table 7 -1).
As described in Figure 4 -
1, a screening period (from Day  -21) will be used to asse ss eligibility 
of patients and will consist of two visits at least [ADDRESS_420025] be available and reviewed by [CONTACT_093]. Patients whose 
eligibility  is confirmed will be enrolled and any  current chelation therapy  will be discontinued 
to undergo a 5-day chelation washout period (only  applicable to patients previously  treated with 
iron chelation therapy) prior to commencing a 48-week randomized treatment period with either 
deferasirox DT (taken as per local label) or deferasirox granule formulation (taken with or 
without a light meal) beginning on Day  1.    
All participants who have completed the co re study  as per protocol and who do not have local 
access to the new formulation (granules or FCT) have the option to continue to the optional 
extension phase of the study  where they will be provided with granules until there is local access 
to the new formulation (granules or FCT) or up to [ADDRESS_420026] demonstrated benefit to granules or DT in the core phase, 
and/or express the wish to continue i n the optional extension phase on granules in order to start 
the optional extension phase.
An end of treatment visit (EOT) will occur within [ADDRESS_420027] dose of study  drug.
For patient s participating in the optional 
extension phase, end of stud y and safet y follow-
up will be performed within [ADDRESS_420028] dose was given in the optional extension phase.
For patients not participating in the optional extension phase, end of stud y and safet y
follow up will occur within [ADDRESS_420029] dose was given in the core phase.
Randomization will be stratified using an interactive voice/web response system (IVRS/I WRS). 
The stratification will be defined by [CONTACT_164737] (2 to <10 years, 10 to <18 years) and by [CONTACT_339577] (Yes/No) .Details on stratification will be outlined in the study  manual provided by [CONTACT_339578].

[COMPANY_001] Confidential Page 47
Amended Protocol Version 06 (Cl ean) Protocol No. CICL670F2202
At the start of treatment, ICT naïve patients will receive either deferasirox DT 20 mg/kg once 
daily  or deferasirox granules 14 mg/kg once da ily.
All ICT pre-treated patients will use a deferasirox DT or an equivalent strength -adjusted 
granules starting dose corresponding to their closest pre-washout dose, please refer to Appendix 
14.1.  
Study  treatment should be administered by [CONTACT_339579] b y all patients aged between 10 and <[ADDRESS_420030] DT dose in the core phase taking dose adjustment guidelines into 
ac
count (please refer to Table 6-2and Appendix 14.1). Patients in granules during the core 
phase will continue on the same dose as was given at the end of the core phase taking dose 
adjustment guidelines into account. Please refer to Table 6-[ADDRESS_420031] dose of study  
treatment, at which time all of the assessments listed for the end of treatment (Visit 777 (for the 
core) or Visit 779 (for the optional extension)) will be performed.
All patients, regardless if they discontinue the study  treatment early or per protocol, will be 
contact[CONTACT_15025] y evaluations for [ADDRESS_420032] dose of study treatment.
One interim analy sis has been added to allow for early  analysis of the core phase data if 
requested b y the health authority . 
Figure 4-1 Study  schema

[COMPANY_001] Confidential Page 48
Amended Protocol Version 06 (Cl ean) Protocol No. CICL670F2202
4.[ADDRESS_420033] completed a minimum of 12 weeks of 
treatment exposure or discontinued from treatment core phase at the time of the cut-off date 
will be included in the interim anal ysis (Section 10.7).
The cut-off for the primary  analysis will be [ADDRESS_420034] completed their 48 week study 
treatment in the core phase including safet y follow -up (if applicable).
4.[ADDRESS_420035] completed the 
treatment phase of the optional extension phase (up to 305 weeks) including the safet y follow -
up period (30 day s after treatment discontin uation).
4.4 Early study  termination
The study  can be terminated at any  time for any  reason by  [CONTACT_5343]. Should this be necessary, 
the patient should be seen as soon as possible and the same assessments should be performed 
as described in Section 7for a prematurel y withdrawn patient. The investigator may be 
informed of additional procedures to be followed in order to en
sure that adequate consideration 
is given to the protection of the patient’s interests. The investigator will be responsible for 
informing IRBs and/or ECs of the earl y termination of the trial.
4.5 Rationale for Public Health Emergency  mitigation procedures
During a Public Health emergency  as declared by  [CONTACT_6586] i.e. pandemic, 
epi[INVESTIGATOR_6519], mitigation procedures to ensure participant safety  and trial integrit y 
are listed in relevant sections. Notification of the Public health emergency  should be discussed 
with [COMPANY_001] prior to implementation of mitigation procedures, and permitted/approved by 
[CONTACT_6588].
[ADDRESS_420036] naïve and pre -treated (at least [ADDRESS_420037] naïve and up to 120 pre -treated) male and 
female children and adolescents aged ≥ 2 and < 18 years at enrollment with any transfusion-
dependent anemia requiring chelation therapy  due to iron overload, and a treatment goal to 

[COMPANY_001] Confidential Page 49
Amended Protocol Version 06 (Cl ean) Protocol No. CICL670F2202
reduce iron burden will be included in this study. At least 96 (48 per treatment arm) patients 
should be iron chelation naïve.
The investigator or designee must ensure that only patients who meet all the following inclusion 
and none of the exclusion criteria are offered enrollment in the study .
5.[ADDRESS_420038] to meet allof the following criteria at screening 
Visit 1 and 2 unless otherwise specified:
1.Written informed consent/assent before any study -specific procedures. Consent will be 
obtained from parent(s) or legal guardians. Investigators willalso obtain consent/assent of 
patients according to local guidelines.
2.Male and female children and adolescents aged ≥ 2 and < 18 y ears. [[LOCATION_009]: Male and 
female children and adolescent aged ≥ 2 and < 18 years old, however children aged ≥ 
2 and ≤ 6years 
can be enrolled only when deferoxamine treatment is contraindicated 
or inadequate in these patients as per investigator decision . Applicable to core phase 
only. Once in the core phase patients can turn 18 years and still be considered eligible, 
also for pa rticipation in the optional extension phase.
3.Any transfusion -dependent anemia associated with iron overload requiring iron chelation 
therap y and with a history  of transfusion of approximately  20 PRBC units and a treatment 
goal to reduce iron burden (300mL  PRBC = 1 unit in adults whereas 4 ml/kg PRBC is 
considered 1 unit for children).
4.Serum ferritin > 1000 ng/mL , measured at screening Visit 1 and screening Visit 2 (the mean 
will be used for eligibility  criteria).
5.Patient has to have participated and completed the 48 weeks core phase treatment as per 
protocol (For optional extension phase eligibility  only ).
5.3 Exclusion criteria
1. Creatinine clearance below the contraindication limit in the locally  approved prescribin g 
information (using Schwartz formula) at screening visit 1 or screening visit 2.
2. Serum creatinine > 1.[ADDRESS_420039] at screening Visit 1 or screening Visit 2.
3.ALT and/or AST > 3.[ADDRESS_420040] at screening visit 1 or screening visit 2.
4.(Criterion no longer applicable, removed as part of Amendment 1): Prior iron chelation 
therap y
5.Liver disease with severity of Child -Pugh class B or C.
6.Significant proteinuria as indicated by a urinary  protein/creatinine ratio > 0.5mg/mg in a 
second morning urine sample at screening Visit 1 or screening Visit 2.
7.Patients with significant impaired gastrointestinal (GI) function or GI disease that may 
significantl y alter the absorption of oral deferasirox (e.g. ulcerative diseases, uncontrolled 
nausea, vomiting, diarrhea, malabsorption sy ndrome , or small bowel resection).
8.Clinical or laboratory  evidence of active Hepatitis B or Hepatitis C (HBsAg in the absence 
of HBsAb OR HCV Ab positive with HCV RNA positive).

[COMPANY_001] Confidential Page 50
Amended Protocol Version 06 (Cl ean) Protocol No. CICL670F2202
9.Patients with psychiatric or addictive disorders which prevent them from giving their 
informed consent or undergoing any of the treatment options or patients unwilling or unable 
to comply  with the protocol.
10.Patients with a known history  of HIV seropositivity  (Elisa or Western blot).
11.History  of malignancy  of any organ system, treated or untreated, within the past [ADDRESS_420041] 
medical therap y, systemic disease (cardiovascular, renal, hepatic, etc.).
15.Female patients of childbearing potential (e.g. are menstruating) who do not agree to 
abstinence or, if sexually  active, do not agree to the use of contraception as defined in 
Section [IP_ADDRESS].4.
16.For prohibited medication please refer to Section 6.3.2
17.Pregnant or nursing (lactating) women
18.Direct (conjugated) bilirubin >2 x UL N at screening visit 1 or screening visit 2.
19.History  or current diagnosis of cardiac disease indicating significant risk of safet y for 
patients participating in the study  such as uncontrolled or significant cardiac disease, 
including an y of the following:
●Clinically  significant (s ymptomatic) cardiac arrh ythmias (e.g., sustained ventricular 
tachycardia, and clinically significant second or third degree AV block without a 
pacemaker).
20.Local access to new formulation (granules or FCT) is available (For optiona l extension 
phase eligibility  only ).
6 Treatment
6.1 Stud y treatment
The sponsor will provide the following open label study  medication:
Deferasirox DT will be provided as 125 mg, 250 mg and 500 mg dispersible tablets for 
oral use (during core phase).
Deferasiro x granules will be provided as stick packs containing 90 mg, 180 mg and 360 
mg granules for oral use (during core and optional extension phase).
6.1.1 Dosing regimen
Having completed the Screening period (including the 5
-day chelation washout period for 
patients previously  treated with iron chelators), eligible patients for the core phase will be 
randomized to one of the following Treatment Arms in a ratio of 1:1:
Treatment Arm 1 with deferasirox DT
Treatment Arm 2 with deferasirox granules

[COMPANY_001] Confidential Page 51
Amended Protocol Version 06 (Cl ean) Protocol No. CICL670F2202
At the start of treatm ent, ICT naïve patients will receive either deferasirox DT 20 mg/kg once 
daily  or deferasirox granules 14 mg/kg once daily . All ICT pre-treated patients will use a 
deferasirox DT or an equivalent strength -adjusted granules starting dose corresponding to th eir 
closest pre -washout dose, please refer to Appendix 14.1 .
When creatinine clearance at study  start is ≥40ml/min and <60 ml/min (where locall y 
applicable), starting dose needs to be reduced by  50%. Thi s means for treatment naive patients 
that they will need to start at 10 mg/kg for DT and 7 mg/kg for granules. For pretreated patients, 
they will need to start at 50% of the pre-washout dose when creatinine clearance ≥40ml/min 
and <60 ml/min during at least one screening visit. For patients with an already  existing reduced 
creatinine clearance (≥40ml/min and <60 ml/min before study  start), a dose reduction of 50% 
is only  necessary  when this was not already  performed.
In the optional extension phase, all patients will be provided with the granules at visit 17. 
Patients on DT formulation during the core phase will receive the equivalent strength- adjusted 
granules dose corresponding to the last DT dose in the core phase taking dose adjustment 
guidelines into account (please refer to Table 6-2and Appendix 14.1). Patients in granules 
during the core phase will continue on the same dose as was given at the end of the core phase 
taking dose adjustment guidelines into account. Please refer to Table 6 -2as applicable.
For each patient the dail y dose is calculated b y the physician based on the patient’s actual bod y
weight, and then rounded up or down to the nearest whole tablet/stick pack according to the 
available strengths of deferasirox formulations (125 mg, 250 mg and 500 mg for the DT and 90 
mg, 180 mg and 360 mg for the granules, see Appendix 14.1 ).
Recommended dose adjustment for better treatment effects based on serum ferritin levels and 
investigator’s judgment, will be allowed for ICT naïve patients after [ADDRESS_420042] pre-treated patients every  3 months. The dose adjustments will be performed in 
steps of 5 -10 mg/kg/day  for deferasirox DT or in steps of 3.5 -7.0 mg/kg/day  for deferasirox 
granules.
During the optional extension phase, dose adjustments in steps of 3.5 to 7.0 mg/kg for 
deferasirox granules are also only  allowed every  3 months.
Dose adjustments based on safet y are allowed at any time point in the study . The maximum 
dose of deferasirox DT will be 40 mg/kg/day  and the maximum dose of deferasirox granules 
will be 28 mg/k g/day .
The starting dose and the dose adjustment considerations must take into account that the 
therapeutic goal is reduction of iron burden (as opposed to maintenance of iron burden).
The investigator should instruct the patient and/or the legal patient’s representative to take the 
study  treatment as prescribed. All doses planned and prescribed to the patient and all dose 
changes, including the reasons for change, during the study  must be recorded in the electronic 
Case Report Form ( eCRF ).
During the regul ar study  visits, the investigator or pharmacist will dispense to the patient and/or 
legal patient’s representative, an appropriate number of deferasirox tablets / stick packs 
depending on the patients calculated dose and Treatment Arm assignment. The numbe r of 
tablets / stick packs of each strength dispensed will be recorded in the Study Drug Dosing Log. 
Each time the deferasirox study  treatment is dispensed to the patient and/or legal patient’s 

[COMPANY_001] Confidential Page 52
Amended Protocol Version 06 (Cl ean) Protocol No. CICL670F2202
representative, the investigator will provide detailed instruc tions on how to prepare and 
administer the dose. Patients / caregivers will be instructed to take / to administer the assigned 
amount of study  drug and to return all unused study  medication including empty  stick packs 
and bottles at their next visit. Study medication returned at each visit will be counted and unused 
study  medication will be recorded by [CONTACT_093]/ pharmacist involved in the study . Drug 
accountability  will be noted by  [CONTACT_339580].
Medication labels will comply  with the legal requirements of the countries where the study  is 
implemented and be printed in the local language. They  will supply  no information about the 
patient. Only the patient identifier will be entered on the medication label by [CONTACT_339581]. The storage 
conditions for study  drug will be described on the medication label.
Patients randomized to Treatment arm [ADDRESS_420043] 30 minutes before the next meal. The patient will disperse the required number 
of deferasirox tablets in an appropriate amount of water, apple juice or orange juice. Gentle 
stirring should be applied and continued until the tablets are fully  disintegrated, which takes 
approximately  1 to 3 minutes. Immediatel y, after full disintegration of the tablets, the entire 
content of the glass should be swallowed.
Patients randomized to Treatment arm 2 should administe r the granules by [CONTACT_339582] a soft food (e.g., yogurt, applesauce or warm porridge). The dose should be immediatel y 
and completely  consumed, and not stored for future use. The granules should be taken once a 
day, preferabl y at the same time each day, and may be taken on an empty  stomach or with a 
light meal.
It is recommended that the doses be timed such that they occur at almost the same time each 
day. For example, if the patient took the study  medication at 8:00AM on first day of treatme nt, 
the subsequent dose would also be taken at approximately  8:00AM on the next day , and so on.  
Table 6-1 Dose and treatment schedule
Study  
treatmentsPharmaceutical form 
and route of 
administration Starting Dose*Dose 
adjustment 
stepsMaximum 
dose Frequency
Deferasirox DT Dispersible tablets, 
p.o.20 mg/kg/day 
(10 mg/kg/day 
when creatinine 
clearance ≥ 40 
and <60 ml/min)+/- 5-10
mg/kg/day40 mg/kg/day Once daily
Deferasirox 
granulesGranules, p.o. 14 mg/kg/day (7 
mg/kg/day 
when creatinine 
clearance ≥ 40 
and <60 ml/min)+/-3.5-7.0
mg/kg/day28 mg/kg/day Once daily
*Iron chelation naïve patients. For all iron chelation pre -treated patients see Section 6.1.1 and Appendix 14.2
for guidance.

[COMPANY_001] Confidential Page 53
Amended Protocol Version 06 (Cl ean) Protocol No. CICL670F2202
6.1.2 Treatment duration
The total duration of study  treatment during the core phase is 48 weeks. The total duration of 
the core phase is approximately  55 weeks (including the Screening, Treatment and Safet y 
Follow -up visits).
The maximum duration of the optional extension phase will be [ADDRESS_420044] access to the new formulation (granules or FCT) the 
possibility  to extend treatment with deferasirox granules until there is local access to the new 
formulation (granules or FCT) or up to [ADDRESS_420045] demonstrated benefit to granules or DT in the core phase, and/or 
express the wish to continue in the optional extension phase on granules in order to start the 
optional extension phase.
6.[ADDRESS_420046] justify  the 
dose change and provide all the supportive clinical andlaboratory  information for complete 
evaluation by [CONTACT_5343]. Any dose adjustment for reasons not included in this section needs to 
be authorized by [CONTACT_5343]. A written reply will be promptly  sent back to the investigator by 
[CONTACT_5343].
Any dose -adjustments for any reason, specified b y the protocol (such as safety, efficacy, other) 
or not, must be recorded on the dosage administration record eCRF together with the reason for 
each dose-adjustment. It is important to keep accurate dose-adjustment records to enab le an 
adequate evaluation of the co -primary  endpoint of compliance.
A summary  of dose adjustment guidelines is presented in Table 6-2.

[COMPANY_001] Confidential Page 54
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
Table 6-2 Criteria for interruption and re -initiation of Deferasirox treatment
Dose modifications for deferasirox
Body weight
Increase/decrease of weight by >10% compared to Visit 
3 (baseline weight) or body weight at last dose 
adjustment due to change in patient’s body weightDose of study medication needs to be adapted using Dosing Table (provided in Appendix 14.2 ). Only when 
weight changes with >10% compared to baseline weight or body weight at last dose adjustment due to 
change in patient’s body weight, dose needs to be adapted. Smaller variations in body weight (<10%) 
during study, does not require adjustments in dose. In this case, baseline body weight can be used to 
calculate correct dose.
Investigations (Renal)
Serum creatinine and/or creatinine clearance
Single increase in serum creatinine ≥33% Maintain dose level and repeat the assessment at next visit as clinically indicated
For pediatric patients:
   -Single increase ≥33% above baseline value (visit 
3/week1) and >ULN
For adult patients:
   -Increases by 33% or more above the baseline (visit 
3/week1) measurement, repeat the serum creatinine 
within 1 week, and if still elevated by 33% or moreDeferasirox dose reduction by 10 mg/kg/day for the DT and by 7 mg/kg/day for the granules is necessary.
If after a dose reduction, a progressive increase in serum creatinine beyond the ULN is observed, a 
treatment interruption is mandated.
If after dose reduction/interruption, resolution of serum creatinine occurs (<33%) at the next study visit and 
within normal limits, dose can be resumed again at 100%. If increase in serum creatinine reoccurs again 
within 2 months according to guidelines above, therapy needs to be reduced to 50% of the last dose.
After 2 months, if the serum creatinine increase does not recur, study medication can be returned to 1 00% 
of the last dose.
Creatinine clearance between 40 and less 60 mL/min
Reduce dose with 50%.
If after dose reduction, resolution of creatinine clearance occurs (>60 ml/min), dose can be resumed again 
at 100%.
Creatinine clearance < 40 mL/min or serum creatinine 
increases > [ADDRESS_420047] be discontinued

[COMPANY_001] Confidential Page 55
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
Dose modifications for deferasirox
Investigations (Hepatic)
Isolated direct (conjugated) Bilirubin elevation
> ULN –[ADDRESS_420048] Maintain dose level
> [ADDRESS_420049] Omit dose with weekly monitoring of LFTsa, or more frequently if clinically indicated, until resolved to ≤ 2.[ADDRESS_420050]:
If resolved in ≤ 14 days, then maintain dose level
If resolved in > 14 days, then dose reduction of 5 or 10 mg/kg/day for deferasirox DT and of 3.5 or 7 
mg/kg/d ay for deferasirox granules.
> 3.[ADDRESS_420051]* Omit dose with weekly monitoring of LFTsa, or more frequently if clinically indicated, until resolved to ≤ 2.[ADDRESS_420052]:
If resolved in ≤ 14 days, then dose reduction of 5 or 10 mg/kg/day for deferasirox DT and of 3.5 or 7 
mg/kg/day for deferasirox granules.
If resolved in > 14 days, then discontinue patient from study drug treatment. The patient needs to be 
monitored weekly (including LFTsa), or more frequently if clinically indicated, until direct (conjugate d) 
bilirubin have resolved to baseline or stabilization over 4 weeks.
> 10.[ADDRESS_420053]* Discontinue patient from study drug treatment
The patient needs to be monitored weekly (including LFTsa), or more frequently if clinically indicated, until 
direct (conjugated) bilirubin have resolved to baseline or stabilization over [ADDRESS_420054] or ALT elevation
> ULN -3.[ADDRESS_420055] Maintain dose level
> 3.[ADDRESS_420056]
For patients with baseline value ≤ 3.[ADDRESS_420057]
For patients with baseline value > 3.0 -5.0 x ULNMaintain dose level. Repeat LFTsaas soon as possible, preferably within 48 -72 hours from awareness of 
the abnormal results; if abnormal lab values are confirmed upon the repeat test, then monitor LFTsa
weekly, or more frequently if clinically indicated, until resolved to ≤ 3.[ADDRESS_420058]
Maintain dose level

[COMPANY_001] Confidential Page 56
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
Dose modifications for deferasirox
> 5.[ADDRESS_420059]
For patients with baseline value ≤ 3.[ADDRESS_420060]
For patients with baseline value > 3.0 -5.0 x ULNOmit dose. Repeat LFTsaas soon as possible, preferably within 48-72 hours from awareness of the 
abnormal results; monitor LFTsaweekly, or more frequently if clinically indicated, until resolved to ≤ 3.[ADDRESS_420061]
If resolved in ≤ 14 days, maintain dose level
If resolved in > 14 da ys, then dose reduction of 5 or 10 mg/kg/day for deferasirox DT and of 3.5 or 7 
mg/kg/day for deferasirox granules.
Maintain dose level. Repeat LFTsaas soon as possible, preferably within 48 -72 hours from awareness of 
the abnormal results; if abnormal la b values are confirmed upon the repeat test, then monitor LFTsa, 
weekly, or more frequently if clinically indicated, until resolved to ≤ 5.[ADDRESS_420062]
> 10.[ADDRESS_420063] Omit dose. Repeat LFTsaas soon as possible, preferably within 48-72 hours from awarene ss of the 
abnormal results; monitor LFTsaweekly, or more frequently if clinically indicated, until resolved to ≤ 
baseline. Then dose reduction of 5 or 10 mg/kg/day for deferasirox DT and of 3.5 or 7 mg/kg/day for 
deferasirox granules.
> 20.[ADDRESS_420064] Discon tinue patient from study drug treatment
Repeat LFTsaas soon as possible, preferably within 48-72 hours from awareness of the abnormal results; 
monitor LFTsaweekly, or more frequently if clinically indicated, until resolved to baseline or stabilization 
over [ADDRESS_420065] or ALT and bilirubin (direct (conjugated) and/or total)
For patients with normal baseline ALT or AST or direct 
(conjugated) bilirubin value:
AST or ALT >3.0xULN combined with direct (conjugated) 
bilirubin >2.[ADDRESS_420066] without evidence of cholestasisc
OR
(Note to study team: If supported by [CONTACT_339583]) For 
patients with elevated baseline AST or ALT or direct 
(conjugated)bilirubin value 
[AST or ALT>2x baseline AND > 3.[ADDRESS_420067]] OR [AST or 
ALT > 8.[ADDRESS_420068]], whichever is lower, combined with 
[direct (conjugated) bilirubin >2x baseline AND >2.0 
xULNPermanently discontinue patient from study drug treatment.
Repeat as s oon as possible, preferably within 48 hours from awareness of the abnormal results, then with 
weekly monitoring of LFTsa), or more frequently if clinically indicated, until AST, ALT, or bilirubin have 
resolved to baseline or stabilization over 4 weeks. Ref er to Section 6.3.2 for additional follow-up 
evaluations as applicable.

[COMPANY_001] Confidential Page 57
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
Dose modifications for deferasirox
For patients with normal baseline ALT or AST or total 
bilirubin value:
AST or ALT >3.0xULN combined with total 
bilirubin >2.0xULN without evidence of cholestasisc
OR
(Note to study team:  If supported by [CONTACT_339583]) For 
patients with elevated baseline AST or ALT or total 
bilirubin value
[AST or ALT>2x baseline AND >3.0xULN]  OR [AST or 
ALT>8.[ADDRESS_420069]], whichever is lower, combined with total 
bilirubin >2x baseline AND >2.0xULNPermanently discontinue patient from study drug treatment.
Repeat as soon as possible, preferably within 48 hours from awareness of the abnormal results, then with 
weekly monitoring of LFTsa), or more frequently if clinically indicated until AST, ALT, or bilirubin have 
resolved to baseline or stabilization over 4 weeks.  Refer to Section 6.3.2 for additional follow -up 
evaluations as applicable.  
Hepatic impairment
Moderate hepatic impairment (Child -Pugh Class B) The study medication will be interrupted and patient monitored. If liver disease prognosis improves, 
deferasirox can be reintroduced at 10 mg/kg/day for DT and at 7 mg/kg/day for granules or 50% of 
previous dose, whichever is less. While monitoring continues, dose may be increased by 5 mg/kg/day for 
DT and by 3.5 mg/kg/day for granules every 2 weeks, to a maximum of 50% of patient’s previous dose if 
the investigator determines that dose in crease is in the best interest of the patient. Study medication must 
be used with caution in such patients.
In patients who develop severe hepatic impairment 
(Child -Pugh Class C) during the studyStudy medication must be discontinued.
Other dose modifications
Changes in Serum Ferritin
The dose of deferasirox DT or granules should be adjusted if necessary every 3 months based on the 
trends in serum ferritin and investigator’s judgement. ICT naïve patients can adapt dose after 4 weeks.
Dose adjustments need to be made in steps of 5 or 10 mg/kg/day for deferasirox DT and of 3.5 or 7 
mg/kg/day for deferasirox granules and are to be tailored to the individual patient’s response and the 
therapeutic goal of (reduction of iron burden). In patients not adequately controlled with deferasirox DT 
doses of 30 mg/kg/day, doses of up to 40 mg/kg/day may be considered. In patients not adequately 
controlled with deferasirox granules doses of 21 mg/kg/day, doses of up to 28 mg/kg/day may be 
considered. The st arting dose and the dose adjustment considerations must take into account that the 
therapeutic goal is reduction of iron burden (as opposed to maintenance of iron burden). Doses above 40 
mg/kg/day for deferasirox DT and above 28 mg for deferasirox granules are not allowed.

[COMPANY_001] Confidential Page 58
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
Dose modifications for deferasirox
500 –1000 ng/mL Dose reductions in steps of 5 to 10 mg/kg/day for deferasirox DT and of 3.5 or 7 mg/kg/day for deferasirox 
granules is required to maintain serum ferritin levels within the target range.
< 500 ng/ml Interruption of study treatment is required until serum ferritin rises above 500 ng/mL
Changes in urine protein/creatinine ratio
For patients who develop proteinuria or a worsening of pre -existing proteinuria (assessed by a dipstick) at any visit, urine samples should be collected and assessed by 
[CONTACT_2237]. [Egypt: Local laboratory]
In case of a single increase of the urinary protein/creatinine ratio the assessment should be repeated at the next visit.
> 0.5 (mg/mg) in two consecutive second -void urine 
samples (a minimum of 48h apart), if all other causes of 
proteinuria have been excluded.Deferasirox dose reduction by 50%
When resolution of UPCR (<0.5mg/mg) at the next study visit , dose can be resumed again at 100%
If increase in UPCR >0.5mg/mg recurs again within 2 months after initial increase, therapy needs to be 
reduced to 50% of the last dose. If increase in UPCR does not recur after 2 months at reduced dose 
(50%) , study medication can be returned to 100% of the last dose
> 1.0 (mg/mg) in one si ngle second -void urine samples. Interrupt study treatment.
When resolution of increase in UPCR (<0.5mg/mg) at the next study visit, dose can be resumed again at 
50% of the last dose. If increase in UPCR does not recur after 1 month at reduced dose (50%), s tudy 
medication can be returned to 100% of the last dose.
In case of persistent proteinuria Study treatment may be discontinued if the investigator believes it is in the best interest of the patient. 
[COMPANY_001] may be contact[CONTACT_339584].
Dose adjustment will be based on 
laboratory results. [Egypt: Local laboratory]
Severe skin reactions
Severe skin reactions, including Stevens -Johnson 
syndrome (SJS) and Toxic epi[INVESTIGATOR_59373] (TEN)Have to be reported during Exjade therapy.
If SJS or TEN are suspected, study treatment must be immediately discontinued and not be reintroduced
Skin Rash (other than SJS)
For skin rash of mild/moderate severity (defined as those 
causing minimal symptoms which require no or minimal 
supportive treatment)Study drug should be continued without dose adjustment. The skin rash may resolve spontaneously 
without further intervention. If the rash persists for >1 week or becomes more severe, treatment with study 
drug will be interrupted.
After the rash resolves, resume study drug at 50% of patient’s last dose. If the rash does not recur, 
increase dose back to 100% of patients dose after 2 weeks.

[COMPANY_001] Confidential Page 59
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
Dose modifications for deferasirox
Severe rash (distressing symptoms requiring 
discontinuation and/or systemic steroids)Discontinue treatment until resolution of rash.
Once the rash has resolved, resume at 50% of patient’s dose. If necessary, a brief course of oral steroids 
may be given concurrently with resumption of study drug. If the rash does not recur, increase by [CONTACT_122288] 5 
mg/kg/day for deferasirox DT and of 3.5 mg/kg/day for deferasirox granules every 2 weeks until patient’s 
last dose is achieved. If the rash recurs, study treatment may be discontinued if the investigator believes 
that it i s in the best interest of the patient.
[COMPANY_001] may be contact[CONTACT_339585] (decreased hearing) and ocular (lens opacities) 
disturbances have been reported with deferasirox 
treatment.Auditory and ophthalmic testing (including fundoscopy) is required before the start of deferasirox treatment.
If disturbances are noted dose reduction or interruption may be considered and a repeated testing 
performed as per investigator’s judgement.
Dose modification criteria for h ypersensitivity  reactions
Cases of serious hypersensitivity reactions (such as 
anaphylaxis and angioedema) have been reported in 
patients receiving deferasirox, with the onset of the 
reaction occurring in the majority of cases within the first 
month of treatment.If reactions are severe, deferasirox should be discontinued and appropriate medical intervention instituted.
Deferasirox should not be reintroduced in patients who have experienced previous hypersensitivity 
reactions on Exjade due to the risk of anaphylactic shock
Dose modification criteria for cy topenias
Unexpected Cytopenias There have been post -marketing reports (both spontaneous and from clinical trials) of cytopenias in 
patients treated with deferasirox. Most of these patients had pre -existing hematological disorders that are 
frequently associated with bone marrow failure. The relationship of these epi[INVESTIGATOR_339537]. In line with the standard clinical management of such hematological disorders, 
blood counts should be monitored regularly.
Dose interruption of treatment with deferasirox should be considered in patients who develop unexplained 
cytopenia.
Reintroduction of therapy with deferasirox may be considered (as per investigator decision), once the 
cause of the cytopenia has been identified.

[COMPANY_001] Confidential Page 60
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
Dose modifications for deferasirox
Gastrointestinal disturbances
Gastrointestinal issues (including diarrhea, constipation, 
nausea, vomiting and abdominal pain)Some basic recommendations, based on practical experience, can be made to guide physicians in 
managing patients who experience diarrhea.
At the first sign of diarrhea, consider anti-diarrheal medication such as loperamide. Remind the pati ent to 
discontinue any laxative preparations or stool softeners they may be taking and to eat small, frequent 
meals. Determine if the patient is lactose intolerant. Deferasirox DT contains lactose in the formulation so 
supplemental lactase may benefit the patient; however the deferasirox granules do not contain lactose. 
Remind the patient to drink [ADDRESS_420070] that the patient take their 
deferasirox DT with water, not with orange juice or apple juice until the diarrhea re solves.
Should the gastrointestinal issues (including diarrhea, constipation, nausea, vomiting and abdominal pain) 
persist, study drug may be discontinued if the investigator believes it is in the best interest of the patient.
[COMPANY_001] may be contact[CONTACT_339584].
All dose modifications should be based on the worst preceding toxicity.
aCore LFTs consist of ALT, AST, GGT, total bilirubin (fractionated [direct and indirect], if direct (conju gated) bilirubin > 2.[ADDRESS_420071]), and alkaline phosphatase 
(fractionated [quantification of isoforms], if alkaline phosphatase > 2.[ADDRESS_420072].)
b“Combined” defined as direct (conjugated) bilirubin  increase to the defined threshold concurrently with ALT/AST increase to the defined threshold
If combined elevations of AST or ALT and direct (conjugated) bilirubin do not meet the defined thresholds, please follow the instructions for isolated elevation of direct 
(conjugated) bilirubin and isolated elevation of AST/ALT, and take a conservative action based on the degree of the elevation s (e.g. discontinue treatment at the 
situation when omit dose is ne eded for one parameter and discontinue treatment is required for another parameter). After all elevations resolve to the defi ned 
thresholds that allow treatment re-initiation, re -start the treatment either at the same dose or at one dose lower if meeting a criterion for dose reduction
c “Cholestasis” defined as ALP elevation (>2.[ADDRESS_420073] and R value <2 ) in patients without bone metastasis, or elevation of ALP l iver fraction in patients with bone 
metastasis
Note: The R value is calculated by [CONTACT_6612], using multiples of the ULN for both values. It denotes the relative pattern of ALT and/or ALP elevation 
is due to cholestatic or hepatocellular liver injury
*Note: If total bilirubin > 3.[ADDRESS_420074] (non -conjugated) componen t only, and hemolysis as the etiology has been ruled out as per institutional 
guidelines (e.g., review of peripheral blood smear and haptoglobin determination), then dose reduction of 5 or 10 mg/kg/day f or deferasirox DT and of 3.5 or 7 
mg/kg/day for defer asirox granules and continue treatment at the discretion of the investigator.

[COMPANY_001] Confidential Page 61
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
6.2.[ADDRESS_420075] to follow -up, the investig ator should show “due diligence” by [CONTACT_5367], e.g., dates of telephone calls, registered letters, etc.
6.2.[ADDRESS_420076] be followed (for 
adverse events and serious adverse events) for at least [ADDRESS_420077] dose of 
treatment.
6.2.4 Follow up on potential drug -induced liver injury (DILI) cases
Patients with transaminase increase combined with TBIL increase may be indicative of 
potential DILI, and should be considered as clinically  important events.
The threshold for potential DILI may depend on the patient’s baseline AST/AL T and TBIL 
value; patients meeting any of the following criteria will require further follow -up as outlined 
below:

[COMPANY_001] Confidential Page 62
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
For patients with normal AL T or AST or TBIL value at baseline: AST or ALT > 3.[ADDRESS_420078] combined with TB IL > 2.0 x UL N
For patients with elevated AST or ALT or TBIL value at baseline: [AST or AL T > 2 x 
baseline AND > 3.[ADDRESS_420079]] OR [AST or ALT > 8.[ADDRESS_420080]], whichever is lower, 
combined with [TBIL > 2 x baseline AND > 2.[ADDRESS_420081]]
Medical review needs to ensure that liver test elevations are not caused by  [CONTACT_15014], defined 
as ALP elevation > 2.[ADDRESS_420082] with R value < 2 in patients without bone metastasis, or elevation 
of AL P liver fraction in patients with bone metastasis.
Note: (The R value is calculated by  [CONTACT_5358], using multiples of the ULN 
for both values. It denotes the relative pattern of ALT and/or ALP elevation is due to cholestatic 
or hepatocellular liver injury ).
In the absence of cholestasis, these patients should be immediately  discontinued from study 
drug treatment, and repeat LFT testing as soon as possible, preferabl y within 48 hours from the 
awareness of the abnormal results. The evaluation should include laboratory  tests, detailed 
history , phy sical assessment and the possibili ty of liver metastasis or new liver lesions, 
obstructions/compressions, etc.
Laboratory  tests should include ALT, AST, albumin, creatine kinase, total bilirubin, direct 
and indirect bilirubin, GGT, prothrombin time (PT)/INR and alkaline phosphatase.
A deta iled histo ry, including relevant information, such as review of ethanol, concomitant 
medications, herbal remedies, supplement consumption, history  of any  pre-existing liver 
conditions or risk factors, should be collected.
Further testing for acute hepatitis A, B, C or E infection and liver imaging (e .g.biliary  
tract) may  be warranted.
Obtain PK sample, as close as possible to last dose of study  drug, if PK analy sis is 
performed in the stud y.
Additional testing for other hepatotropic viral infection (CMV, E BV or HSV), 
autoimmune hepatitis or liver biopsy  may  be considered as clinically  indicated or after 
consultation with specialist/hepatologist.
All cases confirmed on repeat testing meeting the laboratory  criteria defined above, with no 
other alternative cause for LFT abnormalities identified should be considered as “medicall y 
significant”, thus, met the definition of SAE (Section 8.2.1) and reported as SAE using the term 
“potential drug-induced liver injury ”. All events should be followed up with the outcome clearl y 
documented.
6.2.5 Anticipated risks and safety  concerns of the study  drug
Appropriate eligibility  criteria as well as specific dose modification rules are included in this 
protocol. Guidelines for prophy lactic or supportive treatment for expected toxicities, including 
management of study -drug induced adverse events, i.e., please refer to Section 6.2.1 (Table 6-
2).
Refer to preclinical toxicity
 and or clinical data found in the [I nvestigator’s Brochure].

[COMPANY_001] Confidential Page 63
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
6.[ADDRESS_420083] be told to notify the investigational site about any  prior and new medications 
he/she takes after the start of the study  drug. All medications (other than study  drug) and 
significant non-drug therapi[INVESTIGATOR_014] (including physical therap y and herbal/natural medications) 
administered during the study  must be listed on the Concomitant Medications eCRF.
6.3.1 Permitted concom itant therapy  requiring caution and/or action
The concomitant administration of deferasirox and vitamin C has not been formall y studied. 
Doses of vitamin C up to 200 mg/day  have not been associated with adverse consequences.
Use of the following treatments as part of the routine clinical care for the patients was allowed:
Patients were also to continue blood transfusions during the study  protocol according to the 
regimen that they had been receiving prior to enrollment that could allow maintaining a 
hemoglo bin level of ≥9 g/dL. If transfusion needs to be performed on a PK sampling day , PK 
sampling must occur prior to the transfusion.
Caution must be exercised in patients who are taking study  drug in combination with the 
following drugs:
Concomitant administ ration of deferasirox with drugs that have known ulcerogenic 
potential, such as NSAIDs, corticosteroids, or oral bisphosphonates, and use of deferasirox 
in patients receiving anticoagulants may increase the risk of gastrointestinal irritation and 
bleeding.
Deferasirox, as a weak CYP3A4 inducer, may potentiall y decrease serum levels of 
substances metabolized through CYP3A4 (e.g. alfentanil, aprepi[INVESTIGATOR_053], budesonide, buspi[INVESTIGATOR_5331], 
conivaptan, cyclosporine, darifenacin, darunavir, dasatinib, dihydroergotamine, 
dronedarone, eletriptan, eplerenone, everolimus, felodipi[INVESTIGATOR_050], fentany l, hormonal 
contraceptive agents, indinavir, fluticasone, lopi[INVESTIGATOR_054], lovastatin, lurasidone, maraviroc, 
midazolam, nisoldipi[INVESTIGATOR_050], pi[INVESTIGATOR_3924], quetiapi[INVESTIGATOR_050], quinidine, saquinavir, sildenafil, simvastatin, 
sirolimus, tacrolimus, tolvaptan, tipranavir, triazolam, ticagrelor, and vardenafil).
Deferasirox is a moderate inhibitor of CYP2C8 and therefore it may increase serum 
concentrations of substances metabolized through CYP2C8 (e.g. repaglinide, paclitaxel).
Deferasirox can potentially  increase the exposure of the concomitantly  administered 
CYP1A2 substrates (e.g. theoph ylline, clozapi[INVESTIGATOR_050], tizanidine). When deferasirox and 
theophy lline are used concomitantly , monitoring of theoph ylline concentratio n and 
theophy lline dose reduction should be considered.
The concomitant use of deferasirox with potent UGT inducers (e.g. rifampi[INVESTIGATOR_2513], pheny toin, 
phenobarbital, ritonavir) may result in a decrease in deferasirox efficacy  due to a possible 
decrease in defera sirox concentration.

[COMPANY_001] Confidential Page 64
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
6.3.2 Prohibited concomitant therapy
Aluminium containing antacid therapi[INVESTIGATOR_339538].
Concomitant use of bile acid sequestrants decreases deferasirox systemic exposure. Avoid 
the concomitant use of bile acid sequestrants (e.g., cholesty ramine, colesevelam, colestipol) 
with deferasirox.
Concomitant use of any other iron chelation therap y (deferoxamine, deferiprone, 
deferasirox) during stud y treatment phases are not allowed.
Any investigational drug other than study  medication.
6.4 Patient numbering, treatment assignment or randomization
6.4.1 Patient numbering
Each patient is identified in the study  by a Patient Number (Patient No.), that is assigned when 
the patient is first enrolled for screening and is ret ained as the primary  identifier for the patient 
throughout his/her entire participation in the trial. The Patient No. consists of the Center 
Number (Center No.) (as assigned by [CONTACT_5359]) with a sequential patient 
number suffixed to it, so that each patient is numbered uniquel y across the entire database. Upon 
signing the informed consent form, the patient is assigned to the next sequential Patient No.
The investigator or designated staff will contact [CONTACT_64081]. Once assigned, the Patient No. must 
not be reused for an y other patient and the Patient No. for that individual must not be changed, 
even if the patient is re -screened. If the patient fails to be randomized or start treatment for an y 
reason, the reason will be entered into the Screening Log.
IRT must be notified within 2 day s that the patient was not randomized.
6.4.2 Treatment assignment or randomization
Patients will be assigned to one ofthe 2 treatment arms, deferasirox DT or granules (Section 
4.1and Section 6.1) in a ratio of 1:1 during the core phase .
Randomization will be stratified by [CONTACT_164737] (2 to <10 years, 10 to <18 years) and by [CONTACT_339577] (Yes/No)
. The randomization numbers will be generated using the following procedure to 
ensure that treatment assignment is unbiased and concealed from patients and investigator staff. 
A patien
t randomization list will be produced by [CONTACT_15017]  (IRT) 
provider using a validated sy stem that automates the random assignment of patient numbers to 
randomization numbers. These randomization numbers are linked to the different treatment 
arms, which in turn are linked to medication numbers. A separate medication randomization list 
will be produced by [CONTACT_64146] a 
validated system that automates the random assignment of medication numbers to medication 
packs containing each of the study  treatments.
Prior to dosing, all patients who fulfill all inclusion/exclusion criteria will be randomized via 
IRT to one of the treatment arms. The investigator or his/her delegate will call o r log on to the 
IRT and confirm that the patient fulfills all the inclusion/exclusion criteria. The I RT will assign 

[COMPANY_001] Confidential Page 65
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
a randomization number to the patient, which will be used to link the patient to a treatment arm 
and will specify  a unique medication number for the first package of study  treatment to be 
dispensed to the patient. The randomization number will not be communicated to the caller.
During optional extension phase, all patients will be provided with new deferasirox formulation 
(granules). No random ization will be done.
6.4.[ADDRESS_420084] of treatment knowledge, until the pri mary  anal ysis is 
conducted, no aggregated statistical analysis (efficacy  or safet y) will be performed by [CONTACT_3148], 
other than the analy ses specified in the protocol ( Section 4.2).
6.[ADDRESS_420085] the patient or caregiver to take the 
study  drugs as per protocol. Study  drug(s) will be dispensed to the patient by [CONTACT_5361]. All dosages prescribed to the patient and all dose changes 
during the study  must 
be recorded on the Dosage Administration Record eCRF.
As per Section 4.5, during a Public Health emergency as declared by [CONTACT_6620] i.e. pandemic, epi[INVESTIGATOR_6519], that limits or prevents on-site study  visits, 
delivery  of Investigational Medicinal Product (IMP)directly  to a participant’s home may be 
permitted (if allowed by [CONTACT_157082]) in the event the Investigator has decided that an on-site visit by [CONTACT_157083], and that it is in the interest of the participant’s health to 
administer the study  treatment even without performing an on-site visit. The dispatch of IMP 
from the site to the participant’s home remains under the accountability  of the Investigator. 
Each shipment/provisioning will be for a maximum of 1 month’s supply .In this case, regular 
phone calls or virtual contacts (ever y 4 w eeks or more frequently if needed) will occur between 
the site and the participant for instructional purposes, safet y monitoring, drug accountabilit y, 
investigation of any adverse events, ensuring participants continue to benefit 
from treatment 
and discussion of the participant´s health status until the participants can resume visits at the 
study  site.
6.5.1 Study drug packaging and labeling
The study  medication packaging has a 2 -part label. A uniqu e medication number is printed on 
each part of this label which corresponds to one of the treatment arms. Responsible site 
personnel will identify  the study  treatment package(s) to dispense to the patient by [CONTACT_339586] r(s). Site personnel will add the patient number on the 
label. Immediatel y before dispensing the package to the patient, site personnel will detach the 
outer part of the label from the packaging and affix it to the source document (Drug Label Form) 
for tha t patient’s unique patient number.
Medication labels will be in the local language and comply with the legal requirements of each 
country . They  will include storage conditions for the drug.

[COMPANY_001] Confidential Page 66
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
6.5.[ADDRESS_420086] access. Upon receipt, the study treatment should be stored according to the 
instructions specified on the drug labels.
6.5.3 Study drug compliance and accountability
[IP_ADDRESS] Study drug compliance
Patient compliance with study  treatment, the co-primary  variable in this study , will be evaluated 
using the stick pack/tablet count (for detailed informa tion please refer to Section 7.2.1 )
Compliance will be assessed by [CONTACT_1755]/or study  personnel every  4  w eeks and 
information provided by [CONTACT_5363]/or caregiver will be captured in the Drug 
Accountability  Log. This information must be captured in the source document at each patient 
visit.
[IP_ADDRESS] Study drug accountability
Information on study  drug prescribing will be collected on the Dose Administration Record 
(DAR) eCRF and will include the planned daily  dose, actual daily dose taken, reason for the 
dose change, start date and end date.
The investigator or designee must maintain an accurate record of the shipment and dispensing 
of study  treatment in a drug accountability  log. Drug accountability will be noted by [CONTACT_5364]. Patients / caregivers will be asked 
to return all unused stud y treatment and packaging on a regular basis, at the end of the stud y or 
at the time of study  treatment discontinuation.
At study  close-out, and, as appropriate during the course of the study , the investigator will return 
all used and unused study  treatment, packaging, drug labels, and a copy  of the completed drug 
accountability  log to the [COMPANY_001] monitor or to the [COMPANY_001] address provided in the investigator 
folder at each site.
6.5.[ADDRESS_420087] party , as appropriate.
7 Visit schedule and assessments
7.1 Stu
dy flow and visit schedule
Table 7-1lists all of the assessments for the core phase and Table 7-2lists all of the assessments 
for the optional extension phase and both indicate with an “X”, the visits when they are 
performed. Patients in the core phase who complete Visit 16 and decide to proceed to the 
optional extension phase will begin following all the assessments included in the visit 777 in 
Table 7 -1and then follow the optional extension assessment visit 17 listed in Table 7 -2on the 

[COMPANY_001] Confidential Page 67
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
same da y so as to avoid a gap in treatment. Patients who were on the DT arm during core phase 
of study  who have switched to granules at Visit 17 as part of the optional extension phase will 
need to return weekl y (Visits 18, 19 and 20) for the first month after beginning the optional 
extension phase (granules) for serum creatinine and creatinine clearance. Thereafter they will 
follow the same schedule as patients who were on granules arm during the core phase. Visit 
778 should not be completed by [CONTACT_339587]. Should 
a patient discontinue the core phase at or prior to Visit 16, they  should perform Visits 777 and 
778 including safet y follow up as per Table 7 -1.
Patients in the optional extension phase will complete Visit 779 and 780 at the end of the stud y 
or in case of earlier discontinuation.
Patients 
should be seen for all visits to perform the scheduled assessments on the designated 
day, or as close to is as possible, i.e., for the core phase not exceeding ± 2 days fo r assessments 
scheduled in Visits 1 to 6 and ± 7 days for all other visits until End of Treatment Visit 777. For 
the optional extension phase, not exceeding ± 7 day s for all visits until End of Treatment Visit 
779. I n this clinical trial, a week is 7 calen dar day s. For yearly assessments in extension phase, 
i.e. audiometry ,ocular and growth and development examinations, ±30day  window is allowed.
All visits should be scheduled respective to the randomization date (Visit 3) for the core phase , 
rather than in relation to the previous visits. For the optional extension phase, all visits should 
be scheduled respective to Visit 17.
All data obtained from these assessments must be supported in the patient’s source 
documentation. No eCRF pages will be used as a so urce document.
As per Section 4.5, during a Public Health emergency as declared by [CONTACT_6620] i.e. pandemic, epi[INVESTIGATOR_157046]-site study  visits, 
alternative methods of providing continuing care may be implemented 
by [CONTACT_157093]. If allowed by [CONTACT_157094], phone calls, virtual contacts (e.g. tele consult) can replace on-site stu dy visits, for 
the duration of the disruption until it is safe for the participant to visit the site again.
The table indicates which data are entered into the database (D) or remain in source documents 
only (S) (column “Category ”).

[COMPANY_001] Confidential Page 68
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
Table 7-1 Visit evaluation schedule
Study  Procedure
CategoryProtocol Section Screening
([ADDRESS_420088] 
7day s 
apart) Core Treatment PhaseEnd of 
CoreTreatment 
(continue to 
Visit 17 in 
Table 7 -2 if 
going into 
extension 
phase) Study  Evaluation 
Completion (Core 
phase) including 
Safety  Follow up 
if not continuing 
to optional 
extensi on phase
Visit: 1 2 3 4 5 6 7 8 9 10 1112, 13, 
14, 15 
&16 777 778
Week: -3 Weeks 1 2 3 5 9 13 17 21 2529, 33, 
37, 41 & 
45 
(monthly )Within [ADDRESS_420089] dose 
for patients 
not 
participating 
in extension 
phase. (Week 
49 if going into 
extension 
phase.)[ADDRESS_420090] 
dose
Obtain Informed Consent 
(and assent per local 
guidelines)(D) 7.1.1 X
Randomization (D) 6.4 X
Inclusion/exclusion criteria (D) [IP_ADDRESS] X X
Demography (D) [IP_ADDRESS] X
Relevant medical 
history/current medical 
conditions(D) [IP_ADDRESS] X
Prior chelation therapy (D) [IP_ADDRESS] X
Disease history (D) [IP_ADDRESS] X

[COMPANY_001] Confidential Page 69
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
Study  Procedure
CategoryProtocol Section Screening
([ADDRESS_420091] 
7day s 
apart) Core Treatment PhaseEnd of 
CoreTreatment 
(continue to 
Visit 17 in 
Table 7 -2 if 
going into 
extension 
phase) Study  Evaluation 
Completion (Core 
phase) including 
Safety  Follow up 
if not continuing 
to optional 
extensi on phase
Visit: 1 2 3 4 5 6 7 8 9 10 1112, 13, 
14, 15 
&16 777 778
Week: -3 Weeks 1 2 3 5 9 13 17 21 2529, 33, 
37, 41 & 
45 
(monthly )Within [ADDRESS_420092] dose 
for patients 
not 
participating 
in extension 
phase. (Week 
49 if going into 
extension 
phase.)[ADDRESS_420093] 
dose
Prior medications and non -
drug therapi[INVESTIGATOR_014](D) 6.3 X X
Physical examination (S) [IP_ADDRESS] X X X X X X X X X X X X
Vital signs (D) [IP_ADDRESS] X X X X X X X X X X X X X
Height (D) [IP_ADDRESS] X X X X X X X X X X X X X
Weight (D) [IP_ADDRESS] X X X X X X X X X X X X X
Audiometry (D) [IP_ADDRESS] X
Ocular Exam (D) [IP_ADDRESS] X X X
ECG (D) [IP_ADDRESS].1 X X
Echocardiogram (D) [IP_ADDRESS].2 X X
Growth and development (D) [IP_ADDRESS] X X
Transfusion/RBC History (D) [IP_ADDRESS] X
Transfusions (D) [IP_ADDRESS] X X X X X X X X X X X

[COMPANY_001] Confidential Page 70
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
Study  Procedure
CategoryProtocol Section Screening
([ADDRESS_420094] 
7day s 
apart) Core Treatment PhaseEnd of 
CoreTreatment 
(continue to 
Visit 17 in 
Table 7 -2 if 
going into 
extension 
phase) Study  Evaluation 
Completion (Core 
phase) including 
Safety  Follow up 
if not continuing 
to optional 
extensi on phase
Visit: 1 2 3 4 5 6 7 8 9 10 1112, 13, 
14, 15 
&16 777 778
Week: -3 Weeks 1 2 3 5 9 13 17 21 2529, 33, 
37, 41 & 
45 
(monthly )Within [ADDRESS_420095] dose 
for patients 
not 
participating 
in extension 
phase. (Week 
49 if going into 
extension 
phase.)[ADDRESS_420096] 
dose
PK sampling (Pre -dose) (D) 7.2.5 X X X X X X X X X
PK sampling (Post -dose) (D) 7.2.5 X X

[COMPANY_001] Confidential Page 71
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
Study  Procedure
CategoryProtocol Section Screening
([ADDRESS_420097] 
7day s 
apart) Core Treatment PhaseEnd of 
CoreTreatment 
(continue to 
Visit 17 in 
Table 7 -2 if 
going into 
extension 
phase) Study  Evaluation 
Completion (Core 
phase) including 
Safety  Follow up 
if not continuing 
to optional 
extensi on phase
Visit: 1 2 3 4 5 6 7 8 9 10 1112, 13, 
14, 15 
&16 777 778
Week: -3 Weeks 1 2 3 5 9 13 17 21 2529, 33, 
37, 41 & 
45 
(monthly )Within [ADDRESS_420098] dose 
for patients 
not 
participating 
in extension 
phase. (Week 
49 if going into 
extension 
phase.)[ADDRESS_420099] 
dose
Laboratory  assessments -
Blood7.2.4.6
Hematology (D) [IP_ADDRESS].1 X X X X X X X X X X X X
Biochemistry (D) [IP_ADDRESS].2 X X X X X X X X X X X X
Serum Ferritin (D) 7.2.2 X X X X X X X X X X
Serum Creatinine (D) [IP_ADDRESS].2 X X X X X X X X X X X X X
Creatinine clearance (D) [IP_ADDRESS].2 X X X X X X X X X X X X X
Hepatitis testing (D) [IP_ADDRESS].[ADDRESS_420100] (D) [IP_ADDRESS].4 X
Laboratory  assessments -
Urine7.2.4.6
Urine dipstick (D) [IP_ADDRESS].3 X X X X X X X X X X X X X

[COMPANY_001] Confidential Page 72
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
Study  Procedure
CategoryProtocol Section Screening
([ADDRESS_420101] 
7day s 
apart) Core Treatment PhaseEnd of 
CoreTreatment 
(continue to 
Visit 17 in 
Table 7 -2 if 
going into 
extension 
phase) Study  Evaluation 
Completion (Core 
phase) including 
Safety  Follow up 
if not continuing 
to optional 
extensi on phase
Visit: 1 2 3 4 5 6 7 8 9 10 1112, 13, 
14, 15 
&16 777 778
Week: -3 Weeks 1 2 3 5 9 13 17 21 2529, 33, 
37, 41 & 
45 
(monthly )Within [ADDRESS_420102] dose 
for patients 
not 
participating 
in extension 
phase. (Week 
49 if going into 
extension 
phase.)[ADDRESS_420103] 
dose
Microscopic urine 
(in case of positive urine 
dipstick)(D) [IP_ADDRESS].3 X X X X X X X X X X X X X
Proteinuria
(Urine protein/creatinine ratio) (D) [IP_ADDRESS].3X X X X X X X X X X X X X
Urine Pregnancy test (D) [IP_ADDRESS].4 X X
Dispensed stick pack / tablet 
count (D) 7.2.1X X X X X X X X
Study Drug administration (D) 6.1 Daily intake of study drug for 48 weeks
Returned stick pack / tablet 
count (D) 7.2.1X X X X X X X X
PRO / ObsRO 7.2.3
Compliance Questionnaire (D) 7.2.[ADDRESS_420104] day of treatment in core 
phase

[COMPANY_001] Confidential Page 73
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
Study  Procedure
CategoryProtocol Section Screening
([ADDRESS_420105] 
7day s 
apart) Core Treatment PhaseEnd of 
CoreTreatment 
(continue to 
Visit 17 in 
Table 7 -2 if 
going into 
extension 
phase) Study  Evaluation 
Completion (Core 
phase) including 
Safety  Follow up 
if not continuing 
to optional 
extensi on phase
Visit: 1 2 3 4 5 6 7 8 9 10 1112, 13, 
14, 15 
&16 777 778
Week: -3 Weeks 1 2 3 5 9 13 17 21 2529, 33, 
37, 41 & 
45 
(monthly )Within [ADDRESS_420106] dose 
for patients 
not 
participating 
in extension 
phase. (Week 
49 if going into 
extension 
phase.)[ADDRESS_420107] questionnaire (D) 7.2.3 X X X X
Palatability questionnaire (D) 7.2.3X X XX (day of last 
dose)
Concomitant medications (D) 6.3 Recorded on an ongoing basis
Adverse events (D) 8.1 Recorded on an ongoing basis

[COMPANY_001] Confidential Page 74
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
Table 7-2 Visit evaluation schedule (for the optional extension phase)
Study  
Procedure
Category
Protocol
sectionOptional Extension Treatment PhaseOptional 
Extension 
Treatment 
PhaseEnd of 
Treatment 
of 
Optional 
Extension 
PhaseOptional 
Extension 
phase -Study  
Evaluation 
Completion 
(Optional 
extension 
phase) 
including 
Safety  Follow 
up
Visit17 *18 *19 *20 21 22 23 24 25 26 27 28 29 30 31 32 33 From visit 
34 till visit 
[ZIP_CODE] 780
*Prior DT arm only
Week [ADDRESS_420108] dose
Physical 
examination(S) 7.2.4.1X X X X X X X X X X XX X Monthly X
Vital signs (D) [IP_ADDRESS] X X X X X X X X X X X X X Monthly X
Height (D) [IP_ADDRESS] X X X X X X X X X X X X X X Monthly X
Weight (D) [IP_ADDRESS] X X X X X X X X X X X X X X Monthly X
Audiometry (D) [IP_ADDRESS] X X Annually X
Ocular Exam (D) [IP_ADDRESS]   X Annually X
ECG (D) [IP_ADDRESS].1 When 
clinically 
indicated 

[COMPANY_001] Confidential Page 75
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
Study  
Procedure
Category
Protocol
sectionOptional Extension Treatment PhaseOptional 
Extension 
Treatment 
PhaseEnd of 
Treatment 
of 
Optional 
Extension 
PhaseOptional 
Extension 
phase -Study  
Evaluation 
Completion 
(Optional 
extension 
phase) 
including 
Safety  Follow 
up
Visit17 *18 *19 *20 21 22 23 24 25 26 27 28 29 30 31 32 33 From visit 
34 till visit 
[ZIP_CODE] 780
*Prior DT arm only
Week [ADDRESS_420109] dose
Echocardiogram (D) [IP_ADDRESS].2 When 
clinically 
indicated 
Growth and 
development(D) [IP_ADDRESS] X Annually X
Transfusions (D) [IP_ADDRESS] When 
clinically 
indicatedX
Laboratory 
assessments -
Blood7.2.4.6
Hematology (D) [IP_ADDRESS].1X X XX Every 3 
monthsX
Serum Ferritin (D) 7.2.2 X X X X X X X X X X X X X Monthly X
Serum 
Creatinine(D) [IP_ADDRESS].2X X X X X X X X X X X X X XX X Monthly X

[COMPANY_001] Confidential Page 76
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
Study  
Procedure
Category
Protocol
sectionOptional Extension Treatment PhaseOptional 
Extension 
Treatment 
PhaseEnd of 
Treatment 
of 
Optional 
Extension 
PhaseOptional 
Extension 
phase -Study  
Evaluation 
Completion 
(Optional 
extension 
phase) 
including 
Safety  Follow 
up
Visit17 *18 *19 *20 21 22 23 24 25 26 27 28 29 30 31 32 33 From visit 
34 till visit 
[ZIP_CODE] 780
*Prior DT arm only
Week [ADDRESS_420110] dose
Creatinine 
clearance(D) [IP_ADDRESS].2X X X X X X X X X X X X X X X X Monthly X
Liver fun ction 
testing
(ALT, AST, 
TBIL, alk 
phosphatase)(D) [IP_ADDRESS].2
X X X X X X X X X X X X X Monthly X
Laboratory 
assessments -
Urine7.2.4.6
Urine dipstick (D) [IP_ADDRESS].3 X X X X X X X X X X X X X Monthly X
Microscopic 
urine (in case of 
positive urine 
dipstick)(D) [IP_ADDRESS].3
X X X X X X X X X X X X X As needed X
Proteinuria 
(Urine (D) [IP_ADDRESS].3 X X X X X X X X X X X X X Monthly X

[COMPANY_001] Confidential Page 77
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
Study  
Procedure
Category
Protocol
sectionOptional Extension Treatment PhaseOptional 
Extension 
Treatment 
PhaseEnd of 
Treatment 
of 
Optional 
Extension 
PhaseOptional 
Extension 
phase -Study  
Evaluation 
Completion 
(Optional 
extension 
phase) 
including 
Safety  Follow 
up
Visit17 *18 *19 *20 21 22 23 24 25 26 27 28 29 30 31 32 33 From visit 
34 till visit 
[ZIP_CODE] 780
*Prior DT arm only
Week [ADDRESS_420111] dose
protein/creatinin
e ratio)
Urine 
Pregnancy test(D) [IP_ADDRESS].4 At discretion of Investigator X
Dispensed stick 
pack(D) 7.2.1 X X X X X X X X X X X X X X Monthly
Study Drug 
administration (D) 6.1Daily intake of study drug
Returned stick 
pack / tablet 
bottle (D) 7.2.1 X X X X X X X X X X X X X X Monthly X
Concomitant 
medications(D) 6.[ADDRESS_420112] on an ongoing basis
Adverse events (D) 8.[ADDRESS_420113] on an ongoing basis 

[COMPANY_001] Confidential Page 78
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
7.1.1 Screening
Prior to commencement of the screening examination, the patient / caregiver must have given
full informed consent on the appropriate form. Investigators will also obtain consent/assent of 
patients according to local guidelines. Once this has been signed and dated by [CONTACT_5363]/or 
by [CONTACT_18629], the investigator can take the patient throu gh the stud y inclusion and exclusion 
criteria to make sure that the patient is fully  eligible to participate.
Two Screening Visits are needed to perform key safety parameters prior to first dose 
administration as specified in the deferasirox drug label.
Specific safety  examinations like ocular and audiometry  examinations, ECG and 
echocardiograph y (currently  indicated to be performed at screening visit 1) can be performed 
at either screening visit [ADDRESS_420114] be performed at screening (also when entering in 
the optional extension phase at visit 17). The examination(s) can be performed at any time at 
the investigators discretion if sy mptomaticall y/clinically  indicated.
Serum ferritin, serum creatinine and proteinuria (urine protein /creatinine ratio) will be 
measured at Screening (Visits 1 and 2) and the value will be used for eligibility  criteria. The 
serum ferritin samples should be obtained in the absence of known infection.
Pregnancy  test will be required for females of child bearing potential onl y.
The full list of assessments to be performed during the screening period is detailed in Table [ADDRESS_420115] [COMPANY_001] for guidance and see 
Section [IP_ADDRESS] to get information on how to process screen failures.
To enter the optional extension phase, patient must have completed core phase per protocol. 
Patients may proceed with entering the optional extension treatment phase once all Visit 777 
and 17 assessments are performed. Lab results from Visit 777 will be checked as soon as they 
become available and if any  dose modifications are required will occur per Table 6 -2.  
[IP_ADDRESS] Eligibility  screening
Following registering in the IRT for screening, patient eligibility  will be checked once all 
screening procedures are completed. The eligibil ity check will be embedded in the IRT system. 
Please refer and compl y with detailed guidelines in the I RT manual.
[IP_ADDRESS] Information to be collected on screening failures
Patients who sign an informed consent but fail to be randomized and started on treatment for
any reason will be considered a screen failure. The reason for not being started on treatment 
will be entered on the Screening Log.

[COMPANY_001] Confidential Page 79
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
The demographic information and Screening log pages in the eCRF must also be completed for 
Screen Failure patients. No othe r data will be entered into the clinical database for patients who 
are screen failures, unless the patient experienced a Serious Adverse Event during the Screening 
Phase (see Section 8 for SAE reporting details).
If the patient fails to be started on treatment, the IRT must be notified within 2 days of the 
screen fail that the patient was not randomized.
[IP_ADDRESS] Patient demographics and other baseline characteristics
In the core phase, data will be collected on patient characteristics including demographic 
information (age, sex, ethnicity, etc.) and other background or relevant medical history/ current 
medical conditions, transfusion/RBC history  (within 6 months prior to study  entry), disease 
history , prior chela tion history  at Visits 1 and/or 2.
To determine eligibility  to be enrolled into the study, patients will also undergo assessments as 
per the inclusion and exclusion criteria which include vital signs, hematology and biochemistr y 
evaluations, serum ferritin, serum creatinine and creatinine clearance (calculated by [CONTACT_11378] ), [Egypt: Local laboratory will be used for analysis of all specimens collected], 
hepatitis viral testing, a known history  of HIV positive test result (ELISA or Western blot)
which is documented in the source documents, serum pregnancy test and urinaly sis.
Other assessments include ocular, audiometry, ECG, echocardiogram, and growth and 
development exams.
7.1.[ADDRESS_420116] 3 weeks 
of treatment and then every  4 weeks starting from Week 5 until Visit 777 (EOT). 
Having completed the screening period, patients who are eligible will be enrol led and 
randomized to receive either deferasirox DT or deferasirox granules. The target daily dose is 
calculated b y the ph ysician based on the patient’s actual body  weight.
At the start of treatment, iron chelation naïve patients will receive either defera sirox DT 20 
mg/kg once daily or deferasirox granules 14 mg/kg once daily . All ICT pre-treated patients will 
use a deferasirox DT or an equivalent strength -adjusted granules starting dose corresponding to 
their pre -washout dose, please refer to Appendix 14.1.  
For details on stud y design and dose adjustments, see Section [ADDRESS_420117] 
the possibility  to enter the optional extension treatment phase until there is local access to the 
new formulation (granules or FCT) or up to of [ADDRESS_420118] complete the core EOT visit, 30 day safety 
follow up and EOS visit.

[COMPANY_001] Confidential Page 80
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
Patients who discontinue prior to Visit [ADDRESS_420119] 
dose of study  drug. End of study  (Visit 778) and safet y follow- up will be performed 
within [ADDRESS_420120] dose was given in the core phase.
All patients who have completed the core treatment phase per protocol will have an EOT 
visit (Visit 777) at Week 49. Patients who opt to continue to the optional extension 
treatment phase will proceed to Table 7 -2to complete the Visit 17 assessments on the 
same day . At completion of the optional extension treatment phase, or should patients 
discontinue at an y time after starting the extension treatment phase they  will complete the 
End of Treatment of Optional Exte nsion Phase (Visit 779) within 
[ADDRESS_420121] dose of 
study  drug. End of stud y (Visit 780) and safety  follow -up will be performed within [ADDRESS_420122] month (visit 
18, 19 and 20) after beginning the optional extension phase (granules) for serum creatinine and 
creatinine clearance. Thereafte r they will follow the same schedule as patients who were on the 
granules arm during the core phase.
7.1.3 Discontinuation of study treatment
Patients may voluntarily  discontinue from the study  treatment for any reason at any time. If a 
patient decides to discon tinue from the study  treatment, the investigator should make a 
reasonable effort (e.g. telephone, e-mail, letter) to understand the primary  reason for this 
decision and record this information in the patient’s chart and on the appropriate CRF pages. 
They  may be considered withdrawn if they state an intention to withdraw, fail to return for visits, 
or become lost to follow -up for an y other reason.
The investigator should discontinue study  treatmentfor a given patient if, he/she believes that 
continua tion wo uld be detri mental to the patie nt’s well -being.
Study  treatmentmust be discontinued under the following circu mstance s:
Emergence of the following adver se event s, please refer to Section 6.2
Any of the following la boratory  abnormalitie s,please refer to Section 6.2
Pregnancy
Unwillingness to compl y with the prescribed study treatment
Use of prohibited treatm ent refer to Section 6.3.2 .
Any other protocol deviation that results in a significant ri sk to the patient’s saf ety
Patie nts who disconti nue study treat ment should undergo an end of stud y visit within [ADDRESS_420123] dose of the study treatment, at which time all the assessment listed for the End of 
Treatment (EOT) visit will be performed. An EOT eCRF page should be completed for all 
patients (for core or optional extension), giving the date and the reason for stoppi[INVESTIGATOR_339539].
The inve stigator m ust also cont act the IRT to register the patient’s discontinuation from study .

[COMPANY_001] Confidential Page 81
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
7.1.[ADDRESS_420124] alread y been collected may be retained 
and anal yzed at a later date (or as required b y local regulations).
If a pati ent withdraws consent, the investigator should make a reasonable effort (e.g. telephone, 
e
-mail, lette r) to understand t he pri mary reason for this de c ision and rec ord this in f orm ation.
Study  treatmentmust be discontinued and no further assessm ents conduct ed.
Further attempts to c
ontact the patie nt are not allowed unless sa fety findings require 
communication or follow up.
7.1.[ADDRESS_420125] to follow -up, the investigator should show "due diligence" by 
[CONTACT_268295], e.g., dates of tele phone 
calls, registered letters, etc.
7.2 Assessment ty pes
7.2.1 Compliance with prescribed treatment
The stick pack/tablet count will be performed by  [CONTACT_339588] y personnel every  4 weeks 
(week 5, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45 and at EOT(core)/777 visits) during the core phase. 
Assessment of compliance using stick 
pack/tablet counts will be based on the actual count at 
the different time points, taking into account the amount of medication dispensed, returned and 
reported as lost/wasted by  [CONTACT_11581] t in the core phase. Treatment prescribed will be recorded 
at every  visit, including any dose adjustments performed in-between visits. Detailed 
information related to drug dispensation and returns will be captured in source documents (drug 
accountability  logs) by [CONTACT_339589]. 
During the optional extension phase sites will only collect whether or not the stick pack(s) have 
been returned from the previous visit.
7.2.[ADDRESS_420126] will be performed during the core phase at Screening Visits 1 and 2 (in the 
absence of infection) to assess the eligibility  of the patient. The baseline serum ferritin value is 
defined as the average of the two measurements obtained during the screening perio d. 
Thereafter serum ferritin testing will be performed at weeks 5, 9, 13, 17, 21, 25, 29, 33, 37, 41, 
45 and EOT(core)/777 visits to evaluate the clinical benefit related to improved compliance of 
the new formulation. This will be done monthly  as per Exjad e prescribing information during 

[COMPANY_001] Confidential Page 82
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
the extension phase. A central laboratory  will be used for analysis of all specimens collected. 
[Egypt: Local laboratory will be used for analysis of all specimens collected]
Details on the collections, shipment of samples and reporting of results by [CONTACT_339590] [Laboratory  Manual] . [Egypt: Details on the collections, 
shipment of samples and reporting of results by [CONTACT_339591]]
7.2.3 Patient / Observer Reported Outcomes
Patient satisfaction, palatability  and compliance will be measured for both formulations using 
Patient / Observer Reported Outcomes (PRO/ObsRO) questionnaires.
For patients aged between [ADDRESS_420127] been designed as observations made by [CONTACT_339592] (ObsRO).  For these patients the caregivers will continue completing 
the ObsRO questionnaires even after the patient turns 10 y ears for consistency  in responses.  
Three questionnaires were developed to evaluate both formulations: the modified Satisfaction 
with Iron Chelation Therapy  (SICT), a palatability  questionnaire and a compliance diary . All 
questions will be translated into the patient’s native language.
All Patients/caregivers will complete the PRO/ObsRO questions via a handheld electronic 
device and they will receive training on the operation of this device. The device will be 
programmed to ensure that all relevant observations are recorded before submission. 
In case of malfunctioning devices (confirmed by [CONTACT_339593], the patients/caregivers will be authorized to use paper questionnaires until vendor 
fixes issue(s) of devices.  The back -up paper entry process in case of technical issues must be 
followed before an y reporting in the datab ase.   
The modified SICT questionnaire will be completed at Visits 4 (Week 2), 5 (Week 3), 11 (Week 
25), and 777 (within [ADDRESS_420128] dose of treatment for those not continuing to the extension 
phase). The Visit 4 assessment will be considered as baseline since the questionnaire asks for 
patient’s satisfaction with the iron chelation therapy  received ‘in the past week’. The rationale 
for having the modified SICT completed also at Visit [ADDRESS_420129] 
questionnaire within 2-14 days after the baseline data collection to ensure the stability  of the 
measure over a period of time where little change would be expected.
The palatabilit y questionnaire will be completed at Visits 4 (Week 2), 5 (Week 3), 11 (Week 
25), and 777 (day of the last dose of treatment), in order to co-administer this questionnaire 
together with the modified SICT questionnaires. The Visit [ADDRESS_420130] reliability  
within trial.
The handheld devices will be enabled with alarms that will remind the patient / caregiver to 
complete the modified SICT and the palatability questionnaires at the time points specified 
above.

[COMPANY_001] Confidential Page 83
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
The compliance questionnaire will be completed daily , starting at Visit 3 until Visit 777 (day 
of the last dose of treatment). This questionnaire asks whether the study  medication was taken 
by [CONTACT_102] / gi ven by  [CONTACT_339594]. Alarms and reminders 
will prompt patients to complete the compliance questionnaire every  day.
Daily  diary records will be used to calculate the rate of dosing instructions deviations in each 
study  arm (doses missed completely  or not taken at approximately  the same time every  day).
PRO/ObsRO questionnaires as well as the compliance diary  will not be collected during 
optional extension phase.
7.2.4 Safety  and tolerability assessments
Safety  will be monitored by [CONTACT_217970], vital signs, laboratory  evaluations, 
as well as collecting information on adverse events at every  visit. For details on AE collection 
and reporting, refer to Section 8.
As per Section 4.5, during a Public Health emergency as declared by [CONTACT_6620] i.e. pandemic, epi[INVESTIGATOR_6519], that limits or prevents on-site study  visits, 
regular phone or virtual calls can occur (every  4weeks or more frequentl y if needed) for safet y 
monitoring and discuss ion of the participant´s health status until it is safe for the participant to 
visit the site again.
[IP_ADDRESS] Physical examination
A physical examination will be performed during the core phase at Screening visit 1, Visit 3 
and all subsequent visits. The physical examination at Visit 3 will serve as the Baseline physical 
examination for the entire study . The exam will entail an examination of general appearance, 
skin, neck (including thy
roid), eyes, ears, nose, throat, lungs, heart, abdomen, back, lymph 
nodes, extre mities and nervous system. During the optional extension phase, physical exam will 
be done monthly  as per Exjade prescribing information.
Information about the physical examination must be present in the source documentation at the 
study  site.
Significant findings that were present prior to the signing of informed consent must be included 
in the Medical History  page on the patient’s eCRF. Significant new findings that begin or 
worsen after informed consent must be recorded on the Adverse Event page of the patient’s 
eCRF.
[IP_ADDRESS] Vital signs
Vital signs include body
 temperature, respi[INVESTIGATOR_2842], blood pressure and pulse measurements 
and will be measured at all study  visits (including EOT) at the core phase. During the optional 
extension phase, vital signs will be ta ken monthly  as per Exjade prescribing information. After 
the patient has been sitting for five minutes, with back supported and both feet placed on the 
floor, systolic and diastolic blood pressure will be measured three times using an automated 
validated device, e.g. OMRON, with an appropriatel y sized cuff. The repeat sitting 
measurements will be made at 1 
- 2 minute intervals and the mean of the three measurements 

[COMPANY_001] Confidential Page 84
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
will be used. In case the cuff sizes available are not large enough for the patient’s arm 
circumference, a sph ygmomanometer with an appropriatel y sized cuff may be used.
[IP_ADDRESS] Height and weight
Height in centimeters (cm) and body  weight (to the nearest 0.1 kilogram (kg) in indoor clothing, 
but without shoes) will be measured at each Visit). During the optional extension phase, 
assessments will be done monthly  as per Exjade prescribing information.
[IP_ADDRESS] Auditory examination .
Patients will undergo auditory  examinations during the core phase at screening (core phase) and 
Visit 17, annually  and at EOT visit (exte nsion phase).
The auditory  examination should include the following assessments:
Comprehensive audiometry  threshold examination
Interpretation of the audiometry  examinations must be made by a
 qualified physician and 
documented on the CRF page.
Information about the audiometry  results must be present in the source documentation at study 
site. Significant findings of the audiometry  examinations that meet the definition of an AE must 
be recorded in the adverse event summary page of the case report form.
[IP_ADDRESS] Ocular Examination and Central Imaging Assessment
Patients will undergo ophthalmologic examinations during the core phase at Visit 1, 11, 777 
(EOT Core) and at unscheduled visits (if needed). During the optional extension phase, 
assessments will be done annuall y as per Exjade prescribing information and at EOT of 
Extension phase .
The ophtha lmologic examination includes the following assessments:
Distance visual acuity  test: in patients who don’t need correction with glasses or contact 
[CONTACT_13276], visual acuity  test may be performed without correction. In patients who need 
correction (either wear s prescription glasses/contact [CONTACT_339595]), best corrected visual acuity  should be tested. Information about 
visual acuit y without correction, best corrected visual acuit y and prescription/correction 
must be documented in the source records. 
Applanation tonometry
Slit L amp exam and lens photography
Fundus exam and wide angle fundus photograph y of the retina and optic nerve
Interpretation of the ocular examinations must be made by a qualified physician and 
documented on the CRF page.
Information about the results of the ocular examinations, including the lens photographs and 
the wide angle fundus photographs of the retina and optic nerve, must be present in the source 
documentation at study  site. Signific ant findings of the ocular examinations that meet the 
definition of an AE must be recorded in the adverse event summary  page of the case report 
form. 

[COMPANY_001] Confidential Page 85
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
All screening and on-study  wide angle fundus photographs and lens photographs, including 
photograph y acquired prior to the release of Protocol Amendment 6, must be sent to an imaging 
Contract Research Organization (CRO) designated by  [CONTACT_339596]. 
Table 7-3 Central Imaging Assessments Collection Plan
Procedure Screening/Baseline During Treatment (core and extension 
phase)
Wide Angle Fundus Photography Required Core phase : Visit 11 (W eek 25),Visit 
777  (E OT Core) 
Optional Extension phase : Visit 33 
(Week 101), annually thereafter until 
EOT
Any unscheduled fundus photography 
during treatment 
Lens Photography Required Core Phase : Visit 11 (W eek 25), Visit 
777 (E OT Core)  
Optional Extension phase : Visit 33 
(Week 101), annually thereafter until 
EOT
Any unsc heduled lens photography 
during treatment
Details on transferring the fundus and lens photographs for reading by [CONTACT_339597]. All details of the central 
review methodology will b e described in the Central Imaging Review Charter.
[IP_ADDRESS] Laboratory  evaluations
A central laboratory  will be used for analy sis of all specimens collected, except urinary  dipstick 
analysis and urinary  pregnancy  test will be performed by  [CONTACT_234807]. 
[Egypt: Local laboratory will be used for analysis of all specimens collected]
Details on the collections, shipment of samples and reporting of results by [CONTACT_339590] [Central L aboratory  Manual] .
[Egypt: Details on thecollections, shipment of samples and reporting of results by [CONTACT_339598]]
As per Section 4.5, during a Public Health emergency as declared by [CONTACT_6620] i.e. pandemic, epi[INVESTIGATOR_6519], that limits or prevents on-site study  visits, 
if subjects cannot visit the site for safet y lab assessments conducted through central labs, a local 
lab may  be used. 
The results of the local laboratory  will be recorded in the CRF if any of the following criteria 
are met: 
a treatment decision was made based on the local results , or
there are no concomitant central lab results available, or 

[COMPANY_001] Confidential Page 86
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
an AE was documented based on local lab result.
Table 7-4 Central Clinical laboratory  parameters collection plan, [Egy pt: Local 
Laboratory ]
Test Category Test Name
[CONTACT_157131], Hemoglobin, MCH, MCHC, MCV, Platelets, Red blood cells, W hiteblood 
cells( WBC) count with differential, RBC Morphology with Differential (Basophils, 
Eosinophils, Lymphocytes, Monocytes, Neutrophils)
Biochemistry Albumin, Alkaline phosphatase, ALT, AST, Bicarbonate, Calcium, Chloride, Creatinine, 
Creatine kinase, Di rect (conjugated) Bilirubin, Indirect Bilirubin, Total Bilirubin, Total 
Cholesterol, LDL, HDL, Lactate Dehydrogenase (LDH), Total Protein, Triglycerides, Blood 
Urea Nitrogen (BUN) or Urea, Uric Acid, C Reactive Protein (CRP) ,
Urinalysis Microscopic Panel: Red Blood Cells, W hite Blood Cells, Casts, Crystals, Bacteria, 
Epi[INVESTIGATOR_339540] (Dipstick): Color, Bilirubin, Blood, Glucose, Ketones, Leukocytes 
esterase, Nitrite, pH, Protein, Specific Gravity, Urobilinogen
Hepatitis markers HbsAg, Hb sAb, HbcAb, HCV RNA, Anti -HCV
Additional tests Serum ferritin, creatinine clearance, urine protein/creatinine ratio, serum pregnancy test
[IP_ADDRESS].1 Hematology
Hematology  samples will be collected during the core phase at Screening Visits 1 and 2, Visit 
3, 5 - 16 and 777 (EOT) and will be sent to the central laboratory , [Egypt: Local laboratory]. 
During the optional extension phase, hematology samples will be 
collected every  3 months as 
per Exjade prescribing information. Hematology parameters monitored during the study  are 
listed in Table 7-4.
[IP_ADDRESS].2 Clinical chemistry
Clinical chemistry samples will be collected during the core phase at Screening Visits 1 and 2, 
at Visit 3, 5-16, and 777 (EOT) and will be sent to the central laboratory , [Egypt: Local 
laboratory] . During the optional extension phase, monthly  assessments will be done as per 
Exjade prescribing information as per Table [ADDRESS_420131] month of the optional extension phase at Visits 18, 19 and 20 
for serum creatinine and creatinine clearance monitoring. Thereafter they  will follow the same 
schedule as patients who were on granules arm during the core phase. Clinical chemistry 
parameters to be measured are listed in Table 7 -
4.
In accordance with the deferasirox label, serum creatinine, creatinine clearance, alkaline 
phosphatase, ALT/SGPT, AST/SGOT, direct (conju gated) bilirubin, indirect bilirubin, total 
bilirubin must be assessed in duplicate before the initiation of therapy  to establish a reliable pre-
treatment baseline.
In addition, serum creatinine will be measured weekl y during the first three weeks (after the 
first study  drug administration and at Visits 4, 5) and monthly  thereafter (starting with Visit 6) 
till Visit 777 (EOT). During the optional extension phase, monthly  assessments will be done as 
per Exjade prescribing information for patients previously  on the granules arm of the core phase. 
Patients on the DT arm for the core phase of the study  who have decided to switch to granules 
as part of the optional extension phase will need to return weekly  for the first month at Visits 

[COMPANY_001] Confidential Page 87
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
18, 19 and 20. Creatinine clearance will be calculated by [CONTACT_6626] [Egypt: Local 
laboratory] using the Schwartz formula for patients 17 years and younger and the Cockcroft -
Gault formula for patients who turn 18 years old during the study , each time serum creatinine 
is collec ted.
[IP_ADDRESS].3 Urinalysis
Urinaly sis samples will be collected during the core phase at every  study  visit, from Screening 
until Visit 777 (EOT). During the optional extension phase, monthly  assessments will be done 
as per Exjade prescribing information. A midstream, second voided morning urine sample will 
be obtained as this will provide the best results. Urinaly sis parameters assessed are listed in 
Table 7-4.
The microscopic urinalysis will be performed only in case of positive dipstick. Dipsticks will 
be supplied by  [CONTACT_6626], [Egypt: Local laboratory] .
At Screening Visits 1 and 2, a urine sample (at least 15 ml) will be collected and sent to the 
central lab [Egypt: Local laboratory] for urinary protein/creatinine (UPC) ratio to assess the 
eligibility  of the patient. Thereafter UPC ratio will be assessed at every visit, till EOT, as 
described in the [Central Laboratory  Manual] , [Egypt: Local Laboratory Manual] . First 
morning void samples must not be used for this analy sis.
For patients who develop proteinuria or a worsening of pre -existing proteinuria (assessed by  a 
dipstick) at an y visit, please refer to Table 6 - 2.
[IP_ADDRESS].4 Pregnancy and assessments of fertility
Females of child
-bearing potential are defined as all females physiologically  capable of 
becoming pregnant. This includes female pediatric patients who are menarchal or who become 
menarchal during the study .
All menarchal girls and their parents/caregivers should be informe d about the potential risks of 
pregnancy  and the need to prevent pregnancy  during the study. It is important to be sensitive in 
introducing this issue, as understanding and comprehension of puberty , sexual activity, 
pregnancy  and contraception is influence d by [CONTACT_654], as well as factors such as precocit y, socio 
(educational) economic and familial background. These discussions with the patient and her 
parents/caregivers are therefore best performed by [CONTACT_339599]. 
These discussions should take into account the socio- economic, cultural factors and religious 
beliefs of the adolescent participant and her family.
The investigator should also discuss the management of the pregnancy  test results with the 
patient and her parents/caregivers. The privacy  of the patient should be considered in 
accordance with the local law and ethics.
Serum and/or urine pregnancy  tests will be performed for all fema les of child- bearing potential 
according to the schedule in Table 7-1for the core phase. Urine pregnancy  tests will be at the 
EOT visit (777) and then at Investigator’s discretion during the optional extension phase 
treatment period as per schedule in Table 7
-2. Urine pregnancy  tests will also be performed at 

[COMPANY_001] Confidential Page 88
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
the end of treatment in the extension phase as per [COMPANY_001] guidelines for pregnancy  testing in 
clinical trials when basic contraception is requested.
Additional pregnancy  tests may  be performed at the investigator’s discretion during the study . 
Patients becoming pregnant or breastfeeding must be discontinued from study  drug.
However, a patient may choose to remain in the study  should she become pregnant, and be 
followed according to the protocol- defined study  visits.
Female patients of child- bearing potential, who are or might become sexually  active, must be 
informed of the need to prevent pregna ncy during the study .
The basic contraception methods are:
Barrier method: Condom or Occlusive cap (diaphragm or cervical/vault caps). [For [LOCATION_006]: 
with spermicidal foam/gel/film/cream/vaginal suppository ].
Placement of an intrauterine device (IUD) or intraute rine s ystem (IUS).
The decision on the contraceptive method should be reviewed at least every  3 months to 
evaluate the individual need and compatibility  of the method chosen.
Please note that deferasirox may reduce the efficacy  of hormonal contraception thus it is 
recommended to use alternative methods of contraception as described above.
See Section 8.4 for pregnancy  reporting and follow -up requirements.
[IP_ADDRESS].5 Hepatitis Viral tests
Hepatitis Viral testing consists of the following items: Hepatitis B Surface Antibody  (Anti-
HBs), Hepatitis B core Antibody  (HbcAb), Hepatitis C Antibody  (Anti- HCV), Hepatitis B 
surface Antigen (HBsAg), Qualitative w/confirmation, HCV PCR (Quantitative). Hepatitis 
Viral testing will be condu cted at Screening Visit 1 (core phase) to assess trial eligibility .
[IP_ADDRESS] Cardiac assessments
[IP_ADDRESS].1 Electrocardiogram (ECG)
A standard 12 lead ECG will be performed and interpreted by [CONTACT_339600]:
at screening Visit 1
at visit 777 (EOT)
During the optional extension phase, ECG will be performed when clinically  indicated.
Interpretation of the tracing must be made by a qualified physician and documented on the ECG 
CRF page. Each ECG tracing should be labeled with the study number, patient’s initials (where 
regulations permit), patient number, date and kept in the source documents at the study  site. 
Clinically  significant abnormalities present when the patient signed informed consent should 
be reported on the Medical History  eCRF page. Clinically  significant findings must be 
discussed with [COMPANY_001] prior to enrolling the patient in the study . New or worsened clinicall y 
significant findings occurring after informed consent must be recorded on the Adverse Events 
eCRF page.

[COMPANY_001] Confidential Page 89
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
[IP_ADDRESS].[ADDRESS_420132] echocardiogram will be performed and interpreted by  [CONTACT_339601]:
at screening Visit 1
at visit 777 (EOT)
During the optional extension phase, echocardiograph y assessments will be done when 
clinically  indicated.
Interpretation of the echocardiogram must be made by a qualified physician and documented 
on the CRF page. Each echocardiograph y should be labeled with the study  number, patient’s 
initials (where regulations permit), patient number, date and kept in the source documents at 
the study  site. Clinicall y significant abnormalities present when the patient signed informed 
consent should be reported on the Medical History eCRF page. Clinicall y significant findings 
must be discusse d with [COMPANY_001] prior to enrolling the patient in the study. New or worsened 
clinically  significant findings occurring after informed consent must be recorded on the Adverse 
Events eCRF page.
[IP_ADDRESS] Grow th and Development
[IP_ADDRESS].1 Growth velocity assessment in pediatric p atients
At the end of core phase, the growth velocit y will be assessed from the difference between the 
end of -core phase and the baseline height measurements during the core phase. 
During the optional extension phase, growth assessment will be performed annuall y as per 
Exjade prescribing information.
[IP_ADDRESS].2 Pubertal stage
Pubertal stage will be scored at baseline and end of core phase according to Tanner staging 
system. 
During the optional extension phase, pubertal stage assessment will be performed annually  as 
per Exjade prescribing information.
7.2.5 Pharmacokinetics
Detailed instructions for the collection, handling, and shipment of PK samples will be presented 
in the [CICL670F2202 Pharmacokinetics Laboratory Manual] . PK sampling will only be 
performed during the co re phase.
[IP_ADDRESS] PK blood sample collection and handling
[IP_ADDRESS].1 Blood collection plan
PK blood samples will be collected in all patients [Egypt: no PK samples will be collected] at 
weeks 1, 3, 5, 9, 13, 17, 21, 25, 29, 33, 37, 41 and 45 visits to support the assessment of 
compliance (see Table 7-5). Patients / caregivers will be instructed that study  drug should not 
be administered in the morning of these visits.

[COMPANY_001] Confidential Page 90
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
Table 7-5 PK blood collection log (all patients)
Visit Week Day Scheduled time pointPK collection 
numberPK 
Sample NoSample 
volume [mL]
3 1 1 Pre-dose 1 1 2
5 3 1 Pre-dose 2 102 6*** [ADDRESS_420133]-dose 3 hour (+/ -1 hour) [ADDRESS_420134]-dose 3 hour (+/ -1 hour)* 4 13 2
8 13 1 Pre-dose 5 105 14 2
9 17 1 Pre-dose 6 106 15 2
10 21 1 Pre-dose 7 107 16 2
11 25 1 Pre-dose 8 108 17 2
12 29 1 Pre-dose 9 109 18 2
13 33 1 Pre-dose 10 110 19 2
14 37 1 Pre-dose 11 111 20 2
15 41 1 Pre-dose 12 112 21 2
16 45 1 Pre-dose 13 113 22 2
999 Unscheduled** -- -- 1001+ 2
Total 30
PK collection numbers 1 to 13 correspond to the dose taken on the day of the visit.
PK collection numbers 102 to 113 correspond to the dose taken the day before each study visit.
*One PK blood sample should be collected between [ADDRESS_420135] -dose
** Each unscheduled PK blood sample will be uniquely numbered with sam ple number 100X (e.g., 1001, 1002, 
etc.) and will add 2 mL of blood to the total quantity collected
*** Certain PK samples have been removed as part of Protocol Amendment V.01 so PK sample numbers are no 
longer consecutive. Please follow numbering conventi on in Table 7 -5.
On the day s of visit 6 (Week 5) and visit 7 (Week 9) deferasirox should be administered at the 
study  site under supervision of the investigator/site staff. This is to ensure appropriate draws of 
pre-and pos t-dose administration blood samples for PK assessments.
At Week 1, the pre-dose sample should be obtained before the first drug administration. At 
Week 5 and Week 9, the pre -dose PK sample should be obtained within 24 ± [ADDRESS_420136] venipuncture or indwelling cannu la inserted in a forearm 
vein.
Blood samples (2 mL each sample) will be collected at each sampling time into a Vacutainer™ 
tube containing lithium heparin provided by [CONTACT_35970] [Egypt: No PK samples will be 
collected] .Immediatel y after each tube of blood is drawn, it should be inverted gentl y several 
times to ensure the mixing of tube contents with the anticoagulant (avoiding prolonged contact 
[CONTACT_339602]). Samples must be cooled immediately  by [CONTACT_339603] a 
test tube rack sitt ing in an ice -water bath or cry oblock until placed in the centrifuge. Within 30 
minutes of sample draw, the samples are centrifuged at about 5°C for 15 minutes at 2000 g (to 
be adapted according to the radius of the centrifuge). Within 10 minutes after centrifugation, 

[COMPANY_001] Confidential Page 91
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
the upper plasma sample will be transferred into two separate [ADDRESS_420137] 
0.5 mL of plasma and the tube B contains the remaining plasma. Both samples will be stored 
frozen at - 70°C +/ -15°C within [ADDRESS_420138] be captured on the appropriate source documents for PK sample collection at Week 5 and 
Week 9.  I ssues with obtaining samples will be noted in the comments field of the documents.
[IP_ADDRESS].[ADDRESS_420139] be completed in water proof ink and attached to the tube. The labels 
should include the information indicated below ( Table 7
-6)
Table 7-[ADDRESS_420140] initials ABC
Treatment Arm Arm 1, Arm 2
Visit W1, W3, W5, W9, W13, W17, W21, W 25, W 29, W33, W37, W41, W 45
Study  day D1 
PK time point 00:00 (taken pre -dose), 03:00 (taken post-dose)
PK sample number 1, 2, 3, etc.
Sample aliquot Primary or Back-up 
[IP_ADDRESS] PK analytical method
Deferasirox concentration will be measured in plasma using a validated liquid chromatograph y-
mass spectrometry /mass spectrometry  (LC-MS/MS) method with an anticipated lower limit of 
quantifica tion of 0.670 µmol/L  by a [COMPANY_001] Qualified external Service Provider.
Other assessments
No additional tests will be performed on patients entered into this study .
7.2.6 Resource utilization
Not Applicable.
8 Safety  monitoring and reporting
8.1 Adverse events
8.1.1 Definitions and reporting
An adverse event is defined as the appearance of (or worsening of any pre-existing) undesirable 
sign(s), s ymptom(s), or medical condition(s) that occur after patient’s signed informed consent 
has been obtained.

[COMPANY_001] Confidential Page 92
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
Abnormal laboratory values or test results occurring after informed consent constitute adverse 
events only if they induce clinical signs or symptoms, are considered clinically  significant, 
require therapy  (e.g., hematologic abnormalit y that requires transfusion or hematological stem 
cell support), or require changes in study  medication(s).
Except for screening failures, adverse events that begin or worsen after informed consent should 
be recorded in the Adverse Events eCRF. Conditions that were alread y present at the time of 
informed consent should be recorded in the Relevant Medical History /Current Medical 
Conditions eCRF page. Adverse event monitoring should be continued for at least [ADDRESS_420141] dose of study  treatment. Adverse events (including lab abnormalit ies that 
constitute AEs) should be described using a diagnosis whenever possible, rather than individual 
underly ing signs and symptoms. When a clear diagnosis cannot be identified, each sign or 
symptom should be reported as a separate Adverse Event.
Severi ty of adverse events will be assessed in this trial as mild, moderate, severe and life-
threatening, (corresponding to CTCAE Grades 1 –4). CTCAE Grade 5 (death) will not be used 
in this study ; rather, information about deaths will be collected though an EOT form during 
treatment period. Deaths that occur within the [ADDRESS_420142] study  drug dose 
will be collected on the Study Evaluation Completion eCRF (visit 778 in the core phase or visit 
780 in the optional extension phase).
The occurr ence of adverse events should be sought by  [CONTACT_105]-directive questioning of the patient 
(subject) during the screening process after signing informed consent and at each visit during 
the study . Adverse events also may be detected when they are volunteered by [CONTACT_102] 
(subject) during the screening process or between visits, or through physical examination, 
laboratory  test, or other assessments. As far as possible, each adverse event should be evaluated 
to determine:
The severit y grade (mild, moderate, severe and life -threatening corresponding to CTCAE 
Grades 1 –4)
Its duration (Start and end dates or Ongoing at End of Study  )
Its relationship to the study  treatment (Reasonable possibility  that AE is related: No, Yes)
Action taken with respect to study  or inv estigational treatment (none, dose adjusted, 
temporaril y interrupted, permanentl y discontinued, unknown, not applicable)
Whether medication or therap y was given (no concomitant medication/non -drug therap y, 
concomitant medication/non -drug therap y)
Whether i t is serious, where a serious adverse event (SAE) is defined as in Section 8.2.1.
All adverse events should be treated appropriately . If a concomitant 
medication or non-drug 
therap y is given, this action shoul
d be recorded on the Adverse Event eCRF.
Once an adverse event is detected, it should be followed until its resolution or until it is judged 
to be permanent, and assessment should be made at each visit (or more frequently , if necessary ) 
of any changes in severity , the suspected relationship to the study  treatment, the interventions 
required to treat it, and the outcome.

[COMPANY_001] Confidential Page 93
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
8.1.[ADDRESS_420143] abnormalities
[IP_ADDRESS] Definitions and reporting
Laboratory  abnormalities that constitute an Adverse event in their own right (are considered 
clinically  significant, induce clinical signs or symptoms, require concomitant therap y or require 
changes in study  treatment), should be recorded on the Adverse Events eCRF. Whenever 
possible, a diagnosis, rather than a symptom should be provided (e.g. anemia instead of low 
hemoglobin). Laboratory abnormalities that meet the criteria for Adverse Events should be 
followed until they have returned to normal or an adequate explanation of the abnormality  is 
found. When an abnormal laboratory or test r esult corresponds to a sign/s ymptom of an already 
reported adverse event, it is not necessary  to separately  record the lab/test result as an additional 
event.
Laboratory  abnormalities, that do not meet the definition of an adverse event, should not be 
reported as adverse events. A severe event (CTCAE Grade 3) does not automatically indicate a 
SAE unless it meets the definition of serious as defined below and/or as per investigator’s 
discretion. A dose hold or medication for the lab abnormality  may  be requir ed by [CONTACT_339604], by [CONTACT_108], be an adverse event and must be 
reported as such.
8.2 Serious adverse events
8.2.1 Definitions
Serious adverse event (SAE) is defined as one of the following:
Is fatal or life -threatening
Results in persistent or significant disability /incapacity
Constitutes a congenital anomaly /birth defect
Requires inpatient hospi[INVESTIGATOR_1081],
Is medicall y significant, i.e., defined as an event that jeopardizes the patient or may  
require medical or surgical intervention to prevent one of the outcomes listed above
Note that hospi[INVESTIGATOR_14944]:
Routine treatment or monitoring of the studied indication, not associated with any  
deterioration in condition
Elective or pre -planned treatment for a pre -existing condition that is unrelated to the 
indication under study  and has not worsened since signing the informed consent
Social reas ons and respi[INVESTIGATOR_5316]’s 
general condition
Note that treatment on an emergency outpatient basis that does not result in hospi[INVESTIGATOR_5317] y of the definitions of a SAE given above 
is not a serious adverse event

[COMPANY_001] Confidential Page 94
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
8.2.[ADDRESS_420144] be reported as follow -up to the original 
epi[INVESTIGATOR_5319] 24 hours of the investigator receiving the follow -up information. An SAE 
occurring at a different time interval or otherwise considered completely  unrelated to a 
previously  reported one should be reported separately  as a new event.
Information about all SAEs is collected and recorded on the Serious Adverse Event Report 
Form; all applicable sections of the form must be completed in order to provide a clinically 
thorough report. The investigator must assess and record the relationship of each SAE to each 
specific study  treatment (if there is more than one study  treatment), complete the SAE Report 
Form in English, and send the completed, signed form by  [CONTACT_87109] 24 hours to the oncology 
[COMPANY_001] Drug Safety  and Epi[INVESTIGATOR_623]  (DS&E) department.
The telephone and telefax number of the contact [CONTACT_339605][INVESTIGATOR_623]  (DS&E), specific to the site, are listed in the inve stigator folder provided to 
each site. The original copy  of the SAE Report Form and the fax confirmation sheet must be 
kept with the case report form documentation at the study  site.
Follow -up information is sent to the same contact(s) to whom the original SAE Report Form 
was sent, using a new SAE Report Form stating that this is a follow -up to the previously  
reported SAE and giving the date of the original report. Each re-occurrence, complication, or 
progression of the original event should be reported as a follow -up to that event regardless of 
when it occurs. The follow -up information should describe whether the event has resolved or 
continues, if and how it was treated, and whether the patient continued or withdrew from study 
participation.
If the SAE is not previously  documented in the [ Investigator’s Brochure] (new occurrence) and 
is thought to be related to the [COMPANY_001] study  treatment, an oncology  [COMPANY_001] Chief Medical 
Office and Patient Safety (CMO&PS) department associate may urgently  require furth er 
information from the investigator for Health Authority  reporting. [COMPANY_001] may need to issue 
an Investigator Notification (IN), to inform all investigators involved in any study with the same 
drug that this SAE has been reported. Suspected Unexpected Serious Adverse Reactions 
(S[LOCATION_003]Rs) will be collected and reported to the competent authorities and relevant ethics 
committees in accordance with Directive 2001/20/EC or as per national regulatory  requirements 
in participating countries.
8.3 Emergency  unblinding of treatment assignment
Not applicable, this is an open- label treatment study .

[COMPANY_001] Confidential Page 95
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
8.4 Pregnancies
Serum and urine pregnancy  tests will be performed for all females of child- bearing potential 
according to the schedule in Table 7-1for the core phase. Urine pregnancy  tests will be at the 
Investigator’s discretion during the optional extension phase treatment phase as per schedule in 
Table [ADDRESS_420145] s, 
congenital abnormalities, or maternal and/or newborn complications. The study  drug must be 
discontinued, though the patient may choose to remain in the study , if she wishes to do so. If 
the patient chooses to remain in the study , all assessments that ar
e considered as a risk during 
pregnancy  must not be performed. The patient may  continue all other protocol assessments.
Pregnancy  must be recorded on a Pharmacovigilance Pregnancy  Form and reported by [CONTACT_339606]  (CMO&PS) 
Department.
Pregnancy  follow -up should be recorded on the same form and should include an assessment 
of the possible relationship to the [COMPANY_001] study  drug of any pregnancy  outcome. Any SAE 
experienced during pregnancy  must be reported on the SAE Report Form.
After consent is provided, the pregnancy reporting will occur up to one y ear after the estimated 
date of delivery .
8.5 Warnings and precautions
No evidence available at the time of the approval of this study  protocol indicated that special 
warnings or precautions were appropriate, other than those noted in the provided [I nvestigator 
Brochure]. Additional safety  information collected between IB updates will be communicated 
in the form of Investigator Notifications. This information will be included in the patient 
informed consent and should be discussed with the patient during the stud y as needed.
8.6 Data Monitoring Committee
Not applicable.
8.7 Steering Committee
Not applicable.

[COMPANY_001] Confidential Page 96
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
[ADDRESS_420146] of the following:
What protected health informa tion (PHI) will be collected from subjects in this study
Who will have access to that information and wh y
Who will use or disclose that information
The rights of a research subject to revoke their authorization for use of their PHI
In the event that a subject revokes authorization to collect or use PHI, the investigator, by 
[CONTACT_5151], retains the ability  to use all information collected prior to the revocation of subject 
authorization. For subjects that have revoked authorization to collect or use PHI, attempts 
should be made to obtain permission to collect follow -up safet y information (e.g. has the subject 
experienced an y new or worsened AEs) at the end of their scheduled study period.
The data collection system for this study  uses built-in security  featur es to encry pt all data for 
transmission in both directions, preventing unauthorized access to confidential participant 
information. Access to the system will be controlled by a sequence of individually  assigned 
user identification codes and passwords, made available only to authorized personnel who have 
completed prerequisite training.
9.2 Site monitoring
Before study  initiation, at a site initiation visit or at an investigator’s meeting, [COMPANY_001] 
personnel (or designated CRO) will review the protocol and eCRFs with the investigators and 
their staff. During the study , the field monitor will visit the site regularly to check the 
completeness of patient records, the accuracy  of entries on the eCRFs, the adherence to the 
protocol to Good Clinical Practice, the progress of enrollment, and to ensure that study 
treatment is being stored, dispensed, and accounted for according to specifications. Key study 
personnel must be available to assist the field monitor during these visits.
The investigator must maintain source documents for each patient in the study , consisting of 
case and visit notes (hospi[INVESTIGATOR_5320]) containing demographic and medical 
information, laboratory data, electrocardiograms, and the results of any other tests or 
assessments. All info
rmation recorded on eCRFs must be traceable to source documents in the 
patient's file. The investigator must also keep the original signed informed consent form (a 
signed copy is given to the patient/caregiver).
The investigator must give the monitor access to all relevant source documents to confirm their 
consistency  with the eCRF entries. [COMPANY_001] monitoring standards require full verification for 
the presence of informed consent/assent, adherence to the inclusion/exclusion criteria and 
documentation of SAEs. Additional checks of the consistency  of the source data with the eCRFs 
are performed according to the study -specific monitoring plan.

[COMPANY_001] Confidential Page 97
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
9.3 Data collection
This study  is using Electronic Data Capture (EDC), the designated investigator staff will enter 
the data required by [CONTACT_5374] (eCRF). The eCRFs 
have been built using fully validated secure web-
enabled software that conforms to [ADDRESS_420147] been trained. Automatic validation programs check for data discrepancies in the eCRFs 
and, allow modification or verification of the entered data b y the investigator staff.
The Principal Investigator [INVESTIGATOR_20115], 
accurate, and that entr y and updates are performed in a timely  manner. Samples for Central lab, 
PK and ocular examination photographs should be sent to the vendors on timely  manner, [Egypt: 
only safety samples will be sent to Local laboratory, no PK samples will be collected] . 
Please refer to the corresponding section for more information.
9.4 Database management and quality  control
[COMPANY_001] personnel (or designated CRO) will review the data entered by [CONTACT_49432] . Electronic data queries stating the nature of the problem and 
requesting clarification will be created for discrepancies and missing values and sent to the 
investigational site via the EDC system. Designated investigator site staff are required to 
respond promptly  to queries and to make any  necessary  changes to the data.
Concomitant treatments and prior medications entered into the database will be coded using the 
WHO Drug Reference List, which employ s the Anatomical Thera peutic Chemical classification 
system. Medical history /current medical conditions and adverse events will be coded using the 
Medical dictionary  for regulatory  activities (MedDRA) terminology .
Data for PK, Laboratories sampling and ocular examination photographs will be processed 
centrall y and the results will be sent electronically  to [COMPANY_001] (or a designated CRO). [Egypt: 
For Egypt sites, data for laboratories sampling will be processed locally and the results 
will be sent electronically to [COMPANY_001] (or a designated CRO) including normal ranges] .
ObsRO/PRO questionnaires and diary data will be entered into an electronic 
questionnaire/paper questionnaire (onl y in case of ePRO malfunctioning) by [CONTACT_4677]/caregiver. The system will be supplied by  a vendor(s), who will also manage the 
database. The database will be sent electronicall y to [COMPANY_001] personnel (or designated CRO).
Randomization codes and data about all study  treatments dispensed to the patient and all IRT 
assigned dosage chang es will be tracked using an Interactive Response Technology . The system 
will be supplied by a  vendor(s), who will also manage the database. The data will be sent 
electronically  to [COMPANY_001] personnel (or designated CRO).
The occurrence of any protocol violations will be determined. After these actions have been 
completed and the data has been verified to be complete and accurate, the database will be 
declared locked. Authorization is required prior to making any database changes to locked data, 
by [CONTACT_15044].
After database lock, the investigator will receive a CD -ROM or paper copi[INVESTIGATOR_339541] e.

[COMPANY_001] Confidential Page 98
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
[ADDRESS_420148] descriptive analy ses will include:
Frequencies and percentages for categorical data;
n, mean, standard deviation, minimum, median, 25th and 75th percentiles ( as appropriate) 
and maximum for continuous data.
In PK analysis, geometric mean, CV%, CV% of geometric -mean will be included besides the 
analyses mentioned above. Additional information for analysis methods will be available in 
Statistical Analy sis Plan. Statistical analysis will be performed according to treatment 
formulation groups: DT and deferasirox granule formulation.
The handling of any potential impact due to a Public Health emergency (e.g. pandemic, 
epi[INVESTIGATOR_339542].) on the anal yses will be detailed in the SAP.
10.1 Analysis sets
10.1.1 Full A nalysis Set
The Full Anal ysis Set 1 (FAS -1) comprises all I CT naïve patients to whom study  treatment has 
been assigned b y randomization dur ing the core phase.
The Full Analy sis Set 2 (FAS -2) comprises all ICT pre-treated patients to whom study  treatment 
has been assigned b y randomization during the core phase.
The Full Anal ysis Set 3 (FAS -3) comprises all ICT pre-treated and naïve patients towhom study  
treatment has been assigned by  [CONTACT_339607].
According to the intent to treat principle, patients will be analyzed according to the treatment 
and stratification factors they have been assigned to during the randomization procedure.
10.1.[ADDRESS_420149] one dose of granule formulation 
during the core or extension phase.

[COMPANY_001] Confidential Page 99
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
Patients will be analy zed according to the study treatment they actuall y received. A precise 
definition of “actually received” and of the anal ysis set used for pre -dose PK data analyses will 
be added in the SAP.
10.1.[ADDRESS_420150] naïve patients from the FAS-1 without any major 
protocol deviation.
The protocol deviations that will lead to exclusion of patients from the PPS will be detailed in 
the SAP.
10.1.4 Pharmacokinetic A nalysis Set
The Pharmacokinetic Analy sis Set (PAS) consists of all patients who have at least one evaluable 
pre-or post -dose PK concentration (deferasirox).
A PK concentration is considered evaluable if it fulfills all of the following criteria:
The actual dose or leading dose prior to pre -dose sampling must be as planned by  
[CONTACT_990]. In addition, the patient should have received the same dose during the last 4 day s 
prior to sampling (except for Week 1 Day  1).
The elapsed time between dose administration and PK concentrat ion is documented.
The PK concentration must NOT be associated with any  vomiting within 4 hours of 
dosing.
10.2 Patient demographics/other baseline characteristics
Demographic and other background data will be summarized descriptively  by [CONTACT_339608] l separatel y for the FAS -1, FAS -2 and the FAS -3.
Demographic data included age, age categories (2 to <10 years and 10 to <18 years), gender, 
race. Other background data included weight, weight group (<20 kg, 20- <35 kg, 35-<55 kg, 55-
<75 kg, ≥75 kg), height , main underly ing disease, history  of splenectomy  (Yes/No), prior iron 
chelation therap y (Yes/No), prior deferasirox (Yes/No), type of last chelation therap y prior to 
the study , hepatitis B and C status, medical history  by [CONTACT_339609], abnormality  in baseline ECG (Yes/No) and (clinically  significant/non -significant), 
abnormality  in baseline echocardiogram (Yes/No) and (clinicall y significant/non -significant), 
abnormality  in baseline audiometric test (Yes/No) and (clinically  signifi cant/non -significant), 
abnormality  in baseline ocular exam 
(Yes/No) and (clinicall y significant/non -significant, 
baseline creatinine, baseline creatinine group (≤upper limit of normal range (ULN), >ULN -
≤1.5*UL N and >1.5*ULN), baseline creatinine clearance, baseline creatinine clearance group 
(<40, ≥40-<60, , ≥60-<90 and ≥90 mL/min), baseline ALT, baseline ALT group 
(≤ULN, >ULN -≤3*ULN, >3*ULN -≤5*ULN and >5*ULN), baseline AST, baseline AST group 
(≤ULN, >ULN -≤3*ULN, >3*ULN -≤5*ULN and >5*ULN), urine protein/cre atinine ratio (≤0.2 
mg/mg,>0.2- ≤0.5, >0.5 -≤1 mg/mg and >1 mg/mg), baseline serum ferritin and baseline serum 
ferritin group (<1000, ≥1000 to ≤2500, >2500 to ≤5000, >5000 ng/mL).

[COMPANY_001] Confidential Page 100
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
Categorical data will be presented as frequencies and percentages. For continu ous data, mean, 
standard deviation, median, 25th and 75th percentiles, minimum, and maximum will be 
presented.
10.3 Treatments (duration of exposure, concomitant therapi[INVESTIGATOR_014], 
percentage of planned dose taken)
The following variables will be summarized with descri ptive measures separatel y for the Safet y 
Set-1, Safet y Set-2, Safety  Set-3 and Safet y Set-4 by [CONTACT_14509]: duration of exposure, in 
weeks and in categories (core phase: <4 weeks, 4-<12 weeks, 12-<20 weeks, 20-<28 weeks, 
28-<36 weeks, 36 -<44 weeks, ≥44 wee ks and extension phase: <6 months, 6 -<12 months, 12 -
<24 months, 24-<36 months, 36-<48 months, >48 months); average planned (mg/kg/day ) and 
average actual daily  dose; cumulative planned (mg/kg) and total actual dose (mg/kg); 
percentage of planned dose taken ; frequency  of interruptions, decreases and increases in 
planned dose, overall and by  [CONTACT_339610].
The total patient -years while on treatment, calculated as the sum of (overall drug exposure) / 
365.25 will be provided by  [CONTACT_339611].
The duration of exposure, defined as the number of weeks (core phase) / months (extension 
phase) between the start and end of study  medication, will be summarized by [CONTACT_339612]. The end of study  medication day  is the last day  with a n on-zero actual dose of study  
medication as recorded on the drug administration pages.
The average daily dose (planned or actual, in mg/kg) is calculated as the mean dose over all 
days between first and last dose, excluding interim days with zero dose (interruptions). The 
cumulative dose is calculated as the sum over the daily  doses of all day s between first and last 
dose. The current weight is used when calculating the actual dail y dose.
The percentage of planned dose taken is derived as 100 * cumulative actual dose (mg/kg)/ 
cumulative planned dose (mg/kg).
Prior and concomitant medications and significant non-drug therapi[INVESTIGATOR_339543] b y phase. 
Prior medications 
are defin ed to be drugs taken prior to the first dose of study  medication. 
Concomitant medications are medications taken between the first dayof study  medication and 
up to [ADDRESS_420151] 
day of study  medication and continuing after the start date of study  medication . 
10.4 Primary  objective
The primary  objective of this study  is to evaluate patient compliance with study  treatment, as 
measured by [CONTACT_339613]/dispersible tablets and to evaluate 
the change in serum ferritin over time for both formulations of deferasirox in pediatric ICT 
naive patients with iron overload during core phase, after 24 weeks of treatment.
10.4.1 Variables and analy sis set
All analy ses for the primary  objective will be performed on the FAS-1 and presented by 
[CONTACT_1570]: deferasirox DT and deferasirox granule formulation.

[COMPANY_001] Confidential Page 101
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
The co -primary  efficacy  variables are:
Compliance measured b y stick pack /tablet count based on amount of medication 
dispensed, returned and reported as lost/wasted b y the patient or caregiver, over 24 weeks 
of treatment (i.e. assessed at week 25 visit). Compliance will be calculated as the ratio of 
total count consumed to total count prescribed, where
total count consum ed is derived from cumulative dispensed, returned and lost/wasted 
counts over 24 weeks of treatment (i.e. assessed at week 25 visit);
total count prescribed is cumulative prescribed count over 24 weeks of treatment (i.e. 
assessed at week 25 visit).
Change from baseline in serum ferritin after 24 weeks of treatment (i.e. assessed at the 
week 25 visit).
10.4.2 Statistical method of analy sis
The primary  efficacy  analysis will be the comparison of means between the two treatment arms 
of change from baseline after 24 w eeks of treatment in SF and mean relative consumed stick 
pack /tablet count over [ADDRESS_420152] to both endp oints. Therefore, no adjustment for 
multiplicity  of the t ype I error (alpha) is required.
The primary  inferential analy sis described below will be based on the FAS-1.
Let μSF,Gand μSF,DTdenote the mean change from baseline in SF to week 25 visit for granule 
and DT formulations, respectively . Let μC,Gand μC,DTbe similarly  defined for compliance 
measured b y stick pack /tablet count.
The null and the alternative hy pothesis are defined as follows:
H0,SF: μSF,G= μSF,DT no effect of granule formulation with regard to change in SF, and/or
H0,C: μC,G= μC,DT no effect of granule formulation with regard to compliance
versus
H1,SF: μSF,G < μSF,DT mean change in SF favorable for granule formulation compared to DT 
formulation, and
H1,C:μC,G > μC,DT mean compliance favorable for granule formulation compared to DT 
formulation
Analysis of covariance (ANCOVA) will be performed for comparison between both treatment 
groups. The ANCOVA model for compliance endpoint will include treatment group and age 
group (2 to<10 years, 10 to <18 years) as factors. The model for serum ferritin endpoint will 
also include the serum ferritin value at baseline as covariate.
For each of the endpoint the following estimates from the ANCOVA will be provided:
the least squares mean wi th 2-sided 95% confidence interval for each treatment arm
the least squares means with 2-sided 95% confidence interval, p -value for the difference 
between treatment arms

[COMPANY_001] Confidential Page 102
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
10.4.3 Handling of missing values/discontinuations
In case of missing serum ferritin value after [ADDRESS_420153] -baseline serum ferritin value will be excluded from the anal ysis. 
10.4.4 Supportive analy ses
The following supportive and supplementary  analy ses will be provided:
The primary  anal ysis will be repeated for the FAS -2 and FAS -3.
The primary  anal ysis will also be provided for the PPS;
If more than 10% of patients have no serum ferritin value after 24 weeks of treatment, 
supplementary  analy ses will be performed for the primary  anal ysis for serum ferritin using 
imputation techniques. Details will be provided in the study  SAP.
Other supportive analy ses may  be detailed in the SAP.
10.5 Secondary  objectives 
10.5.1 To evaluate both formulations on change in serum ferritin and 
compliance measured by  [CONTACT_339552] /tablet count after [ADDRESS_420154] descriptive statistics by  [CONTACT_2939].
In addition at the time of primary  analysis if more than 10% of patients have no serum ferritin 
value after 48 weeks of treatment or missing compliance measured by [CONTACT_339552]/tablet count
over [ADDRESS_420155] naïve 
and pre -treated patients
Absolute and relative change from baseline in serum ferritin for core phase will be summarized 
after 24 weeks (i.e. assessed at week 
25 visit) and [ADDRESS_420156]
descriptive statistics b y treatment arm for the FAS-1 and FAS -2. The 95% confidence intervals 
for mean will additionally be provided.
A forest plots will be presented with change in SF after [ADDRESS_420157] 95%CI. Point estimates and 95% CI will be generated for the FAS-
1, FAS -[ADDRESS_420158] deviation values of serum ferritin will be plotted by 
[CONTACT_339614].

[COMPANY_001] Confidential Page 103
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
10.5.3 To evaluate both formulations on patient satisfaction and palatability  
using PRO/ObsRO questionnaires
The FAS-1, FAS-2 and the FAS-3 will separately  be used for the analysis of patient satisfaction 
and palatability  using a PRO/ObsRO questionnaire for the core phase.
For the SICT questionnaire, the score for each domain will be the mean of the score of items 
included in the corresponding domain. Standard descriptive analyses will be performed for both 
formulations for each domain score at Week 2, Week 3, Week 25 and the EOT (core)/777 visits 
as well as their absolute changes at Week 25 and EOT (core)/[ADDRESS_420159] descriptive analy ses include: n, mean, standard deviation, minimum, median and 
maximum. The 95% confidence intervals for the absolute changes in all domains at Week 25 
and EOT (core) /[ADDRESS_420160] descriptive analyses include: n, mean, standard deviation, minimum, 
median and maximum. The 95% confidence interval for the absolute change of the overall score 
at the Week [ADDRESS_420161] day of study  drug from Week 2 will be presented for both 
formulations.
Details about scoring and anal yses will be included in the SAP.
10.5.4 To evaluate both formulations on overall safety , measured by  
[CONTACT_339615] y Set 1, Safety  Set 2 and the Safet y Set-3 will separatel y be used. The overall 
observation period will be divided into three mutually  exclusive segments:
1.Pre-treatment period: from day  of patient’s informed consent to the day  before first dose 
of study  medication
2.On-treatment period: from day  of first dose of study  medication to [ADDRESS_420162]-treatment period: starting at day  [ADDRESS_420163] dose of study  medication.
[IP_ADDRESS] Adverse events (A Es)
Summary  tables for adverse events (AEs) have to include only AEs that started or worsened 
during the on-treatment perio d, the treatment -emergent AEs. However, all safet y data 
(including those from the pre and post-treatment periods) will be listed and those collected 
during the pre -treatment and post -treatment period are to be flagged.
The incidence of treatment- emergent adverse events (new or worsening from baseline) will be 
summarized by [CONTACT_5379]/or preferred term, severit y, type of adverse event, 
relation to study  treatment by [CONTACT_339616]. Exposure -adjusted adverse event incidence, 
defined as number of patients with new or worsened AEs during period/[total number of days 
patient was on treatment summed for all patients/365.25 days], will be presented.

[COMPANY_001] Confidential Page 104
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
An overall summary  of type of AEs (e.g. serious, leading to study  drug discontinuation , 
requiring dose adjustment or/and interruption ) will be presented by [CONTACT_339617].
Specific groupi[INVESTIGATOR_339544]. Such groups consist of adverse 
events for which there is a specific clinical interest in connection with Deferasirox treatment or 
adverse events which are similar in nature (although not identical). Note that certain adverse 
events may  be reported within multiple groupi[INVESTIGATOR_14839]/AESI s.
AESI s are defined by [CONTACT_133416]. All AESI definitions or AE groupi[INVESTIGATOR_339545]  (eCRS). The latest version of the eCRS available 
at the time of the anal ysis will be used.
Incidence of AESI will be summarized by  [CONTACT_63790][INVESTIGATOR_007], preferred term and treatment arm.
Summary  tables for adverse events (AEs) will be repeated for the optional extension phase on 
the Safet y Set 4.
[IP_ADDRESS] Laboratory  abnormalities
All laboratory  values will be converted into S I units and the severit y grade calculated using the 
low/normal/high classifications based on laboratory normal ranges and for selected parameters 
(see Table 10 -1below) by  [CONTACT_339618]/extended ranges.
The following summaries will be generated separatel y for hematology, biochemistry  and 
urinary laboratory  tests:
shift tables using normal/notable/extended ranges to compare baseline to the worst on -
treatment value
listing of all laboratory  data with values flag ged to show the corresponding 
normal/notable/extended ranges (see Table 10 -1below).
For laboratory  parameters observed values (and changes from baseline), and per subsequent 
quarter will be summarized by [CONTACT_339619] (n, mean, standard deviation, 
minimum, lower quartile, median, upper quartile and maximum).
Laboratory  abnormalities will be described for the optional extension phase on the Safet y Set 
4.
In addition to the above mentioned tables and listings, other exploratory  analy ses, for example 
figures plotting time course of raw or change in laboratory  tests over time or box plots might 
be specified in the SAP.

[COMPANY_001] Confidential Page 105
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
Table 10-1 Definition of notable/extended ranges for laboratory  tests
Laboratory  test Criteria for notable ranges
Platelet count < 100 x 109/L (extended range <50×109/L)
Absolute neutrophils < 1.5 x 109/L (extended range <0.5×109/L)
Serum creatinine > 33% increase from baseline and > ULN at two consecutive 
measurements at least 7 days apart
Creatinine clearance <60 mL/min at two consecutive measurements at least 7 days apart 
(extended range <40 mL/min at two consecutive measurements at 
least 7 days apart)
Urinary protein/urinary creatinine ratio ≥ 1.0 (mg/mg) at two consecutive measurements at least [ADDRESS_420164] >[ADDRESS_420165] and >2 x baseline value (extended range >10×ULN 
and >2×baseline value)
10.5.5 To evaluate compliance using a daily  PRO/ObsRO questionnaire
Patient adherence to medication regimen instructions will be assessed via daily  diary records 
(PRO / ObsRO questionnaire) providing information on two dimensions: whether the study  
medication is consumed andthe time of medication intake. These data will be summarized over 
time by [CONTACT_339620]. The rate of dosing instructions deviations 
(doses missed completely  or not taken at approximately  the same time every  day) will be 
calculated for each study  arm.
The FAS-1, FAS-2 and FAS-3 will separately  be used for the analysis of compliance using a 
daily  PRO/ObsRO questionnaire.
Details about scoring and anal yses will be included in the SAP.
10.5.6 Pharmacokinetics
The PAS will be used to sum marize (pre -dose) Cmin and (post -dose) Cmax concentrations and 
to assess  patients’ compliance and analysis of PK concentrations. PK/PD (PK/safet y and 
PK/Efficacy ) analyses will be based on the Safety  Setor FAS accordingl
y. Other anal yses and 
listings of PK concentration will use the FAS.
[IP_ADDRESS] To evaluate pre-dose PK data to support the assessment of 
compliance
Pre-dose PK concentrations (Cmin) from the PAS will be analy zed to support the assessment 
of compliance. Predicted individual Cmin concentrations will be derived from a power model 
considering dose and potential other covariates, such as body  weight. Predicted individual Cmin 
concentrations will be compared to respective observed pre -dose concentrations at steady -state 
of all patients. Distributions of the difference between predicted and observed Cmin values will 
be shown graphically  by [CONTACT_339621].
[IP_ADDRESS] Description of individual PK concentrations and parameters
PK concentrations will be summarized by [CONTACT_3148], visit and time point. PK parameters will 
be summarized by  [CONTACT_10659].

[COMPANY_001] Confidential Page 106
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
Descriptive statistics of PK concentration and PK parameters will include arithmetic and 
geometric means, median, SD, CV%, CV% of the geometric mean, minimum and maximum. 
Zero concentrations w ill not be included in the geometric mean calculation.
All analy ses will be based on the PAS.
[IP_ADDRESS] To explore PK/PD relationship
Serum ferritin change from baseline will be fitted by  a linear mixed effect model with log -
transformed matching pre -dose concentrat ions as covariates and subject as random effect.
Serum creatinine change from baseline, serum creatinine clearance change from baseline and
urine protein creatinine ratio change from baseline will be fitted by  a linear mixed effect model 
with log-transform ed matching pre-dose and post-dose concentrations respectivel y as 
covariates and subject as random effect.
Incidence of notable serum creatinine events as defined in Table 10-[ADDRESS_420166] -compartment models, may  be established 
if appropriate to further explore exposure efficacy  or safet y relationship and will be reported 
separately .
[IP_ADDRESS] Data handling princip les
Biofluid concentrations will be expressed in mass per volume units. All concentrations below 
the limit of quantitation or missing data will be reported as such in the concentration data listings. 
Concentrations below the limit of quantitation will be treated as zero in summary  statistics.
10.6 Other analy ses
10.6.1 Other safety  data
Data from vital signs, body  weight, 
ECG, echocardiogram, ocular, and auditory  examinations 
will be listed and summarized with descriptive statistics as appropriate separately  for each 
Safety  Set. All new or worsened abnormalities will be recorded on the AE eCRF page.
[IP_ADDRESS] Cardiac evaluation
ECG and Echocardiogram will be performed at baseline and EOT in the core phase. ECG will 
be performed when clinically  indicated during the optional extension phase. Abnormalities will 
be reported together with an overall interpretation of the findings. Any abnormalities at baseline 
will be summarized. At post-baseline assessment, the investigator will flag all abnormalities 
s will be recorded 

[COMPANY_001] Confidential Page 107
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
on the AE eCRF page. All findings of patients with new or worsened clinically  significant 
abnormalities will be listed.
[IP_ADDRESS] Vital signs and body  weight
Measurements of vital signs and body  weight done more than 30 day s after discontinuation of 
study  medication will be excluded from the anal ysis but will be listed.
The change from baseline in diastolic blood pressure, systolic blood pressure, pulse rate, and 
weight will be summarized by [CONTACT_339622] n, mean, SD, minimum, median, and 
maximum values.
A listing will be provided for all vital signs and weight. Notable pulse rate and weight values 
are flagged. The criteria for notably  abnormal pulse rate and weight are display ed in Table 10 -
2.
Table 10
-2 Definition of notable ranges for pulse rate and weight
Parameter
Weight High Increase from baseline ≥ 10%
Low Decrease from baseline ≥ 10%
Pulse rate (beats per minute) High112-18 months
18-24 months
2-3 years
3-4 years
4-6 years
6-8 years
8-12 years
12-15 years
15-18 years> 140
> 135
> 128
> 123
> 117
> 111
> 103
> 96
> 92
Low1 12-18 months
18-24 months
2-3 years
3-4 years
4-6 years
6-8 years
8-12 years
12-15 years
15-18 years< 103
< 98
< 92
< 86
< 81
< 74
< 67
< 62
< 58
1: Fleming et al 2011.
[IP_ADDRESS] Auditory and ocular assessment evaluations
Auditory  evaluations will be performed at baseline, visit 17 if entering the optional extension 
phase and annually  during the optional extension phase and ocular evaluations at baseline, 
Week 25 visit (Visit 11) and at EOT(core) visit (Visit 777) during the core phase and annually 

[COMPANY_001] Confidential Page 108
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
during the optional extension phase. Any abnormalities at baseline will be summarized. 
Abnormalities will be reported together with an overall interpretation of the findings. All new 
or worsened abnormalities will be recorded on the AE eCRF page. All findings of patients with 
new or worsened clinically  significant abnormalities will be listed.
[IP_ADDRESS] Grow th and Development
For pediatric patients, growth velocity and pubertal stage will be listed at baseline, at EOT visit 
777 and annually  during the optional extension phase and summarized using descriptive 
statistics as appropriate.
[IP_ADDRESS] Serum ferritin during the optional extension phase
Change from baseline in serum ferritin at every  year will be described for the Safet y Set [ADDRESS_420167] completed a minimum of 12 weeks of treatment exposure or discontinued from treatment 
core phase 
at the time of the cutoff date will be included in the interim analy sis.
All the analy ses included in the interim analysis will be descriptive. Testing of hy potheses will 
not be performed and no decisions regarding the future course of the trial is anticipated at the 
time of the IA and the trial will continue. Therefore adjustment for multiplicity  is not performed.  
Descriptive statistics will be provided by [CONTACT_339623] (i.e. change 
from baseline in serum ferritin and compliance measured by [CONTACT_339552] /tablet count) and key 
safet y data. 
Details on the anal yses will be described in the statistical analysis plan.
10.8 Sample size calculation
The primary  objective of this study  is to evaluate patient compliance (using stick packs or 
tablets counts) and change in serum ferritin (SF) over time for both formulations of deferasirox 
in pediatric ICT naïve patients with iron overload.
The sample size was estimated to demonstrate superiority  and statistical significance for both 
co-primary  endpoints.
The assumptions made for this study  were:
For serum ferritin:
An expected improvement between both formulations in SF change from baseline after 24 
weeks of treatment of −450ng/mL with a standard deviation (SD) of 900 ng/mL based on 
results from study  CICL670A0107 in pediatric patients treated with Exjade on ≥25 
mg/kg/day  after 24 weeks of treatment.

[COMPANY_001] Confidential Page 109
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
For compliance using stick packs or tablets counts:
An expected improvement between both formulations in mean relative consumed tablet 
count of 10% with a SD equal to 17.625% based on the pooled anal ysis on pediatric 
patients (77) from Exjade studies [ICL670A2206] (39), [ICL670A2204] (24) and 
[ICL670A2214] (14).
The sample size, driven by [CONTACT_339624], has been determined to obtain 76% 
power at a one-sided 5% level of significance for showing superiority  of granule formulation 
over DT formulation with respect to change from baseline after [ADDRESS_420168] 76% power to detect a difference in means of 400.0 
ng/mL assuming that the common SD is 800.0 ng/mL  using a two group t-test with a 0.[ADDRESS_420169] a difference of 10% or 
more in mean compliance is about 84%.
Considering a potential of 
5% dropout ratepatients, the required sample size to achieve the 
primary  objective is 48 chelation naïve patients for each trea tment group (96 patients in total).
In addition, the clinical trial will enroll patients previously  treated with iron chelation patients. 
Considering that a direct comparison of granule and DT formulations in terms of efficacy  is not 
foreseen in previousl ychelated patients, the required sample size is not based on power 
calculations as usual. The selection of number of patients is based on the precision in the 
estimate of SF change after 48 weeks of treatment and on practical considerations.
A maximum of 120 (60 patients will be in each formulation group) previously  chelated patients 
will be enrolled. Sixty  patients will provide an estimate of SF change with precision (half -width 
of 95% confidence interval) equal to 303.6.
Table 10-3 below lists the precisions in the estimates of SF change for different numbers of 
patients using the estimated SD obtained from the [CICL670A0107] study  results in pediatric 
patients treated with Exjade on ≥25 mg/kg/day  at wee k 48 of treatment.
Table 10-3 Precision in the estimate of the serum ferritin change
Number of patients Half-width of 95%  confidence interval in the estimate of the SF change
40 371.8
45 350.6
50 332.6
55 317.1
60 303.6
The total required sample size for this clinical trial is up to 108 patients for each treatment group 
(up to 216 patients in total), including 48 iron chelation naive patients per group (96 patients in 
total).

[COMPANY_001] Confidential Page 110
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
11 Ethical considerations and administrative procedures
11.1 Regulatory  and ethical compliance
This clinical study  was designed, shall be implemented and reported in accordance with the 
ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with applicable local 
regulations (including European Directive 2001/20/EC and US Code of Federal Regulations 
Title 21), and with the ethical principles laid down in the Declaration of Helsinki.
11.2 Responsibilities of the investigator and IRB/IEC/REB
The protocol and theproposed informed consent form must be reviewed and approved by a 
properl y constituted Institutional Review Board/I ndependent Ethics Committee/Research 
Ethics Board (IRB/IEC/REB) before study  start. Prior to study  start, the investigator is required 
to sign a protocol signature [CONTACT_5389]/her agreement to conduct the study  in 
accordance with these documents and all of the instructions and procedures found in this 
protocol and to give access to all relevant data and records to [COMPANY_001] monitors, auditors, 
[COMPANY_001] Clinical Quality  Assurance representatives, designated agents of [COMPANY_001], 
IRBs/IECs/REBs and regulatory  authorities as required.
11.3 Informed consent procedures
Eligible patients may only be included in the study  after providing written (witnessed, where 
required by [CONTACT_6617]), IRB/IEC/REB -approved informed consent or, if incapable of 
doing so, after such consent has been provided by a legally  acceptable representative of the 
patient. In cases where the patient’s representative gives consent, the patient should be informed 
about the study  to the extent possible given his/her understanding. If the patient is capable of 
doing so, he/she should indicate assent by [CONTACT_18684] a sepa rate assent form.
Informed consent must be obtained before conducting an y stud y-specific procedures (i.e. all of 
the procedures described in the protocol). The process of obtaining informed consent should be 
documented in the patient source documents. The date when a subject’s Informed Consent was 
actuall y obtained will be captured in their eCRFs.
[COMPANY_001] will provide to investigators, in a separate document, a proposed informed consent 
form (ICF) that is considered appropriate for this study  and complies with the ICH GCP 
guideline and regulatory  requirements. Any changes to this ICF suggested by [CONTACT_5381]/IEC/REB, and a copy of the 
approved version must be provided to the [COMPANY_001] monitor af ter IRB/ IEC/REB approval.
Women of child bearing potential should be informed that taking the study  medication may 
involve unknown risks to the fetus if pregnancy  were to occur during the study  and agree that 
in order to participate in the study  they must adhere to the contraception requirement for the 
duration of the study . If there is any question that the patient will not reliably compl y, they 
should not be entered in the study .
As per Section 4.5, during a Public Health emergency as declared by [CONTACT_6620] i.e. pandemic, epi[INVESTIGATOR_6519], that may challenge the ability  to obtain 

[COMPANY_001] Confidential Page 111
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
a standard written informed consent due to limits that prevent an on -site visit, I nvestigator may 
conduct the informed consent discussion remotely  (e.g. telephone, videoconference) if 
allowable b y a local Heath Authority. 
Guidance issued by [CONTACT_157092] y documented (e.g. the presence of an impartial witness, sign/dating separate ICFs 
by [CONTACT_6622], etc.).
11.4 Discontinuation of the study
[COMPANY_001] reserves the right to discontinue this study  under the conditions specified in the clinical 
study  agreement. Specific conditions for terminating the study are outlined in 
Section 4.4
11.5 Publication of study  protocol and results
[COMPANY_001] assures that the key design elements of this protocol will be posted in a publicl y 
accessible database such as clinicaltrials.gov. In addition, upon study  completion and 
finalization of the study  report the results of this study  will be either submitted for publication 
and/or posted in a publicly  accessible database of clin ical study  results.
11.[ADDRESS_420170] keepi[INVESTIGATOR_5324], in 
compliance with Section 4.9 of the ICH E6 GCP, and regulatory and institutional requirements 
for the protection of confidentiality  of subjects. As part of participating in a [COMPANY_001] -sponsored 
study , each site will permit authorized representatives of the sponsor(s) and regulatory agencies 
to examine (and when required b y applicable law, to copy ) clinical records for the purposes of 
quality  assurance reviews, audits and evaluation of the study  safet y and progress.
Source data are all information, original records of clinical findings, observations, or other 
activities in a clinical trial necessary  for the reconstruction and evaluation of the trial. Examples 
of these original documents and data records include, but are not limited to, hospi[INVESTIGATOR_1097], 
clinical and office charts, laboratory  notes, memoranda, subjects’ diaries or evaluation 
checklists, pharmacy  dispensing records, recorded data from automated instruments, copi[INVESTIGATOR_5117], microfiches, 
photographic negatives, microfilm or magnetic media, x-rays, and subject files and records kept 
at the pharmacy , at the laboratories, and medico -technical departments involved in the clinical 
trial.
Data collection is the responsibility  of the clinical trial staff at the site under the supervision of 
the site Pr incipal I nvestigator. The study  case report form (eCRF) is the primary data collection 
instrument for the stud y. The investigator should ensure the accuracy, completeness, legibility, 
and timeliness of the data reported in the eCRFs and all other required reports. Data reported 
on the eCRF, that are derived from source documents, should be consistent with the source 
documents or the discrepancies should be explained. All data requested on the eCRF must be 
recorded. Any missing data must be explained. For electronic CRFs an audit trail will be 
maintained by  [CONTACT_5382].

[COMPANY_001] Confidential Page 112
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
The investigator/institution should maintain the trial documents as specified in Essential 
Documents for the Conduct of a Clinical Trial (ICH E6 Section 8) and as required by [CONTACT_339625]/or guidelines. The investigator/institution should take measures to prevent 
accidental or premature destruction of these documents.
Essential documents (written and electronic) should be retained for a period of not less than 
fifteen (15) years from the completion of the Clinical Trial unless Sponsor provides written 
permission to dispose of them or, requires their retention for an additional period of time 
because of applicable laws, regulations and/or guidelines.
11.[ADDRESS_420171] ensure anon ymity of the patients; patients must not be identified by [CONTACT_5384]. Signed informed consent/assent forms and patient 
enrollment log must be kept strictly  confidentia l to enable patient identification at the site.
11.8 Audits and inspections
Source data/documents must be available to inspections by [CONTACT_5385].
11.[ADDRESS_420172] be 
considered aprotocol amendment, and unless such an amendment is agreed upon by [CONTACT_5386]/IEC/REB it cannot be implemented. All significant protocol 
deviations will be recorded and reported in the CSR.
12.[ADDRESS_420173] be approved by [CONTACT_5343], Health Authorities where required, and the IRB/IEC/REB. Only 
amendments that are required for patient safet y may be implemented prior to IRB/IEC/REB 
approval. Notwithstanding the need for approval of formal protocol amendments, the 
investigator is expected to take any immediate action required for the safety  of any patient 
included in this study , even if this action represents a deviation from the protocol. In such cases, 
[COMPANY_001] should be notified of this action and the IRB/IEC at the study  site should be informed 
according to local regulations (e.g. [LOCATION_006] requires the notification of urgent safet y measures 
within 3 day s) but not later than 10 working da ys.

[COMPANY_001] Confidential Page 113
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
13 References (available upon request)
Borgna -Pi[INVESTIGATOR_40962] C, Rugolotto S, De Stefano P et al (2004) Survival and complications in 
patients with thalassemia major treated with transfusion and deferoxamine. Haematologica; 
89:1187- 1193Cappellini MD, Cohen A, Pi [INVESTIGATOR_99331] A, et al. (2006) A Phase III study  of deferasirox 
(ICL670), a once -daily  oral iron chelator, in patients with ß- thalassemia. Blood; 107:3455 -62
Cappellini MD (2008a) Long- term efficacy  and safet y of deferasirox. Blood Rev; Suppl 
2:S35 -41
Cappellini MD, Elalfy  M, Kattamis J, et al. (2008b) Efficacy  and safet y of once -daily, oral 
iron chelator deferasirox (Exjade) in a large group of regularl y transfused patients with β -
thalassemia major. ASH, San Francisco, [LOCATION_003], 6 -9 December 2008; Poster III -960
Fleming S , Thompson M, Stevens R, et al (2011) Normal ranges of heart rate and respi[INVESTIGATOR_339546] 18 y ears of age: a s ystematic review of observational studies. 
Lancet ;377:1011-8. 
Gabutti V, Pi[INVESTIGATOR_99331] A. (1996) Results of long -term iron -chelati ng therapy . Acta Haematol ; 
95:26 -36
Haghpanah S, Zarei T, Zahed Zi,et al. (2014) Compliance and satisfaction with deferasirox 
(Exjade®) compared with deferoxamine in patients with transfusion -dependent beta -
thalassemia. Hematology; 19: 187 -191
Inati A, Khoriat y E, Musallam KM (2011) Iron in Sickle -Cell Disease: What Have We 
Learned Over the Years? Pediatr Blood Cancer; 56:182-190
Kushner J, Porter J, and Olivieri N (2001) Secondary  Iron Overload. Hematology ; 47-61
Mednick LM, Braunstein J, Neufeld E (2010) Oral Chelation: Should I t Be Used With Young 
Children? Pediatr Blood Cancer; 55:603 -605
Osborne RH, De Abreu Lourenço R, Dalton A, et al (2007) Qualit y of life related to oral 
versus subcutaneous iron chelation: a time trade -off study . Value Health;10(6):451 -6
Osterberg L, Blaschke T (2005) Adherence to Medication. N Engl J Med; 353:487-97
Partridge AH, Avorn J, Wang PS, Winer EP (2002) Adherence to Therapy With Oral 
Antineoplastic Agents. Journal of the National Cancer Institute; 94( 9):652 -
661
Rudd P, By[CONTACT_339626] y RL, Zachary  V et al (1989) The natural history  of medication compliance in a 
drug trial: L imitations of pi[INVESTIGATOR_10685]. Clin Pharmacol Ther, Vol 46, No 2: 169 -
176Trachtenberg F, Vichinsky  E,  Haines, D, et al (2011) Iron chelation adherence t
o 
deferoxamine and deferasirox in thalassemia.  Am J Hematol;  86(5): 433 –436  
Tuleu C (2011) Acceptability  and Palatability  –methods available for assessment.
Vichinsky  E (2008) Oral Iron Chelators and the Treatment of Iron Overload in Pediatric 
Patients With Chronic Anemia.Pediatrics;121;1253
-1256
Vichinsky et al (2012) Standards ofCare Guidelines forThalassemia (Internet) Available
from: http://thalassemia.com/documents/SOCGuidelines2012.pdf (Accessed 29 Jan 2015).
Weatherall DJ (2010) The inh erited diseases of hemoglobin are an emerging global health 
burden. Blood; 115: 4331-4336.

[COMPANY_001] Confidential Page 114
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
Workshop on Paediatric Formulations II for Assessors in National Regulatory Agencies, Nov 
8, 2011, EMA/432389/2011, Human Medicines Development and Evaluation.

[COMPANY_001] Confidential Page 115
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
14 Appendices
14.1 Equivalent dose guidance
All iron chelation pre -treated patients well- managed on treatment with deferasirox will use the 
same starting DT dose or an equivalent granules dose (see Table 14 -1).
For patients pre- treated with deferoxamine, a starting dose of DT or an equivalent granules dose 
that is numerically  half that of the deferoxamine dose (e.g. a patient receiving 40 mg/kg/day  of 
deferoxamine for 5 days per week (or equivalent) could be transferr ed to a starting daily  dose 
of 20 mg/kg/day  of DT or 14 mg/kg/day  of granules), see Table 14 - 2.
Dose equivalence between deferiprone and deferasirox is not established in clinical studies. 
For 
patients p re-treated with deferiprone (DFP), investigators should decide on the starting dose of 
DT or granules in the study , taking into consideration the iron overload status of the patients 
and their transfusional regimen.
Table 14-1 Patients pre -treated with deferasirox
Previous dose of
Deferasirox DT (mg/kg/day )Equivalent dose to be used
Deferasirox DT (mg/kg/day ) Deferasirox granules (mg/kg/day )
5 5 3.5
10 10 7
15 15 10.5
20 20 14
25 25 17.5
30 30 21
35 35 24.5
40 40 28
Table 14-2 Patients pre -treated with deferoxamine
Previous dose of
Deferoxamine (mg/kg/day )Equivalent dose to be used
Deferasirox DT (mg/kg/day ) Deferasirox granules (mg/kg/day )
10 5 3.5
20 10 7
30 15 10.5
40 20 14
50 25 17.5
60 30 21
70 35 24.5
80 40 28

[COMPANY_001] Confidential Page 116
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
Table 14-3 Examples of light meal
Example 1: amount kcalg total 
fats
Wheat Bread or Toast 2 slices 138 2
jams, preserves, all flavors 1 Tablespoon 109 0
banana medium (7 -7 7/8" long) 105 0
orange juice 1 cup 114 0
skim milk 1 cup 83 0
Total: 549 2
Example 2: amount kcalg total 
fats
Pi[INVESTIGATOR_339547] 1 medium (5.25" across) pi[INVESTIGATOR_17399] 124 1
hummus or deli chicken/turkey 1 Tablespoon hummuus or 2 oz. meat 27 1
apple medium (2.75" across) 72 0
salsa, red, cooked 6 Tablespoons 26 0
carrots & celery sticks4 carrot sticks (3" long) and small 5" stalk 
of celery 14 0
Total:263-
295 2
Example 3: amount kcalg total 
fats
yogurt, fruit, low -fat 6 oz. 173 2
banana medium (7 -7 7/8" long) 105 0
orange juice 1 cup 114 0
skim milk 1 cup 83 0
Total: 475 2
Example 4: amount kcalg total 
fats
vegetable chicken noodle soup, canned 1 cup 70 2
baked potato, peel not eaten 1 medium (2.25 -3" across) 121 0
skim milk 1 cup 83 0
banana medium (7 -7 7/8" long) 105 0
Total: 379 2

[COMPANY_001] Confidential Page 117
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
Example 5: amount kcalg total 
fats
egg whites, cooked, no fat added [ADDRESS_420174] 2 slices 138 2
jams, preserves, all flavors 1 Tablespoon 109 0
orange juice 1 cup 114 0
skim milk 1 cup 83 0
Total: 502 2
Example 6: amount kcalg total 
fats
chicken, boneless, skinless baked 0.5 cup diced 111 2
salsa, red, cooked 6 Tablespoons 26 0
white rice, cooked, no fat added 0.5 cup 102 0
black beans, canned or cooked from dry, no 
fat added 0.5 cup 99 0
skim milk 1 cup 83 0
Total: 421 2

[COMPANY_001] Confidential Page 118
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
14.2 Dosing tables (Deferasirox DT, Deferasirox granules)
For each patient the investigator and/or pharmacist will calculate a target daily  dose taking into 
account patient’s body  weight at randomization. When the calculated dose cannot be reached 
with the deferasirox tablet / stick pack strengths available, the closest daily  dose available will 
be prescribed. The following dosing tables provide an efficient combination of tablet / stick 
pack strengths reaching a certain dail y dose for each body weight range.  
Examples illustrating this approach are provided belo w:
For a patient with a body weight of 46 kg and a deferasirox DT dose of 20 mg/kg/day , the 
calculated daily  dose is [ADDRESS_420175] daily  dose the patient can receive i s 875 mg, b y 
taking 3 deferasirox tablets: 1 x125 mg + 1 x250 mg + 1 x500 mg. This combination can 
be found in the ‘Tablets’ column, for patients receiving 20 mg/kg/day  of deferasirox DT 
and with a bod y weight between 41- 46 kg.
For a patient with a bod yweight of 46 kg and a deferasirox granules dose of 14 
mg/kg/ day, the calculated daily  dose is [ADDRESS_420176] daily  dose the patient can 
receive is 630 mg, b y taking 3 stick packs: 1 x90 mg + 1 x180 mg + 1 x 360 mg. This 
combination can be found in the ‘Stick packs’ column, for patients receiving 14 
mg/kg/day  of deferasirox granules and with a body  weight between [ADDRESS_420177] ed for each dosing group using lower and upper body 
weight limits of 5 and 140 kg, respectively. This is taking into account that the study  will enroll 
male or female children and adolescents, ≥ 2 and < 18 years. However, for some patients with 
a low bod y weight (e.g. below 19 kg in the 5 mg/kg/day dosing group) the dosing requirements 
given in Section 6.1.[ADDRESS_420178] strength available (Eg: 125 mg 
for DT, or 90 mg for granule s). In such cases a written request will be sent to [COMPANY_001], to advise 
on the individual patient enrolment / dose adjustments options.

[COMPANY_001] Confidential Page 119
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
Table 14-4 Dosing table for deferasirox DT
Body weight ranges per dosing group (kg) Tablets
5 mg/kg/day
[kg]10 mg/kg/day  
[kg]15 mg/kg/day  
[kg]20 mg/kg/day  
[kg]25 mg/kg/day  
[kg]30 mg/kg/day  
[kg]35 mg/kg/day  
[kg]40 mg/kg/day  
[kg] 125 mg 250 mg 500 mg
19 -37 10 -18 9 -12 5 – 9 5 - 7 5 - 6 5 1
38 -62 19 -31 13 -20 10 -15 8 -12 7 -10 6 - 8 5 - 7 1
63 -87 32 -43 21 -29 16 -21 13 -17 11 -14 9 -12 8 -10 1 1
88 -112 44 -56 30 -37 22 -28 18 -22 15 -18 13 -16 11 -14 1
113 -137 57 -68 38 -45 29 -34 23 -27 19 -22 17 -19 15 -17 1 1
138 -140 69 -81 46 -54 35 -40 28 -32 23 -27 20 -23 18 -20 1 1
82 -93 55 -62 41 -46 33 -37 28 -31 24 -26 21 -23 1 1 1
94 -106 63 -70 47 -53 38 -42 32 -35 27 -30 24 -26 2
107 -118 71 -79 54 -59 43 -47 36 -39 31 -33 27 -29 1 2
119 -131 80 -87 60 -65 48 -52 40 -43 34 -37 30 -32 1 2
132 -140 88 -95 66 -71 53 -57 44 -47 38 -41 33 -35 1 1 2
96 -104 72 -78 58 -62 48 -52 42 -44 36 -39 3
105 -112 79 -84 63 -67 53 -56 45 -48 40 -42 1 3
113 -120 85 -90 68 -72 57 -60 49 -51 43 -45 1 3
121 -129 91 -96 73 -77 61 -64 52 -55 46 -48 1 1 3
130 -137 97 -103 78 -82 65 -68 56 -58 49 -51 4
138 -140 104 -109 83 -87 69 -72 59 -62 52 -54 1 4
110 -115 88 -92 73 -77 63 -66 55 -57 1 4
116 -121 93 -97 78 -81 67 -69 58 -60 1 1 4
122 -128 98 -102 82 -85 70 -73 61 -64 5
129 -134 103 -107 86 -89 74 -76 65 -67 1 5
135 -140 108 -112 90 -93 77 -80 68 -70 1 5
113 -117 94 -97 81 -83 71 -73 1 1 5
118 -122 98 -102 84 -87 74 -76 6
123 -127 103 -106 88 -91 77 -79 1 6

[COMPANY_001] Confidential Page 120
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
Body weight ranges per dosing group (kg) Tablets
5 mg/kg/day
[kg]10 mg/kg/day  
[kg]15 mg/kg/day  
[kg]20 mg/kg/day  
[kg]25 mg/kg/day  
[kg]30 mg/kg/day  
[kg]35 mg/kg/day  
[kg]40 mg/kg/day  
[kg] 125 mg 250 mg 500 mg
128 -132 107 -110 92 -94 80 -82 1 6
133 -137 111 -114 95 -98 83 -85 1 1 6
138 -140 115 -118 99 -101 86 -89 7
119 -122 102 -105 90 -92 1 7
123 -127 106 -108 93 -95 1 7
128 -131 109 -112 96 -98 1 1 7
132 -135 113 -116 99 -101 8
136 -139 117 -119 102 -104 1 8
140 120 -123 105 -107 1 8
124 -126 108 -110 1 1 8
127 -130 111 -114 9
131 -133 115-117 1 9
134 -137 118 -120 1 9
138 -140 121 -123 1 1 9
124 -126 10
127 -129 1 10
130 -132 1 10
133 -135 1 1 10
136 -139 11
140 1 11

[COMPANY_001] Confidential Page 121
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
Table 14-5 Dosing table for deferasirox granules
Body weight ranges per dosing group (kg) Stick packs
3.5 mg/kg/day  
[kg]7 mg/kg/day  
[kg]10.5 
mg/kg/day  [kg]14 mg/kg/day  
[kg]17.5 
mg/kg/day  [kg]21 mg/kg/day  
[kg]24.5 
mg/kg/day  [kg]28 mg/kg/day  
[kg] 90 mg 180 mg 360 mg
19 -38 10 -19 7 -12 5 – 9 5 - 7 5 - 6 5 1
39 -64 20 -32 13 -21 10 -16 8 -12 7 -10 6 - 9 5 - 8 1
65 -90 33 -45 22 -30 17 -22 13 -18 11 -15 10 -12 9 -11 1 1
91 -115 46 -57 31 -38 23 -28 19 -23 16 -19 13 -16 12 -14 1
116 -140 58 -70 39 -47 29 -35 24 -28 20 -23 17 -20 15 -17 1 1
71 -83 48 -55 36 -41 29 -33 24 -27 21 -23 18 -20 1 1
84 -96 56 -64 42 -48 34 -38 28 -32 24 -27 21 -24 1 1 1
97 -109 65 -72 49 -54 39 -43 33 -36 28 -31 25 -27 2
110 -122 73 -81 55 -61 44 -48 37 -40 32 -34 28 -30 1 2
123 -135 82 -90 62 -67 49 -54 41 -45 35 -38 31 -33 1 2
136 -140 91 -98 68 -73 55 -59 46 -49 39 -42 34 -36 1 1 2
99 -107 74 -80 60 -64 50 -53 43 -45 37 -40 3
108 -115 81 -86 65 -69 54 -57 46 -49 41 -43 1 3
116 -124 87 -93 70 -74 58 -62 50 -53 44 -46 1 3
125 -132 94 -99 75 -79 63 -66 54 -56 47 -49 1 1 3
133 -140 100 -106 80 -84 67 -70 57 -60 50 -52 4
107 -112 85 -90 71 -75 61 -64 53 -56 1 4
113 -118 91 -95 76 -79 65 -67 57 -59 1 4
119 -125 96 -100 80 -83 68 -71 60 -62 1 1 4
126-131 101 -105 84 -87 72 -75 63 -65 5
132 -138 106 -110 88 -92 76 -78 66 -69 1 5
139 -140 111 -115 93 -96 79 -82 70 -72 1 5
116 -120 97 -100 83 -86 73 -75 1 1 5
121 -126 101 -105 87 -90 76 -78 6
127 -131 106 -109 91 -93 79 -81 1 6
132 -136 110 -113 94 -97 82 -85 1 6

[COMPANY_001] Confidential Page 122
Amended Protocol Version 06 (Clean ) Protocol No. CICL670F2202
Body weight ranges per dosing group (kg) Stick packs
3.5 mg/kg/day  
[kg]7 mg/kg/day  
[kg]10.5 
mg/kg/day  [kg]14 mg/kg/day  
[kg]17.5 
mg/kg/day  [kg]21 mg/kg/day  
[kg]24.5 
mg/kg/day  [kg]28 mg/kg/day  
[kg] 90 mg 180 mg 360 mg
137 -140 114 -117 98 -101 86 -88 1 1 6
118 -122 102 -104 89 -91 7
123 -126 105 -108 92 -94 1 7
127 -130 109 -112 95 -98 1 7
131 -135 113 -115 99 -101 1 1 7
136 -139 116 -119 102 -104 8
140 120 -123 105 -107 1 8
124 -126 108 -110 1 8
127 -130 111 -114 1 1 8
131 -134 115 -117 9
135 -137 118 -120 1 9
138 -140 121 -123 1 9
124 -126 1 1 9
127 -130 10
131 -133 1 10
134 -136 1 10
137 -139 1 1 10
140 11
